<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Transfusion thresholds for guiding red blood cell transfusion - Carson, JL - 2021 | Cochrane Library</title> <meta content="Transfusion thresholds for guiding red blood cell transfusion - Carson, JL - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002042.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Transfusion thresholds for guiding red blood cell transfusion - Carson, JL - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002042.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002042.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Transfusion thresholds for guiding red blood cell transfusion" name="citation_title"/> <meta content="Jeffrey L Carson&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Rutgers Robert Wood Johnson Medical School" name="citation_author_institution"/> <meta content="jeffrey.carson@rutgers.edu" name="citation_author_email"/> <meta content="Simon J Stanworth&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Jane A Dennis&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Marialena Trivella" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Nareg Roubinian" name="citation_author"/> <meta content="Kaiser Permanente Division of Research Northern California" name="citation_author_institution"/> <meta content="Dean A Fergusson" name="citation_author"/> <meta content="Ottawa Hospital Research Institute" name="citation_author_institution"/> <meta content="Darrell Triulzi" name="citation_author"/> <meta content="University of Pittsburgh" name="citation_author_institution"/> <meta content="Carolyn Dorée" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Paul C Hébert" name="citation_author"/> <meta content="University of Montreal Hospital Research Centre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD002042.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002042.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002042.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002042.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Anemia [therapy]; *Erythrocyte Transfusion; Hematocrit; Hemoglobins; Prospective Studies; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002042.pub5&amp;doi=10.1002/14651858.CD002042.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002042\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002042\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","pt","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002042.pub5",title:"Transfusion thresholds for guiding red blood cell transfusion",firstPublishedDate:"Dec 21, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002042.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002042.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002042.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002042.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002042.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002042.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002042.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002042.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002042.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002042.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>24711 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002042.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/appendices#CD002042-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/supinfo/CD002042StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/supinfo/CD002042StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Transfusion thresholds for guiding red blood cell transfusion</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="JLC, SJS and JAD contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jeffrey L Carson</a><sup>a</sup></li> <li class="author custom-tooltip" title="JLC, SJS and JAD contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0005">Simon J Stanworth</a><sup>a</sup></li> <li class="author custom-tooltip" title="JLC, SJS and JAD contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0006">Jane A Dennis</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0007">Marialena Trivella</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0008">Nareg Roubinian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0009">Dean A Fergusson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0010">Darrell Triulzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0011">Carolyn Dorée</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information#CD002042-cr-0012">Paul C Hébert</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information/en#CD002042-sec-0126">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002042.pub5">https://doi.org/10.1002/14651858.CD002042.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002042-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002042-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002042-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002042-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002042-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002042-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD002042-abs-0008">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002042-abs-0001" lang="en"> <section id="CD002042-sec-0001"> <h3 class="title" id="CD002042-sec-0001">Background</h3> <p>The optimal haemoglobin threshold for use of red blood cell (RBC) transfusions in anaemic patients remains an active field of research. Blood is a scarce resource, and in some countries, transfusions are less safe than in others because of inadequate testing for viral pathogens. If a liberal transfusion policy does not improve clinical outcomes, or if it is equivalent, then adopting a more restrictive approach could be recognised as the standard of care.  </p> </section> <section id="CD002042-sec-0002"> <h3 class="title" id="CD002042-sec-0002">Objectives</h3> <p>The aim of this review update was to compare 30‐day mortality and other clinical outcomes for participants randomised to restrictive versus liberal red blood cell (RBC) transfusion thresholds (triggers) for all clinical conditions. The restrictive transfusion threshold uses a lower haemoglobin concentration as a threshold for transfusion (most commonly, 7.0 g/dL to 8.0 g/dL), and the liberal transfusion threshold uses a higher haemoglobin concentration as a threshold for transfusion (most commonly, 9.0 g/dL to 10.0 g/dL). </p> </section> <section id="CD002042-sec-0003"> <h3 class="title" id="CD002042-sec-0003">Search methods</h3> <p>We identified trials through updated searches: CENTRAL (2020, Issue 11), MEDLINE (1946 to November 2020), Embase (1974 to November 2020), Transfusion Evidence Library (1950 to November 2020), Web of Science Conference Proceedings Citation Index (1990 to November 2020), and trial registries (November 2020). We  checked the reference lists of other published reviews and relevant papers to identify additional trials. We were aware of one trial identified in earlier searching that was in the process of being published (in February 2021), and we were able to include it before this review was finalised. </p> </section> <section id="CD002042-sec-0004"> <h3 class="title" id="CD002042-sec-0004">Selection criteria</h3> <p>We included randomised trials of surgical or medical participants that recruited adults or children, or both. We excluded studies that focused on neonates. </p> <p>Eligible trials assigned intervention groups on the basis of different transfusion schedules or thresholds or 'triggers'. These thresholds would be defined by a haemoglobin (Hb) or haematocrit (Hct) concentration below which an RBC transfusion would be administered; the haemoglobin concentration remains the most commonly applied marker of the need for RBC transfusion in clinical practice. We included trials in which investigators had allocated participants to higher thresholds or more liberal transfusion strategies compared to more restrictive ones, which might include no transfusion. As in previous versions of this review, we did not exclude unregistered trials published after 2010 (as per the policy of the Cochrane Injuries Group, 2015), however, we did conduct analyses to consider the differential impact of results of trials for which prospective registration could not be confirmed.   </p> </section> <section id="CD002042-sec-0005"> <h3 class="title" id="CD002042-sec-0005">Data collection and analysis</h3> <p>We identified trials for inclusion and extracted data using Cochrane methods. We pooled risk ratios of clinical outcomes across trials using a random‐effects model. Two review authors independently extracted data and assessed risk of bias. We conducted predefined analyses by clinical subgroups. We defined participants randomly allocated to the lower transfusion threshold as being in the 'restrictive transfusion' group and those randomly allocated to the higher transfusion threshold as being in the 'liberal transfusion' group. </p> </section> <section id="CD002042-sec-0006"> <h3 class="title" id="CD002042-sec-0006">Main results</h3> <p>A total of 48 trials, involving data from 21,433 participants (at baseline), across a range of clinical contexts (e.g. orthopaedic, cardiac, or vascular surgery; critical care; acute blood loss (including gastrointestinal bleeding); acute coronary syndrome; cancer; leukaemia; haematological malignancies), met the eligibility criteria. The haemoglobin concentration used to define the restrictive transfusion group in most trials (36) was between 7.0 g/dL and 8.0 g/dL.  Most trials included only adults; three trials focused on children. </p> <p>The included studies were generally at low risk of bias for key domains including allocation concealment and incomplete outcome data. </p> <p>Restrictive transfusion strategies reduced the risk of receiving at least one RBC transfusion by 41% across a broad range of clinical contexts (risk ratio (RR) 0.59, 95% confidence interval (CI) 0.53 to 0.66; 42 studies, 20,057 participants; high‐quality evidence), with a large amount of heterogeneity between trials (I² = 96%). </p> <p>Overall, restrictive transfusion strategies did not increase or decrease the risk of 30‐day mortality compared with liberal transfusion strategies (RR 0.99, 95% CI 0.86 to 1.15; 31 studies, 16,729 participants; I² = 30%; moderate‐quality evidence) or any of the other outcomes assessed (i.e. cardiac events (low‐quality evidence), myocardial infarction, stroke, thromboembolism (all high‐quality evidence)). High‐quality evidence shows that the liberal transfusion threshold did not affect the risk of infection (pneumonia, wound infection, or bacteraemia). Transfusion‐specific reactions are uncommon and were inconsistently reported within trials. </p> <p>We noted less certainty in the strength of evidence to support the safety of restrictive transfusion thresholds for the following predefined clinical subgroups: myocardial infarction, vascular surgery, haematological malignancies, and chronic bone‐marrow disorders. </p> </section> <section id="CD002042-sec-0007"> <h3 class="title" id="CD002042-sec-0007">Authors' conclusions</h3> <p>Transfusion at a restrictive haemoglobin concentration decreased the proportion of people exposed to RBC transfusion by 41% across a broad range of clinical contexts. Across all trials, no evidence suggests that a restrictive transfusion strategy impacted 30‐day mortality, mortality at other time points, or morbidity (i.e. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. </p> <p>Despite including 17 more randomised trials (and 8846 participants), data remain insufficient to inform the safety of transfusion policies in important and selected clinical contexts, such as myocardial infarction, chronic cardiovascular disease, neurological injury or traumatic brain injury, stroke, thrombocytopenia, and cancer or haematological malignancies, including chronic bone marrow failure.  </p> <p>Further work is needed to improve our understanding of outcomes other than mortality. Most trials compared only two separate thresholds for haemoglobin concentration, which may not identify the actual optimal threshold for transfusion in a particular patient. Haemoglobin concentration may not be the most informative marker of the need for transfusion in individual patients with different degrees of physiological adaptation to anaemia. Notwithstanding these issues, overall findings provide good evidence that transfusions with allogeneic RBCs can be avoided in most patients with haemoglobin thresholds between the range of 7.0 g/dL and 8.0 g/dL. Some patient subgroups might benefit from RBCs to maintain higher haemoglobin concentrations; research efforts should focus on these clinical contexts. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002042-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002042-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002042-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002042-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002042-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002042-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002042-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002042-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002042-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002042-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002042-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002042-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002042-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002042-abs-0002" lang="en"> <h3>Is it safe to use lower blood counts (haemoglobin levels) as a trigger for blood transfusion in order to give fewer blood transfusions? </h3> <p><b>Key messages</b> </p> <p>•There is no evidence that giving blood transfusions to patients with lower blood counts (haemoglobin levels of 7.0 g/dL to 8.0 g/dL) compared to higher blood counts (9.0 g/dL to 10.0 g/dL) affects risks of death, heart attack, myocardial infarction, stroke, pneumonia, blood clots or infection. </p> <p>• Giving blood only to patients with lower blood counts (7.0 g/dL to 8.0 g/dL) would reduce the amount of blood transfused substantially. It would also reduce the risk of unnecessary transfusions (transfusions can have harmful effects). </p> <p>• More research is needed to:</p> <p>‐ establish the blood count at which a blood transfusion is needed in people who have suffered a heart attack, brain injury, or have cancer; and to </p> <p>‐ improve our understanding of outcomes other than death, including quality of life.</p> <p><b>What happens in people who need blood transfusions?</b> </p> <p>Doctors and healthcare professionals often give blood transfusions to people who lose blood through surgery, bleeding, or illness. For example, blood transfusions may help patients with anaemia to recover after surgery, but they should only be given when they help people to get better from their medical condition. Blood is a limited resource and transfusion is not risk‐free, especially for people in low‐income countries where the blood used in transfusions may not be tested for harmful viruses such as HIV or hepatitis. </p> <p><b>What did we want to find out?</b> </p> <p>The blood count measures the amount of haemoglobin in the blood. Haemoglobin is a protein that gives blood its red colour and carries oxygen around the body. A normal blood count is around 12 grams a decilitre (12 g/dL). We wanted to find out if it is safe to withhold blood transfusion until the blood count drops to between 7.0 g/dL to 8.0 g/dL, rather than transfusing sooner at higher blood counts of between 9.0 g/dL to 10.0 g/dL. </p> <p><b>What did we do?</b> </p> <p>We examined the results of studies that allocated patients to one of two groups by chance (for example, by flipping a coin). In one group, the patients only received blood transfusions if their blood count fell below a higher threshold (typically, 9.0 g/dL to 10.0 g/dL). In the other group, the patients only received blood transfusions if their blood counts fell below a lower threshold (typically, 7.0 g/dL to 8.0 g/dL). </p> <p><b>What did we find?</b> </p> <p>We found 48 studies that involved 21,433 patients. The patients had been hospitalised for a range of reasons including: bone (orthopaedic), heart (cardiac) or vascular surgery; critical care; acute blood loss (for example, through bleeding in the stomach or intestines); heart diseases; cancer and blood cancers. The studies compared higher or lower blood count thresholds for blood transfusion. (The ‘threshold’ is the blood count level that would need to be met before a transfusion would be given.) </p> <p><i>Transfusion</i> </p> <p>We found that patients who received transfusions only at lower blood count thresholds were 41% less likely to receive a blood transfusion than those who received them only at higher blood count thresholds. If the lower threshold were applied routinely by medical staff, it would lead to a substantial reduction in the quantity of blood needed. </p> <p><i>Death and harmful events</i> </p> <p>There was no clear difference in the risk of dying within 30 days of receiving, or not receiving, a transfusion for patients in the two different threshold groups. </p> <p>There was also no clear difference between the low and high threshold groups for the number of serious harmful events that occurred after patients received, or did not receive, blood transfusions. The harmful events recorded included infection (pneumonia, wound infection, and blood poisoning), heart attacks, strokes, and problems with blood clots. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We found that most of the studies provided a high quality of evidence; they were adequately conducted and used methods that minimised biases that could make the validity of the results uncertain. </p> <p>We are confident in the evidence regarding likelihood of receiving a transfusion, death within 30 days of transfusion, heart attack, stroke and infection. We are moderately confident in the evidence for problems caused by blood clots, but too few occurred in either group for us to be more confident. </p> <p>Too few studies evaluated quality of life for us to be able to see whether it varied between groups. </p> <p><b>How up to date is this evidence?</b> </p> <p>This Cochrane Review updates our previous work on this subject (last published in 2016). Seventeen new studies are included. The evidence is up to date to November 2020. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002042-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002042-sec-0105"></div> <h3 class="title" id="CD002042-sec-0106">Implications for practice</h3> <section id="CD002042-sec-0106"> <p>Analysis of published evidence reveals that transfusing at a restrictive strategy of 7.0 g/dL to 8.0 g/dL, compared with a liberal haemoglobin threshold of 9.0 g/dL to 10.0 g/dL, across a broad range of hospitalised patients does not have an adverse effect on clinical outcomes, including 30‐day mortality, myocardial infarction, congestive heart failure, and infection. </p> <p>Given there is no evidence of additional benefit of red blood cell (RBC) transfusion at higher haemoglobin concentration thresholds (9.0 g/dL to 10.0 g/dL), and that blood for transfusion is a costly and scarce biological resource with finite risks, a restrictive transfusion trigger policy (7.0 g/dL to 8.0 g/dL) could be widely adopted. A restrictive transfusion policy is not associated with increased adverse events and reduces both risk of exposure to RBC transfusion and the total number of units transfused.  </p> <p>Trial interventions varied on the haemoglobin concentration used to define the restrictive transfusion group. About half of the trials used a 7.0‐g/dL threshold, and the other half used a threshold of 8.0 g/dL to 9.0 g/dL.  However, within each clinical subgroup, the number of clinical trials (and the total numbers of enrolled patients) testing restrictive thresholds at 7.0 g/dL varied. The exact implications for transfusion practice regarding the nature of restrictive haemoglobin thresholds will, therefore, vary by clinical group.  </p> <p>In critical care trials, a 7.0‐g/dL threshold was used most frequently and shown to have a similar safety profile to higher thresholds for mortality (RR 1.06, 95% CI 0.85 to 1.32). Similarly, a restrictive threshold of 7.0 g/dL was used in trials including patients with acute blood loss from gastrointestinal bleeding; evidence indicates that these patients have lower risk of 30‐day mortality with restrictive transfusion that uses a 7.0‐g/dL threshold.   </p> <p>In patients undergoing cardiac surgery, a restrictive threshold of 7.5 g/dL (rather than 7.0 g/dL) was used in the largest trials and shown to have a risk for mortality which was similar to that of higher thresholds.   </p> <p>In trials of orthopaedic surgery, the restrictive strategy used most frequently was 8.0 g/dL, which had a similar risk profile for mortality as higher transfusion thresholds. In this clinical subgroup, it is not possible to conclude that 7.0 g/dL is as efficacious as 8.0 g/dL, without testing lower thresholds in trials.   </p> <p>In other clinical subgroups, the results do not provide adequate evidence to conclude which specific restrictive transfusion threshold should be applied. These subgroups include vascular surgery and haematological malignancies, where trials are insufficient in number or recruit only small numbers of participants. </p> <p>The analysis does provide some evidence that a restrictive strategy might be appropriate for patients with underlying cardiovascular disease. The REALITY trial conducted in patients with acute myocardial infarction found fewer deaths and fewer major adverse cardiac events (MACE) with a restrictive threshold of 8.0 g/dL (<a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a>). However, pooled analysis of all three trials in people with acute myocardial infarction (820 participants) reveals that the risk ratio of 1.61 and very wide 95% confidence intervals (0.38 to 6.88) are also consistent with the possibility of significant benefit for more liberal transfusion policies.   </p> <p>In summary, it is not possible to suggest a single restrictive transfusion threshold across all clinical groups and patients with anaemia.  While it is possible that a 7.0‐g/dL threshold could be used in most adult patients, in some settings trial data for thresholds of 7.0 g/dL do not exist. Without these data, it is impossible to be certain of the effects of higher or lower thresholds in these settings. Trials that should clarify the optimal threshold in some of the most important subgroups that currently lack data are now underway (<a href="./references#CD002042-bbs1-0004" title="">Ongoing studies</a>).   </p> <p>Evidence is insufficient to evaluate the effects of different strategies on functional recovery. Quality of life is an important outcome in many trial settings, for example, people who are transfusion dependent and are managed in outpatient settings. In our review, most included randomised trials were based on patients hospitalised for the management of 'acute' anaemia. In contrast, patients with chronic bone marrow failure, such as myelodysplasia, are transfusion dependent for prolonged periods of time at home, and this may persist for years, yet our understanding of the impact of different transfusion policies on quality of life and functional outcomes for these patients is incomplete. </p> <p>For countries where there are concerns about microbiological screening and the safety of donated blood, the data in this updated review constitute a strong basis for avoiding liberal RBC transfusion in many clinical settings. The benefits of minimising allogeneic RBC transfusion are likely to be greatest when there is doubt about the safety of the blood supply (<a href="./references#CD002042-bbs2-0165" title="WHO.Global status report on blood safety and availability. www.who.int/worldblooddonorday/media/who_blood_safety_factsheet_2011.pdf (accessed 17 January 2021);Fact Sheet 279:1-173.">WHO 2016</a>). There is a need for practice and research to implement our review findings, with support for education and training and updating of robustly constructed guidelines (<a href="./references#CD002042-bbs2-0116" title="KwanJL , LoL , FergusonJ , GoldbergH , Diaz-MartinezJP , TomlinsonG , et al.Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials. BMJ2020;370:m3216:1-10. [DOI: 10.1136/bmj.m3216]">Kwan 2020</a>; <a href="./references#CD002042-bbs2-0131" title="PavenskiK , StanworthS , FungM , WoodEM , PinkJ , MurphyMF , et al, International Collaboration for Transfusion Medicine Guidelines (ICTMG).Quality of evidence-based guidelines for transfusion of red blood cells and plasma: a systematic review. Transfusion Medicine Reviews2018;S0887-7963(18):30017-8.">Pavenski 2018</a>; <a href="./references#CD002042-bbs2-0150" title="SmithJD , LiDH , RaffertyMR .The implementation research logic model: a method for planning, executing, reporting, and synthesizing implementation projects. Implementation Science2020;15(84):doi.org/10.1186/s13012-020-01041-8. [DOI: 10.1186/s13012-020-01041-8]">Smith 2020</a>; <a href="./references#CD002042-bbs2-0162" title="VlaarAP , OczkowskiS , deBruinS , WijnbergeM , AntonelliM , AubronC , et al.Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine. Intensive Care Medicine2020;46:673-96. ">Vlaar 2020</a>). </p> </section> <h3 class="title" id="CD002042-sec-0107">Implications for research</h3> <section id="CD002042-sec-0107"> <p>The totality of research evidence now allows us to make firmer recommendations for research priorities. Further randomised trials should be targeted to address specific research questions when the strength of evidence‐based recommendations has significant uncertainty, rather than repeating trials in clinical settings or at haemoglobin thresholds for which the evidence base is better defined. Acute cardiovascular disease is a high‐priority area, for which a restrictive approach may not be as safe, but ongoing larger trials have the potential to provide additional evidence (<a href="./references#CD002042-bbs2-0079" title="NCT02619136.Myocardial ischemia and transfusion (MINT) [Myocardial ischemia and transfusion: a pilot, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in patients with myocardial infarction]. www.clinicaltrials.gov/ct2/show/NCT02619136 (first posted 2 December 2015). [CTG: NCT02619136]NCT02981407.Myocardial Ischemia and Transfusion (MINT). clinicaltrials.gov/ct2/show/NCT02981407 (first posted 5 December 2016). [CTG: NCT02981407]">NCT02981407</a>; <a href="./references#CD002042-bbs2-0144" title="ShahA , StanworthSJ , DochertyAB .Restrictive blood transfusion - is less really more?Anaesthesia2020;75(4):433–7.">Shah 2020</a>). Limited data are available for participants in clinical contexts of acute coronary syndrome, myocardial infarction, neurological injury/traumatic brain injury, acute neurological disorders, and stroke. Areas of uncertainty in cancer and haematological malignancy include chronic bone marrow failure and the role of transfusion at different thresholds for patients receiving radiotherapy (<a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>). Liberal thresholds for red cell transfusion could provide important additive benefits for important outcomes such as fatigue and quality of life for elderly patients with chronic bone marrow failure, who may be transfusion dependent for many years (<a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>). </p> <p>Although one large pragmatic trial has been undertaken in critically ill children (<a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>), many children with anaemia, although eligible, were not recruited into this trial, and further research is warranted to examine the generalisability of these trial findings for all groups of sick infants and children, including those with cardiac disorders. Patients with severe burn injuries who require large volumes of red cells may also present in a clinical context that requires further research. </p> <p>In summary, we believe that in these selected clinical contexts, clinical goals and pathophysiology preclude generalisation from the completed trials included in this review to date, and there remains uncertainty regarding optimal transfusion practices in these subgroups.  </p> <p>There is a need to continue to update this review, given the large number of ongoing trials, which reflects an active programme of research in the field of red cell transfusion research. All new trials should be adequately powered and apply consistent definitions for clinical outcomes, such as infection, myocardial infarction and ischaemic heart disease (<a href="./references#CD002042-bbs2-0107" title="DochertyAB , AlamS , ShahAS , MossA , NewbyDE , MillsNL , et al, TROPICCAL Investigators.Unrecognised myocardial infarction and its relationship to outcome in critically ill patients with cardiovascular disease. Intensive Care Medicine2018;44(12):2059-69.">Docherty 2018</a>). Outcomes of importance in trials will continue to include mortality, along with outcomes that are more specific and relevant to the clinical setting, such as function and quality of life measures and bleeding endpoints in transfusion‐dependent patients with cancer and haematological malignancy. All new trials should be prospectively registered, to assist researchers in assessing risk of selective outcome reporting and other matters related to research integrity. </p> <p>Trials are also needed to evaluate haemoglobin concentrations below 7.0 g/dL, such as 6.0 g/dL (<a href="./references#CD002042-bbs2-0170" title="YaoRQ , RenC , ZhangZC , ZhuYB , XiaZF , YaoYM .Is haemoglobin below 7.0 g/dL an optimal trigger for allogenic red blood cell transfusion in patients admitted to intensive care units? A meta-analysis and systematic review. BMJ Open2020;10:e030854. ">Yao 2020</a>), which may be especially relevant in countries with suboptimal blood safety and inadequate blood supply (<a href="./references#CD002042-bbs2-0072" title="MaitlandK , KiguliS , Olupot-Olupot, EngoruC , MallewaM , Saramago GoncalvesP , et al, the TRACT Group.Immediate transfusion in African children with uncomplicated severe anaemia. New England Journal of Medicine2019;381(5):407-19. [DOI: 10.1056/NEJMoa1900105] [ISRCTN: ISRCTN84086586]MaitlandK , Polupot-OlupotP , KiguliS , ChagalukaG , AlarokerF , OpokaRO , et al, TRACT Group.Transfusion volume for children with severe anemia in Africa. New England Journal of Medicine2019;381(5):420-31. [DOI: 10.1056/NEJMoa1900100]">Maitland 2019</a>). One randomised feasibility trial identified as ongoing in children undergoing allogeneic haematopoietic stem cell transplantation is comparing restrictive versus liberal red cell transfusion strategies using haemoglobin concentrations of &lt; 6.5 g/dL and &lt; 8.0 g/dL respectively (<a href="./references#CD002042-bbs2-0077" title="ISRCTN17438123.A small pilot feasibility study for a possible randomised control trial comparing clinical outcomes and quality of life following two different transfusion strategies in children undergoing allogeneic hematopoietic stem cell transplant (HSCT) [RePAST: Red cell transfusion in Paediatric Allogeneic HSCT - A feasibility randomised controlled trial comparing restrictive versus liberal red cell (RBC) transfusion strategies in children undergoing allogeneic haematopoietic stem cell transplant (HSCT)]. www.isrctn.com/ISRCTN17438123 (first posted 23 May 2019). [ISRCTN: ISRCTN17438123]">ISRCTN17438123</a>). Further research should recognise the need for gender‐specific reference ranges for haemoglobin concentration (<a href="./references#CD002042-bbs2-0094" title="ButcherA , RichardsT ,  Stanworth SJ, KleinAA .Diagnostic criteria for pre-operative anaemia - time to end sex discrimination. Anaesthesia2017;72(7):811-4.">Butcher 2017</a>).   </p> <p>A limitation of this trial‐level meta‐analysis is the difficulty in analysing subgroups of patients with varying underlying diseases, age, and clinical settings. This is especially important when considering transfusion thresholds because there are pathophysiological and clinical data to suggest that the optimal transfusion threshold could differ according to the patient's underlying co‐morbidity (e.g. cardiovascular disease), gender and age. One approach to address this limitation would be to conduct individual patient data meta‐analysis by obtaining and analysing detailed information on each patient enrolled in the trials. </p> <p>Research is needed to identify methods used to measure oxygen delivery to vital organs directly, and to define the need for red cell transfusion more precisely. This recognises the challenge of applying haemoglobin concentration as an imperfect surrogate marker of transfusion requirements (<a href="./references#CD002042-bbs2-0091" title="BaekJH , BuehlerPW .Can molecular markers of oxygen homeostasis and the measurement of tissue oxygen be leveraged to optimize red blood cell transfusions?Current Opinion in Hematology2019;26(6):453-60. [DOI: 10.1097/MOH.0000000000000533]">Baek 2019</a>; <a href="./references#CD002042-bbs2-0121" title="MuellerMM , Van RemoortelH , MeybohmP , ArankoK , AubronC , BurgerR , et al, Group LCC Pbm Frankfurt.Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA2019;321(10):983-97.">Mueller 2019</a>; <a href="./references#CD002042-bbs2-0126" title="OchocinskaMJ , SpitalnikSL , AbuhamadA , Bennett-GuerreroE , CarloWA , CherukuriM , et al.NIH Workshop 2018: towards minimally-invasive or non-invasive approaches to assess tissue oxygenation pre- and post-transfusion. Transfusion Medicine Reviews2020;S0887-7963(20):30074-2. [DOI: doi: 10.1016/j.tmrv.2020.12.003]">Ochocinska 2020</a>). Although it is beyond the scope of this review, further research should explore factors related to the red cell product used for transfusion, including differences in processing and characteristics of the product. As one example of a donor‐specific factor that may be highly relevant for interpretation of trial results, our analysis revealed that only 16 trials clearly specified use of leuco‐depleted red cells in the trial protocol (<a href="./references#CD002042-bbs2-0161" title="TurnerML .Safety of blood, blood derivatives, and plasma-derived products,. Handbook of Clinical Neurology2018;153:463-72.">Turner 2018</a>).   </p> <p>Consideration should be given to aspects of trial design in the future. The most common design identified in eligible studies in our review remains the parallel two‐arm trial, in which two (arguably arbitrarily defined) thresholds for haemoglobin concentration are compared. A two‐arm trial design, while simple and pragmatic, may be an inefficient approach for identifying the exact optimal threshold for transfusion in a setting ‐ it may indeed be a different threshold than those tested in the trial. We and other groups have highlighted the fact that the actual separation of haemoglobin concentrations attained in trials varies considerably (<a href="./references#CD002042-bbs2-0158" title="TrentinoKM , FarmerSL , LeahyMF , SanfilippoFM , IsbisterJP , MayberryR , et al.Systematic reviews and meta-analyses comparing mortality in restrictive and liberal haemoglobin thresholds for red cell transfusion: an overview of systematic reviews. BMC Medicine2020;18:154; https://doi.org/10.1186/s12916-020-01614-w. [DOI: 10.1186/s12916-020-01614-w]">Trentino 2020a</a>; <a href="./references#CD002042-bbs2-0159" title="TrentinoKM , FarmerSL , IsbisterJP , SanfilippoFM , LeahyMF , HofmannA , et al.Restrictive versus liberal transfusion trials: are they asking the right question?Anesthesia and Analgesia2020;131(6):1950-5. [DOI: 10.1213/ANE.0000000000005227]">Trentino 2020b</a>), and this separation rarely approaches the hoped for differences defined by protocol trial interventions.  </p> <p>Allied research is needed to address the optimal target haemoglobin concentration post transfusion, which will depend on the dose of transfusion given. Doses of red cells in adults are increasingly recommended as single‐unit transfusions in non‐bleeding patients, but the evidence base is limited (<a href="./references#CD002042-bbs2-0148" title="ShihAW , LiuA , ElsharawiR , CrowtherMA , CookRJ , HeddleNM .Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion2018;58(12):2841-60.">Shih 2018</a>). The question of optimal dose for transfusion is particularly relevant for children and infants, given that a common paediatric dose is 10 mL/kg to 15 mL/kg, which is much greater proportionately by weight than the single unit dose (or bag) commonly used in adults (<a href="./references#CD002042-bbs2-0124" title="NewHV , BerrymanJ , Bolton-MaggsPH , CantwellC , ChalmersEA , DaviesT , et al, British Committee for Standards in Haematology .Guidelines on transfusion for fetuses, neonates and older children. . British Journal of Haematology 2016 ;175(5):784-828.">New 2016</a>).  </p> <p>Ultimately, the optimal threshold for transfusion is likely to vary between patients, and new trial designs are needed that can test and evaluate targeted or personalised approaches to the need for transfusion, possibly incorporating individual physiological parameters. Indeed, it has been argued that current trials do not allow a genuine 'standard of care' arm (<a href="./references#CD002042-bbs2-0163" title="WangJK , KleinHG .Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sanguinis2010;98(1):2-11.">Wang 2010</a>), which would mirror current clinical practice by clinicians at the bedside. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002042-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002042-sec-0008"></div> <div class="table" id="CD002042-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Liberal compared with restrictive transfusion protocols for guiding red blood cell transfusion</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Liberal compared with restrictive transfusion protocols for guiding red blood cell transfusion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children (haemodynamically stable) with potential need for RBC transfusion<br/><b>Setting:</b> inpatients<br/><b>Intervention:</b> restrictive transfusion threshold<br/><b>Comparison:</b> liberal transfusion threshold </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with liberal transfusion protocol</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with restrictive transfusion protocol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants exposed to blood transfusion (all studies)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.53 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20,057<br/>(42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>815 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000<br/>(432 to 538) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30‐Day mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.86 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16,729<br/>(31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000<br/>(71 to 96) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.87 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,370<br/>(23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/>(28 to 40) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Congestive heart failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.53 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7247<br/>(16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(19 to 45) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cerebrovascular accident ‐ stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/>(0.64 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13,985<br/>(19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(11 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rebleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.59 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3412<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/>(93 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thromboembolism</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.11<br/>(0.65 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4201<br/>(13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(10 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.88 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17,104<br/>(25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(126 to 153) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RBC:</b> red blood cell; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded once for inconsistency, as there was no consistency in the direction of the effect (despite the relatively low statistical heterogeneity), and we downgraded once for imprecision, as there were very low numbers of events. </p> <p><sup>b</sup>Despite relatively low statistical heterogeneity, there was no consistency in the direction of the effect, hence we downgraded once for inconsistency. </p> <p><sup>c</sup>Downgraded once for imprecision, as there were few events (and hence a wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002042-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002042-sec-0009"></div> <section id="CD002042-sec-0010"> <h3 class="title" id="CD002042-sec-0010">Description of the condition</h3> <p>Patients who are ill in hospital are frequently anaemic, with low haemoglobin concentrations. The causes of anaemia are diverse, including loss of blood from surgery, bleeding, excessive blood sampling for laboratory tests, or as a consequence of illness. Additionally, patients with cancer may develop anaemia because the underlying disease, or chemotherapy, affects production of red cells in their bone marrow. Anaemia both decreases the oxygen content of blood supplied to the tissues, including the myocardial muscles of the heart, and increases myocardial oxygen demand by requiring higher cardiac output to maintain adequate oxygen delivery throughout the body (<a href="./references#CD002042-bbs2-0140" title="SabatineMS , MorrowDA , GiuglianoRP , BurtonPB , MurphySA , McCabeCH , et al.Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation2005;111(16):2042-9.">Sabatine 2005</a>). </p> <p>It is well known that anaemia is linked with multiple clinical symptoms; it is also associated with worse outcomes among patients who are anaemic before and after surgery or critical illness, or who have cardiovascular disease (<a href="./references#CD002042-bbs2-0097" title="CarsonJL , DuffA , PosesRM , BerlinJA , SpenceRK , TroutR , et al.Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet1996;348(9034):1055-60.">Carson 1996</a>; <a href="./references#CD002042-bbs2-0115" title="KunzJV , SpiesCD , BichmannA , SiegM , MuellerA .Postoperative anaemia might be a risk factor for postoperative delirium and prolonged hospital stay: a secondary analysis of a prospective cohort study. PLOS ONE2020;15(2):e0229325. https://doi.org/10.1371/journal.pone.0229325.">Kunz 2020</a>; <a href="./references#CD002042-bbs2-0146" title="ShanderA , JavidrooziM , NaqviS , AregbeyenO , CaylanM , DemirS , et al.An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion2014;54(10 Pt 2):2688-95.">Shander 2014</a>). However, it does not necessarily follow that correction of anaemia will improve outcomes, whether by red blood cell (RBC) transfusions (addressed in this review) or by alternative treatments such as intravenous iron (<a href="./references#CD002042-bbs2-0135" title="RichardsT , BaikadyRR , ClevengerB , ButcherA , AbeysiriS , ChauM , et al.Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet2020;396:1353–61.">Richards 2020</a>). Anaemia is generally well tolerated by many people, therefore, the benefits of administering potentially corrective treatments such as red cell transfusion need to be weighed against the risks. </p> </section> <section id="CD002042-sec-0011"> <h3 class="title" id="CD002042-sec-0011">Description of the intervention</h3> <p>The main treatment option for raising the haemoglobin concentration rapidly in patients with anaemia is RBC transfusion. RBCs for transfusion are collected from whole blood donations from blood donors. These are centrifuged to concentrate them before they are added to anticoagulant and storage solutions. Autologous transfusions, which are collected from and stored for the same individual, are not indicated for sicker hospitalised patients with anaemia. </p> <p>Red cell transfusions are life‐saving for patients with major bleeding. Red cell transfusions will treat severe anaemia successfully and may reduce the risks of major complications related to severe anaemia, such as myocardial infarction and heart failure. Uncertainties about the role of red cell transfusions are less clear for patients with less severe degrees of anaemia, and this is the focus of this review. </p> <p>There are recognised risks of blood transfusion, as with any medical intervention (<a href="./references#CD002042-bbs2-0104" title="DelaneyM , WendelS , BercovitzRS , CidJ , CohnC , DunbarNM , et al, Biomedical Excellence for Safer Transfusion (BEST) Collaborative.Transfusion reactions: prevention, diagnosis, and treatment. Lancet2016;388(10061):2825-36. [DOI: 10.1016/S0140-6736(15)01313-6]">Delaney 2016</a>). These risks, and the general availability of RBC transfusion vary throughout the world. In countries with well‐regulated blood supplies and effective blood donor screening policies, the safety of allogeneic red cell transfusion has improved significantly over the past 30 years, and overall risks are very low. These risks continue to be well monitored through national haemovigilance systems (e.g. the UK's Serious Hazards of Transfusion; <a href="./references#CD002042-bbs2-0149" title="Narayan S (Ed), PolesD , et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group.The 2019 Annual SHOT Report (2020). https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2019-Final-Bookmarked-v2.pdf.">SHOT Annual Report 2019</a>), which document very few cases of transfusion‐transmitted infection; these findings reinforce earlier data from many countries (<a href="./references#CD002042-bbs2-0172" title="ZouS , StramerSL , NotariEP , KuhnsMC , KrysztofD , MusaviF , et al.Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion2009;49(8):1609-20.">Zou 2009</a>; <a href="./references#CD002042-bbs2-0173" title="ZouS , DorseyKA , NotariEP , FosterGA , KrysztofDE , MusaviF , et al.Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion2010;50(7):1495-504.">Zou 2010</a>). In resource‐limited countries, the supply of blood remains inadequate, with highly variable rates of donation per 1000 individuals. Furthermore, blood may not be as safe in these countries as it is in resource‐rich countries because it is not tested rigorously, and countries may lack quality control for viral pathogens, specifically transfusion‐transmissible infections such as HIV, hepatitis B, hepatitis C, and syphilis (<a href="./references#CD002042-bbs2-0165" title="WHO.Global status report on blood safety and availability. www.who.int/worldblooddonorday/media/who_blood_safety_factsheet_2011.pdf (accessed 17 January 2021);Fact Sheet 279:1-173.">WHO 2016</a>). In some resource‐limited countries, a significant proportion of the blood supply is collected from family or paid blood donors ‐ not from voluntary unpaid donors ‐ and donor screening policies may not be efficiently applied. The prevalence of diseases such as HIV can be higher in low‐income countries than in high‐income countries, which presents a risk for transfusion transmission. All these points are described in the latest report on Global Blood Safety and Availability produced by the Blood Transfusion Safety Programme in the World Health Organization (WHO) Department of Service Delivery and Safety (<a href="./references#CD002042-bbs2-0165" title="WHO.Global status report on blood safety and availability. www.who.int/worldblooddonorday/media/who_blood_safety_factsheet_2011.pdf (accessed 17 January 2021);Fact Sheet 279:1-173.">WHO 2016</a>).  </p> <p>Other risks of transfusion that have been described include acute transfusion reactions, volume overload, and transfusion‐related acute lung injury (<a href="./references#CD002042-bbs2-0104" title="DelaneyM , WendelS , BercovitzRS , CidJ , CohnC , DunbarNM , et al, Biomedical Excellence for Safer Transfusion (BEST) Collaborative.Transfusion reactions: prevention, diagnosis, and treatment. Lancet2016;388(10061):2825-36. [DOI: 10.1016/S0140-6736(15)01313-6]">Delaney 2016</a>; <a href="./references#CD002042-bbs2-0149" title="Narayan S (Ed), PolesD , et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group.The 2019 Annual SHOT Report (2020). https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2019-Final-Bookmarked-v2.pdf.">SHOT Annual Report 2019</a>; <a href="./references#CD002042-bbs2-0157" title="ToyP , GajicO , BacchettiP , LooneyMR , GropperMA , HubmayrR , et al.Transfusion-related acute lung injury: incidence and risk factors. Blood2012;119(7):1757-67.">Toy 2012</a>). Less well‐defined, but potentially important, adverse effects include loss of red cell nitric oxide production, which is thought to induce local vasodilatation; pro‐thrombotic effects from factors in the supernatant or changes in blood viscosity following transfusions; and immunomodulatory (or pro‐inflammatory) effects of different cellular products in the red cell component (<a href="./references#CD002042-bbs2-0171" title="YoussefLA , SpitalnikSL .Transfusion-related immunomodulation: a reappraisal. Current Opinion in Hematology2017;24(6):551-7.">Youssef  2017</a>). Such harmful effects of RBC transfusions may be manifested, for example, as increased risks of infection (<a href="./references#CD002042-bbs2-0137" title="RohdeJM , DimcheffDE , BlumbergN , SaintS , LangaKM , KuhnL , et al.Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA2014;311(13):1317-26.">Rohde 2014</a>). </p> <p>Blood transfusion is expensive when one considers that around two million components (of which 1.6 million are units of RBCs) are issued across the UK alone each year (<a href="https://www.shotuk.org" target="_blank">www.shotuk.org</a>). The direct cost of each collected bag of red cells fails to capture the many associated costs related to hospital blood‐banking practice and safe patient administration (<a href="./references#CD002042-bbs2-0154" title="StokesEA , WordsworthS , StavesJ , MundyN , SkellyJ , RadfordK , et al.Accurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health Service. Transfusion2018;58(4):846-53.">Stokes 2018</a>). In 2008, the mean payment for one unit of leuco‐reduced RBCs in the USA was USD 223 (<a href="./references#CD002042-bbs2-0164" title="US Department of Health and Human Services, Office of the Assistant Secretary for Health.Report of the US Department of Health and Human Services. The 2009 National Blood Collection and Utilization Survey Report. www.hhs.gov/ophs/bloodsafety/2007nbcus_survey.pdf (accessed 11 October 2016).">Whitaker 2011</a>). However, when costs of administration as well as acquisition expenses of RBC transfusion were considered, the estimated cost derived from four USA and European hospitals rose to USD 761 per unit (standard deviation ± USD 294) (<a href="./references#CD002042-bbs2-0145" title="ShanderA , HofmannA , OzawaS , TheusingerOM , GombotzH , SpahnDR .Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion2010;50(4):753-65.">Shander 2010</a>). </p> <p>The impact of the storage age of red cells has been addressed in other systematic reviews (<a href="./references#CD002042-bbs2-0143" title="ShahA , BrunskillSJ , DesboroughMJ , DoreeC , TrivellaM , StanworthSJ .Transfusion of red blood cells stored for shorter versus longer duration for all conditions. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD010801. [DOI: 10.1002/14651858.CD010801.pub3]">Shah 2018</a>; <a href="./references#CD002042-bbs2-0153" title="SteinerME , NessPM , AssmannSF , TriulziDJ , SloanSR , DelaneyM , et al.Effects of red-cell storage duration on patients undergoing cardiac surgery. New England Journal of Medicine2015;372(15):1419-29.">Steiner 2015</a>; <a href="./references#CD002042-bbs2-0160" title="TrivellaM ,  Stanworth SJ, BrunskillS , DuttonP , AltmanDG .Can we be certain that storage duration of transfused red blood cells does not affect patient outcomes?BMJ2019;365:l2320.">Trivella 2019</a>). Treatment options other than red cell transfusions for anaemia include erythropoietin and oral, or intravenous, iron therapy, which have been the topics of other recent trials and reviews (<a href="./references#CD002042-bbs2-0135" title="RichardsT , BaikadyRR , ClevengerB , ButcherA , AbeysiriS , ChauM , et al.Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet2020;396:1353–61.">Richards 2020</a>; <a href="./references#CD002042-bbs2-0138" title="RomanMA , AbbascianoRG , PathakS , OoS , YusoffS , WozniakM , et al.Patient blood management interventions do not lead to important clinical benefits or cost-effectiveness for major surgery: a network meta-analysis. British Journal of Anaesthesia2020;S0007-0912(20):30342-1. [DOI: 10.1016/j.bja.2020.04.087]">Roman 2020</a>). </p> </section> <section id="CD002042-sec-0012"> <h3 class="title" id="CD002042-sec-0012">How the intervention might work</h3> <p>The main clinical rationale for transfusing RBCs in anaemic patients is to improve oxygen delivery to tissue beds and vital organs such as the myocardium and brain. Transfusions may reduce compensatory work done by the heart to increase cardiac output in the face of anaemia. These benefits may manifest as better functional activity in patients and, ultimately, improved survival. Red blood cell transfusion is one of the few readily available treatments that consistently raises haemoglobin concentration and may restore tissue oxygenation adequately when oxygen demand exceeds supply (<a href="./references#CD002042-bbs2-0163" title="WangJK , KleinHG .Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sanguinis2010;98(1):2-11.">Wang 2010</a>). </p> <p>There is a long history of randomised controlled trials that have compared outcomes for participants allocated to different policies or schedules of red cell transfusion; these have now been completed and reported (<a href="./references#CD002042-bbs2-0121" title="MuellerMM , Van RemoortelH , MeybohmP , ArankoK , AubronC , BurgerR , et al, Group LCC Pbm Frankfurt.Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA2019;321(10):983-97.">Mueller 2019</a>; <a href="./references#CD002042-bbs2-0125" title="National Institutes of Health (NIH).Perioperative red blood cell transfusion. JAMA1988;260(18):2700-3.">NIH 1988</a>). These studies presented results after randomising participants to either 'restrictive' triggers (where, typically, participants are transfused only when their haemoglobin concentration falls below 7.0 g/dL to 8.0 g/dL) or 'liberal' triggers (where participants are transfused at a higher haemoglobin concentration of around 9.0 g/dL to 10.0 g/dL). Historically, the widely accepted clinical standard was to transfuse patients when haemoglobin level dropped below 10.0 g/dL or when haematocrit fell below 30% (<a href="./references#CD002042-bbs2-0163" title="WangJK , KleinHG .Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sanguinis2010;98(1):2-11.">Wang 2010</a>). Many guidelines based on the evolving evidence base now recommend that a range of haemoglobin values between 6.0 g/dL to 10.0 g/dL can be safely used for directing transfusions, depending on the presence of serious comorbidity (<a href="./references#CD002042-bbs2-0089" title="Association of Anaesthetists of Great Britain and Ireland.Blood transfusion and the anaesthetist - red cell transfusion. www.aagbi.org/publications/guidelines/docs/red_cell_08.pdf 2008 (accessed 11 October 2016).">AAGBI 2008</a>; <a href="./references#CD002042-bbs2-0090" title="American Society of Anesthesiologists (ASA) Task Force on Perioperative Blood Transfusion and Adjuvant Therapies.Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology2006;105(1):198-208.">ASA 2006</a>; <a href="./references#CD002042-bbs2-0098" title="CarsonJL , GrossmanBJ , KleinmanS , TinmouthAT , MarquesMB , FungMK , et al, Clinical Transfusion Medicine Committee of theAABB.Red blood cell transfusion: a clinical practice guideline from the AABB. Annals of Internal Medicine2012;157(1):49-58.">Carson 2012a</a>; <a href="./references#CD002042-bbs2-0100" title="CarsonJL , GuyattG , HeddleNM , GrossmanBJ , CohnCS , FungMK , et al.Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA2016;316:2025-35.">Carson 2016a</a>; <a href="./references#CD002042-bbs2-0121" title="MuellerMM , Van RemoortelH , MeybohmP , ArankoK , AubronC , BurgerR , et al, Group LCC Pbm Frankfurt.Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA2019;321(10):983-97.">Mueller 2019</a>; <a href="./references#CD002042-bbs2-0122" title="NapolitanoLM , KurekS , LuchetteFA , CorwinHL , BariePS , TishermanSA , et al.Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Critical Care Medicine2009;37(12):3124-57.">Napolitano 2009</a>). </p> </section> <section id="CD002042-sec-0013"> <h3 class="title" id="CD002042-sec-0013">Why it is important to do this review</h3> <p>Much of the earlier evidence comparing restrictive and liberal thresholds for red cell transfusion comes from trials based in critical care. In 1999, the landmark TRICC trial (<b>t</b> ransfusion <b>r</b> equirements <b>i</b> n <b>c</b> ritical <b>c</b>are) reported similar mortality in participants transfused at a restrictive trigger less than 7.0 g/dL compared with a liberal trigger less than 10.0 g/dL (<a href="./references#CD002042-bbs2-0021" title="HébertPC , WellsG , BlajchmanMA , MarshallJ , MartinC , PagliarelloG , et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine1999;340(6):409-17. McIntyreL , HébertPC , WellsG , FergussonD , MarshallJ , YetisirE , et al, Canadian Critical Care Trials Group.Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?Journal of Trauma2004;57(3):563-8. ">Hébert 1999</a>). The number of randomised trials continues to expand, as has been reported in previous iterations of this Cochrane Review (<a href="./references#CD002042-bbs2-0174" title="CarlessPA , HenryDA , CarsonJL , HebertPC , McClellandB , KerK .Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042.pub2]">Carless 2010b</a>; <a href="./references#CD002042-bbs2-0175" title="CarsonJL , CarlessPA , HebertPC .Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042.pub3]">Carson 2012b</a>; <a href="./references#CD002042-bbs2-0177" title="HillS , CarlessPA , HenryDA , CarsonJL , HebertPPC , HendersonKM , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Hill 2000</a>; <a href="./references#CD002042-bbs2-0178" title="HillSR , CarlessPA , HenryDA , CarsonJL , HebertPC , McClellandDB , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Hill 2002</a>; <a href="./references#CD002042-bbs2-0179" title="HillSR , CarlessPA , HenryDA , CarsonJL , HebertPC , McClellandDB , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Hill 2005</a>). By 2012, the number of participants enrolled in trials had doubled from 6264 to 12,587 (<a href="./references#CD002042-bbs2-0175" title="CarsonJL , CarlessPA , HebertPC .Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042.pub3]">Carson 2012b</a>); this number rose to 19,049 participants in a targeted update published in 2018, which specifically focused on patients with cardiovascular disease (<a href="./references#CD002042-bbs2-0101" title="CarsonJL , StanworthSJ , AlexanderJH , RoubinianN , FergussonDA , TriulziDJ , et al.Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease. American Heart Journal2018;200:96-101.">Carson 2018</a>). As further new trials continue to be published, there remains an ongoing need to update this systematic review, to ensure that new and updated guidelines on the use of red cell transfusions are based on the most recent literature reports of the effectiveness and safety of RBC transfusion (<a href="./references#CD002042-bbs2-0100" title="CarsonJL , GuyattG , HeddleNM , GrossmanBJ , CohnCS , FungMK , et al.Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA2016;316:2025-35.">Carson 2016a</a>). In addition, new studies focus on relevant and specific clinical contexts, for which previous levels of evidence for supporting best practice were very limited. This allows this updated review to inform transfusion practice in relevant subpopulations of patients. </p> <p>The purpose of this updated review was to identify, appraise, and summarise the data from all randomised controlled trials (RCTs) that studied the clinical impact of varying thresholds for transfusion with RBCs. We remain interested in whether results of RCTs support the trend for increasingly restrictive RBC transfusion practices across different trial settings without harm to patients and to what extent RBCs need to be given more liberally in selected patient subgroups.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002042-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002042-sec-0014"></div> <p>The aim of this review update was to compare 30‐day mortality and other clinical outcomes for participants randomised to restrictive versus liberal red blood cell (RBC) transfusion thresholds (triggers) for all clinical conditions. The restrictive transfusion threshold uses a lower haemoglobin concentration as a threshold for transfusion (most commonly, 7.0 g/dL to 8.0 g/dL), and the liberal transfusion threshold uses a higher haemoglobin concentration to direct transfusion (most commonly, 9.0 g/dL to 10.0 g/dL). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002042-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002042-sec-0015"></div> <section id="CD002042-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002042-sec-0017"> <h4 class="title">Types of studies</h4> <p>To examine evidence for the effects of transfusion thresholds on the use of red blood cell (RBC) transfusions and evidence for any change in clinical outcomes, we included randomised controlled trials (RCTs) in which comparison groups were assigned on the basis of a transfusion 'threshold' (sometimes termed a 'trigger'), defined as haemoglobin concentration or haematocrit level (with or without a specified level of haemodynamic instability) that had to be reached before RBC transfusion was administered. We required trials in which groups of participants were transfused with RBCs at higher haemoglobin or haematocrit levels (transfusion threshold) than those in a lower transfusion group, or were compared to those transfused in accordance with current standard transfusion practices. We excluded trials that were not designed to include any clinical outcomes relevant to this review.  </p> </section> <section id="CD002042-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials of surgical or medical participants, involving adults or children, or both. We excluded studies enrolling neonates, given the distinct pathophysiology and clinical features of neonate anaemia, which is the topic of a separate Cochrane Review (<a href="./references#CD002042-bbs2-0166" title="WhyteR , KirpalaniH .Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD000512. [DOI: 10.1002/14651858.CD000512.pub2]">Whyte 2011</a>). </p> </section> <section id="CD002042-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention considered was use of transfusion thresholds ('triggers') as a means of guiding allogeneic or autologous RBC transfusion, or both. A liberal transfusion threshold most often refers to transfusion of blood when the haemoglobin level falls below 9.0 g/dL to 10.0 g/dL. A restrictive transfusion threshold most often refers to transfusion of blood when the haemoglobin level falls below 7.0 g/dL to 8.0 g/dL. </p> <p>We also included trials that compared transfusion and no transfusion while defining the no transfusion group as the restrictive strategy. Such trials may define a second threshold as a lower limit under which participants' haemoglobin should not fall without initiation of transfusion; this is consistent with all other trials in which clinical discretion is allowed for severe symptomatic anaemia. </p> </section> <section id="CD002042-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated clinical outcomes for efficacy, and we assessed complications of transfusion for safety. </p> <section id="CD002042-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for the analysis was 30‐day mortality. Mortality is a clinically relevant outcome that is widely cited in studies including patients with acute illness, critical illness, and perioperative care.  </p> </section> <section id="CD002042-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We examined three categories of secondary outcomes:</p> <p> <ul id="CD002042-list-0001"> <li> <p>mortality at different time intervals;</p> </li> <li> <p>morbidity outcomes;</p> </li> <li> <p>subgroups for mortality and morbidity.  </p> </li> </ul> </p> <p>We recorded and analysed mortality at different time points, including during hospital admission, at 90 days, and over the long term (median follow‐up, 3.1 years).  </p> <p>We evaluated morbidity that occurred during hospitalisation, including cardiac events (both as a composite outcome that included myocardial infarction, cardiac arrhythmias, cardiac arrest, pulmonary oedema, and angina, and individually when feasible), non‐fatal and fatal myocardial infarction, congestive heart failure, cerebral vascular accident (stroke), rebleeding, infection, thromboembolism, renal failure, mental confusion, function, and fatigue. </p> <p>Infection was defined in three ways: sepsis or bacteraemia, pneumonia alone, or pneumonia plus wound infection. For the 2021 update, we added a specific outcome of 'transfusion‐specific reactions', as defined and reported in included studies. These events are uncommon, but they are important. </p> <p>We defined all morbidity outcomes according to the definitions provided in individual trials. We evaluated subgroups based on transfusion thresholds and clinical context. </p> <p>We recorded information on quality of life and functional outcomes. We also compared use of RBC transfusion as a measure of implementation of the transfusion intervention between groups by proportions of participants exposed to transfusion, units of blood transfused, and mean haemoglobin levels. </p> <p>As this review is an update, we have continued to include some of these secondary outcomes for historical reasons. As stronger evidence is accrued, we believe that in future updates of this review, reporting of some of these outcomes may need to be modified or omitted. </p> </section> </section> </section> <section id="CD002042-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002042-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases and ongoing trial registries:</p> <p> <ul id="CD002042-list-0002"> <li> <p>CENTRAL (Cochrane Central Register of Controlled Trials; 2020, Issue 11), in the Cochrane Library (www.cochranelibrary.com); </p> </li> <li> <p>MEDLINE via OvidSP (from 1946 to 16 November 2020);</p> </li> <li> <p>Embase via OvidSP (from 1974 to 16 November 2020);</p> </li> <li> <p>PubMed (for e‐publications ahead of print only, on 16 November 2020);</p> </li> <li> <p>Transfusion Evidence Library (<a href="http://www.transfusionevidencelibrary.com" target="_blank">www.transfusionevidencelibrary.com</a>; 1950 to 16 November 2020); </p> </li> <li> <p>Web of Science Conference Proceedings Citations Index (CPCI‐S, 1990 to 16 November 2020); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched to 16 November 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched to 16 November 2020). </p> </li> </ul> </p> <p>We combined searches in MEDLINE and Embase with adaptations of the Cochrane RCT search filter as detailed in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002042-bbs2-0117" title="LefebvreC , ManheimerE , GlanvilleJ .Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). We did not restrict our search by date, language, or publication status. We present search strategies for the 2012 update in <a href="./appendices#CD002042-sec-0111">Appendix 1</a>, for the 2016 update and trial registries in <a href="./appendices#CD002042-sec-0117">Appendix 2</a> and <a href="./appendices#CD002042-sec-0118">Appendix 3</a>, respectively, and for the 2020 update in <a href="./appendices#CD002042-sec-0119">Appendix 4</a>. </p> </section> <section id="CD002042-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the references of all identified trials, relevant review articles, and current treatment guidelines for further literature. We limited these searches to 'first‐generation' reference lists (i.e. reference lists of papers retrieved directly by database searches). </p> <p>We contacted experts in the field to identify information relevant to the review. When possible and when necessary, we contacted authors of published studies for clarification of trial methods and data. We emailed all authors of trials that did not report our primary outcome of 30‐day mortality, but this was not possible for older trials for which contact information was not available. We searched the reference lists of relevant reviews and transfusion trials. </p> </section> </section> <section id="CD002042-sec-0026"> <h3 class="title" id="CD002042-sec-0026">Data collection and analysis</h3> <section id="CD002042-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JLC and SJS) independently screened the titles or abstracts of the search results, or both, and selected trials that met the inclusion criteria. We resolved disagreements by discussion until we reached consensus. We identified trials in which participants were randomised to a restrictive transfusion strategy (transfusion threshold or protocol, or both) or to a control group that was randomised to a liberal transfusion strategy. </p> </section> <section id="CD002042-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>JLC and Paul Carless (a prior review author) extracted all data for earlier versions of this review. For this 2021 update, JLC and SJS independently extracted study characteristics and outcomes of new trials added since the last review, using a data extraction form. Information recorded on the extraction form included study type, presence of a transfusion threshold, transfusion protocol, type of surgery involved, clinical setting, treatment outcomes, and general comments, as well as details relevant to assessment of risk of bias for key domains described below. JLC entered data into Review Manager 5.4; NR checked data; JD added new items into tables to meet contemporary MECIR (Methodological Expectations for Cochrane Intervention Reviews) standards, which were checked by both JLC and SJS. We contacted authors of trials to request missing data. </p> <p>We used the data extraction form to record data on the following outcomes:</p> <p> <ul id="CD002042-list-0003"> <li> <p>number of participants exposed to allogeneic blood;</p> </li> <li> <p>amount of allogeneic blood transfused;</p> </li> <li> <p>number of participants receiving any transfusion (allogeneic blood, autologous blood, or both). </p> </li> </ul> </p> <p>For trials involving surgical participants, we recorded the following:</p> <p> <ul id="CD002042-list-0004"> <li> <p>postoperative complications (infection, haemorrhage, non‐fatal myocardial infarction, cardiac events, renal failure, stroke, thromboembolism, pulmonary oedema, mental confusion); </p> </li> <li> <p>mortality, blood loss, haemoglobin and haematocrit levels (on admission, pre‐ and post‐transfusion, and at discharge); </p> </li> <li> <p>demographics (age, sex);</p> </li> <li> <p>type of surgery; and</p> </li> <li> <p>medical condition.</p> </li> </ul> </p> <p>We extracted data for allogeneic blood transfusion if it was expressed as packed RBCs. We documented information regarding the use of fresh frozen plasma or platelets, or both. </p> </section> <section id="CD002042-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Cochrane tool for assessing risk of bias as described in Section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002042-bbs2-0111" title="HigginsJT , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p>JLC, SJS, and JD assessed the following domains for each study:</p> <p> <ul id="CD002042-list-0005"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (assessments were made separately with regard to objective (e.g. mortality) and subjective (e.g. self‐reported quality of life) outcomes); </p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other potential sources of bias.</p> </li> </ul> </p> <p>We completed a risk of bias table for each trial, incorporating a description of the trial's performance against each of the above domains and our overall judgement of the risk of bias for each entry as follows: 'low', 'unclear' (indicating unclear or unknown risk of bias), or 'high' risk of bias. </p> </section> <section id="CD002042-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We obtained the risk ratio (RR) for allogeneic blood transfusion in the intervention group compared with the control group and corresponding 95% confidence intervals (CIs) for each trial. We adopted a similar approach for other outcomes of transfusion. When the event rate was low, we considered using the Peto odds ratio when criteria for this method were fulfilled. We also entered the mean number of units of RBCs transfused to each group and the corresponding standard deviations. We used the mean difference (MD) and 95% CI to express average mean reduction in the number of units of RBC administered to the intervention group compared with the control group. </p> </section> <section id="CD002042-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant. In all trials except one (<a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>), randomisation was done at the individual participant level. In this trial in people with gastrointestinal bleeding, randomisation was done at the level of the hospital (cluster), but analysis occurred at the level of the individual participant. The intraclass correlation coefficient (ICC) was very low (0.0001) for the outcome of mortality; therefore we included the data and considered the participant as the unit of randomisation and ignored the clustering. We performed a sensitivity analysis from which we excluded this trial, to see what effect, if any, this had on the analysis. We did not evaluate any outcomes with repeated measures. </p> </section> <section id="CD002042-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We performed all analyses on an intention‐to‐treat basis. We undertook no imputations for missing data. We received information on 30‐day mortality from three authors (<a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0045" title="ColomoA , Hernandez-GeaV , Muniz-DiazE , MadozP , AracilC , Alvarez-UrturiC .Transfusion strategies in patients with cirrhosis and acute gastrointestinal bleeding. Hepatology2008;48(4 Suppl):413A. VillanuevaC , ColomoA , BoschA , ConcepciónM , Hernandez-GeaV , AracilC , et al.Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine2013;368(1):11-21. ">Villanueva 2013</a>; <a href="./references#CD002042-bbs2-0047" title="WebertKE , CookRJ , CoubanS , CarruthersJ , LeeKA , BlajchmanMA , et al.A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion2008;48(1):81-91. ">Webert 2008</a>). Levels of missing data were never higher than 10%, which we consider acceptable. </p> </section> <section id="CD002042-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined statistical heterogeneity using both the I² statistic and the Chi² test. The I² statistic describes the percentage of total variation across studies due to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity; moderate or substantial heterogeneity is considered to exist when I² exceeds 50% or 85%, respectively (<a href="./references#CD002042-bbs2-0111" title="HigginsJT , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). For the Chi² test, we used a P value &lt; 0.10 to indicate the presence of statistically significant heterogeneity. Because of the anticipated significant clinical heterogeneity of trials, we analysed data using a random‐effects model. We also anticipated a high level of heterogeneity related to transfusion rates because practice in the different specialties of the trials would vary considerably according to specialty‐specific protocols. Therefore, as described later, we chose to provide a summary statistic for the outcomes of transfusion even when I² was very high, because of the clinically relevant information this provides. </p> </section> <section id="CD002042-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>When more than 10 studies were available, we examined funnel plots for the primary outcome of 30‐day mortality and the proportion of participants transfused, to assess the potential for publication bias. We used the proportion of participants transfused because all trials reported this outcome, and this may reflect overall risk of publication bias better than 30‐day mortality, which was not reported in all of the trials. We sought evidence of selective outcome reporting by comparing plans from described registrations/protocols (when available) with final reports. </p> </section> <section id="CD002042-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed all analyses using Review Manager 5.4 software (<a href="./references#CD002042-bbs2-0133" title="Review Manager 5 (RevMan 5).Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 5a</a>). We entered data for numbers of participants exposed to red cell transfusions, anticipated to be allogeneic blood in most trials and patients. We present the results using haemoglobin concentration in grams per decilitre (g/dL). Based on study reporting, we converted haematocrit to haemoglobin concentration by dividing by three. When studies presented transfusion volume as millilitres (mL), we converted these amounts to units by dividing by 300 (as in most countries, a standard unit of red blood cells is 300 mL). We pooled data for all outcomes and presented data stratified by subgroups for the primary outcome of 30‐day mortality and proportion of participants transfused by using a random‐effects model (<a href="./references#CD002042-bbs2-0105" title="Der SimonianR , LairdN .Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">Der Simonian 1986</a>), and we presented the pooled result along with its 95% CI. We used Peto odds ratios for outcomes with event rates less than 1%. For continuous variables, we estimated the pooled mean difference and the 95% CI by using the generic inverse variance method. </p> </section> <section id="CD002042-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Prespecified subgroups, as established in prior reviews, consisted of the following clinical contexts:  </p> <p> <ul id="CD002042-list-0006"> <li> <p>acute blood loss/trauma;</p> </li> <li> <p>cancer;</p> </li> <li> <p>cardiac surgery;</p> </li> <li> <p>critical care;</p> </li> <li> <p>orthopaedic surgery;</p> </li> <li> <p>myocardial infarction;</p> </li> <li> <p>vascular surgery; and</p> </li> <li> <p>haematological malignancy.</p> </li> </ul> </p> <p>We examined 30‐day mortality and the proportion of participants exposed to transfusion stratified by the transfusion threshold (difference between liberal and restrictive transfusion thresholds: ≥ 2.0 g/dL and &lt; 2.0 g/dL; and restrictive transfusion threshold &lt; 7.0 g/dL versus one of 8.0 g/dL to 9.0 g/dL). We also examined a post hoc subgroup of enrolled participants with myocardial infarction compared with all other clinical specialties, and we combined cardiac surgery with myocardial infarction because of emerging evidence that participants with acute myocardial infarction might differ from other anaemic participants (<a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>). </p> <p>For the primary outcome of 30‐day mortality, we also compared findings between prospectively registered trials and those that were unregistered, or were registered long after recruitment began. Blood components are not subject to the same legal requirements for prospective registration as medical devices or pharmaceutical interventions. As in prior versions of this review, we did not exclude unregistered trials published after 2010 (as per the <a href="https://injuries.cochrane.org/editorial-policy-2015" target="_blank">Cochrane Injuries Group policy</a>), and we did conduct analyses to consider differential impact of the results of all trials for which proof of prospective registration could (or could not) be confirmed. </p> </section> <section id="CD002042-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis to assess effects of studies with high risk of bias for allocation concealment for the primary outcome; however, as in earlier versions of the review, sensitivity analyses for secondary outcomes were not informative. We repeated the analysis while excluding the cluster randomised trial (<a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>). </p> </section> <section id="CD002042-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have presented judgements about the quality of evidence in a summary of findings table (according to guidelines developed by the GRADE Working Group) (<a href="./references#CD002042-bbs2-0142" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , FlasziouP , GuyattGH .Chapter 11. Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Schünemann 2011</a>). We rated the quality of evidence as 'high', 'moderate', 'low', or 'very low', according to the following five GRADE domain considerations of: risk of bias, inconsistency, indirectness, imprecision, and publication bias. </p> <p>This table includes the following outcomes:</p> <p> <ul id="CD002042-list-0007"> <li> <p>number of people receiving blood transfusions;</p> </li> <li> <p>30‐day mortality;</p> </li> <li> <p>myocardial infarction;</p> </li> <li> <p>congestive heart failure;</p> </li> <li> <p>cerebrovascular accident (stroke);</p> </li> <li> <p>rebleeding; and</p> </li> <li> <p>thromboembolism.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002042-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002042-sec-0039"></div> <section id="CD002042-sec-0040"> <h3 class="title">Description of studies</h3> <p>Details of the selection process for, and characteristics of, the included studies are offered below, along with information about interventions and trial design. </p> <section id="CD002042-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD002042-fig-0001">Figure 1</a> for the PRISMA flowchart describing trial selection for the present update. </p> <div class="figure" id="CD002042-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow of studies for 2021 update" data-id="CD002042-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow of studies for 2021 update</p> </div> </div> </div> <p>In the previous review, published in 2016, we included 31 studies.</p> <p>For this 2021 update, we identified and analysed 17 additional trials (<a href="./references#CD002042-bbs2-0001" title="AkyildizB , Ulgen TekerekN , PamukcuO , DursunA , KarakukcuM , NarinN , et al.Comprehensive analysis of liberal and restrictive transfusion strategies in pediatric intensive care unit. Journal of Tropical Pediatrics2018;64(2):118-25. ">Akyildiz 2018</a>; <a href="./references#CD002042-bbs2-0002" title="BergaminFS , AlmeidaJP , LandoniG , GalasF , FukushimaJT , FominskiyE , et al.Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients: randomized controlled trial. Critical Care Medicine2017;45(5):766-73. ">Bergamin 2017</a>; <a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a>; <a href="./references#CD002042-bbs2-0015" title="GilliesMA , GhaffarS , MoppettIK , DochertyAB , ClarkeS , ReaN , et al.A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). British Journal of Anaesthesia2020;126:77-86. ">Gillies 2020</a>; <a href="./references#CD002042-bbs2-0016" title="GobattoAL , LinkMA , SollaDJ , BassiE , TiernoPF , PaivaW , et al.Transfusion requirements after head trauma: a randomized feasibility controlled trial. Critical Care2019;23(1):89. [CTG: NCT02203292 ]">Gobatto 2019</a>; <a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>; <a href="./references#CD002042-bbs2-0025" title="JansenAJ , vanden BoschJ .Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold [Letter to the Editor]. Transfusion2020;60(4):879-81. [ISRCTN: ISRCTN43616311]">Jansen 2020</a>; <a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a>; <a href="./references#CD002042-bbs2-0028" title="KolaG , SureshkumarS , MohsinaS , SreenathGS , KateV .Restrictive versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi Journal of Gastroenterology2020;27(1):13-9. [DOI: 10.4103/sjg.SJG_152_20]">Kola 2020</a>; <a href="./references#CD002042-bbs2-0030" title="Laine, A, Niemi, T, Schramko Al.Transfusion threshold of hemoglobin 80g/L is comparable to 100g/L in terms of bleeding in cardiac surgery: a prospective randomized study. Journal of Cardiothoracic and Vascular Anesthesia2018;32(1):131-9. ">Laine 2018</a>; <a href="./references#CD002042-bbs2-0032" title="GalanJ , MateoE , CarmonaP , GajateL , MazerCD , Martinez-ZapataMJ .Restrictive or liberal transfusion for cardiac surgery: Spanish TRICCS results of a randomized multicenter international parallel open-label clinical trial [Transfusión Restrictiva o liberal en cirugía cardiaca: Resultados españoles de un ensayo clínico aleatorizado, multicéntrico, internacional, paralelo y abierto]. Medicina Intensiva (English edition)2020;In press/epub: no volume:Epub: no pagination. [DOI: 10.1016/j.medin.2020.07.011]GargAX , BadnerN , BagshawSM , CuerdenMS , FergussonDA , GregoryAJ , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Safety of a restrictive versus liberal approach to red blood cell transfusion on the outcome of AKI in patients undergoing cardiac surgery: a randomized clinical trial. Journal of the American Society of Nephrology: JASN2019;30(7):1294-304. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Restrictive or liberal red-cell transfusion for cardiac surgery. New England Journal of Medicine2017;377(22):2133-44. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. New England Journal of Medicine2018;379(13):1224-33. ">Mazer 2017</a>; <a href="./references#CD002042-bbs2-0034" title="MøllerA , NielsenHB , WetterslevJ , PedersenOB , HellemannD , WinkelP , et al.Low vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial. Blood2019;133(25):2639-50. MøllerA , ShahidiS , WetterslevJ , HellemanD , PedersenOB , MarcussenKV , et al.Cardiac output in the transfusion triggers in vascular surgery trial. Acta Anaesthesiologica Scandinavica2019;63:e12. ">Møller 2019</a>; <a href="./references#CD002042-bbs2-0036" title="PalmieriTL , HolmesJH , ArnoldoB , PeckM , CochranA , KingBT , et al.Restrictive transfusion strategy is more effective in massive burns: results of the TRIBE multicenter prospective randomized trial. Military Medicine2019;184 (Suppl 1):11-5. [DOI: doi: 10.1093/milmed/usy279]PalmieriTL , HolmesJH , ArnoldoB , PeckM , PotenzaB , CochranA , et al.Transfusion requirement in burn care evaluation (TRIBE). A multicenter randomized prospective trial of blood transfusion in major burn injury. Annals of Surgery2017;266:595-602. ">Palmieri 2017</a>; <a href="./references#CD002042-bbs2-0039" title="RobitailleN , LacroixJ , AlexandrovL , ClaytonL , CortierM , SchultzKR , et al.Excess of veno-occlusive disease in a randomized trial on a higher trigger for red cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biology of Blood and Marrow Transplantation2013;19:468-73. ">Robitaille 2013</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>; <a href="./references#CD002042-bbs2-0043" title="TayJ , AllanDS , ChatelainE , CoyleD , ElemaryM , FulfordA , et al.Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial. Journal of Clinical Oncology2020;38(13):1463-73. ">Tay 2020</a>; <a href="./references#CD002042-bbs2-0048" title="YakymenkoD , FrandsenKB , ChristensenIJ , NorgaardA , JohanssonPI , DaugaardG , et al.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfusion Medicine2018;28(3):208-15. ">Yakymenko 2018</a>) (<a href="#CD002042-fig-0001">Figure 1</a>), leading to a total of 48. We identified one of these trials ‐ <a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a> ‐ as an ongoing trial when we searched trials registers in November 2020; it has subsequently been published and is included in the analysis. We reviewed eligibility for one analysis after peer review and included data from it only in a narrative synthesis (<a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>). This analysis treated the outcomes of two linked studies (DAHANCA 5 and DAHANCA 7) as a single trial (<a href="./references#CD002042-bbs2-0112" title="HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14.">Hoff 2011a</a>; <a href="./references#CD002042-bbs2-0113" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]">Hoff 2011b</a>; <a href="./references#CD002042-bbs2-0128" title="OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46.">Overgaard 1998</a>; <a href="./references#CD002042-bbs2-0129" title="OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40.">Overgaard 2003</a>). </p> <p>Many of the included trials have been reported within multiple papers, which are included as secondary references. Whilst the focus of this review was the main (first) report of outcome data, reports of secondary or subgroup analyses (e.g. long‐term outcomes) occasionally offered complementary information useful for data extraction and assessment of bias. </p> </section> <section id="CD002042-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD002042-sec-0043"> <h5 class="title">Participants</h5> <p>This updated systematic review includes a total of 21,433 trial participants (at baseline) across 48 trials described in 70 publications. By comparison, in the 2016 Cochrane review (<a href="./references#CD002042-bbs2-0176" title="CarsonJL , StanworthSJ , RoubinianN , FergussonDA , TriulziD , DoreeC , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Carson 2016b</a>), we reported on an analysis of 31 trials that enrolled 12,587 participants.   </p> <p>The clinical context of the 48 trials was varied:</p> <p> <ul id="CD002042-list-0008"> <li> <p>11 studies involved orthopaedic surgery (<a href="./references#CD002042-bbs2-0006" title="CarsonJL , TerrinML , BartonFB , AaronR , GreenburgAG , HeckDA , et al.A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion1998;38(6):522-9. ">Carson 1998</a>; <a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>; <a href="./references#CD002042-bbs2-0013" title="FanYX , LiuFF , JiaM , YangJJ , ShenJC , ZhuGM , et al.Comparison of restrictive and liberal transfusion strategy on postoperative delirium in aged patients following total hip replacement: a preliminary study. Archives of Gerontology and Geriatrics2014;59(1):181-5. ">Fan 2014</a>; <a href="./references#CD002042-bbs2-0014" title="FossNB , KristensenMT , JensenPS , PalmH , KrasheninnikoffM , KehletH .The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion2009;49(2):227-34. ">Foss 2009</a>; <a href="./references#CD002042-bbs2-0015" title="GilliesMA , GhaffarS , MoppettIK , DochertyAB , ClarkeS , ReaN , et al.A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). British Journal of Anaesthesia2020;126:77-86. ">Gillies 2020</a>; <a href="./references#CD002042-bbs2-0017" title="BlandfortS , GregersenM , BorrisLC , DamsgaardEM .Blood transfusion strategy and risk of postoperative delirium in nursing homes residents with hip fracture. A post hoc analysis based on the TRIFE randomized controlled trial. Aging Clinical and Experimental Research2017;29(3):459-66. GregersenM , BorrisLC , DamsgaardEM .Blood transfusion and overall quality of life after hip fracture in frail elderly patients - the transfusion requirements in frail elderly randomized controlled trial. Journal of the American Medical Directors Association2015;16(9):762-6. GregersenM , BorrisLC , DamsgaardEM .Postoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture: the TRIFE randomized controlled trial. Acta Orthopaedica2015;86(3):1-10. GregersenM , DamsgaardEM , BorrisLC .Blood transfusion and risk of infection in frail elderly after hip fracture surgery: the TRIFE randomized controlled trial. European Journal of Orthopaedic Surgery &amp; Traumatology2015;25(6):1031-8. ">Gregersen 2015</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1608190206454582114384736063601&amp;format=REVMAN#STD-Grover-2005" target="_blank">Grover 2005</a>; <a href="./references#CD002042-bbs2-0031" title="LotkePA , BarthP , GarinoJP , CookEF .Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration. Journal of Arthroplasty1999;14(6):647-50. ">Lotke 1999</a>; <a href="./references#CD002042-bbs2-0035" title="NielsenK , JohanssonPI , DahlB , WagnerM , FrausingB , BørglumJ , et al.Perioperative transfusion threshold and ambulation after hip revision surgery - a randomized trial. BMC Anesthesiology2014;14:89-98. ">Nielsen 2014</a>; <a href="./references#CD002042-bbs2-0037" title="ParkerMJ .Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery. Injury2013;44(12):1916-8. ">Parker 2013</a>; <a href="./references#CD002042-bbs2-0041" title="So-OsmanC , NelissenR , BrandR , FaberF , SlaaRT , StiggelboutA , et al.The impact of a restrictive transfusion trigger on post-operative complication rate and well-being following elective orthopaedic surgery: a post-hoc analysis of a randomised study. Blood Transfusion (Trasfusione del sangue)2013;11(2):289-95. So-OsmanC , NelissenR , Te SlaaR , CoeneL , BrandR , BrandA .A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells. Vox Sanguinis2010;98(1):56-64. So-OsmanC .A restrictive transfusion trigger is a method for blood saving in elective orthopaedic surgery. Vox Sanguinis2004;87(Suppl 3):52. ">So‐Osman 2013</a>); </p> </li> <li> <p>seven involved critical care (<a href="./references#CD002042-bbs2-0010" title="deAlmeidaJP , VincentJL , GalasFR , deAlmeidaEP , FukushimaJT , OsawaEA , et al.Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology2015;122(1):29-38. ">de Almeida 2015</a>; <a href="./references#CD002042-bbs2-0016" title="GobattoAL , LinkMA , SollaDJ , BassiE , TiernoPF , PaivaW , et al.Transfusion requirements after head trauma: a randomized feasibility controlled trial. Critical Care2019;23(1):89. [CTG: NCT02203292 ]">Gobatto 2019</a>; <a href="./references#CD002042-bbs2-0020" title="HébertPC , WellsG , MarshallJ , MartinC , TweeddaleM , PagliarelloG , et al.Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group [published erratum appears in JAMA 1995 Sep 27;274(12):944]. JAMA1995;273(18):1439-44. ">Hébert 1995</a>; <a href="./references#CD002042-bbs2-0021" title="HébertPC , WellsG , BlajchmanMA , MarshallJ , MartinC , PagliarelloG , et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine1999;340(6):409-17. McIntyreL , HébertPC , WellsG , FergussonD , MarshallJ , YetisirE , et al, Canadian Critical Care Trials Group.Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?Journal of Trauma2004;57(3):563-8. ">Hébert 1999</a>; <a href="./references#CD002042-bbs2-0023" title="HolstLB , HaaseN , WetterslevJ , WernermanJ , GuttormsenAB , KarlssonS , et al.Lower versus higher hemoglobin threshold for transfusion in septic shock. New England Journal of Medicine2014;371(15):1381-91. RygårdSL , HolstLB , WetterslevJ , WinkelP , JohanssonPI , WernermanJ , et al, TRISS Trial Group, Scandinavian Critical Care Trials Group.Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Medicine2016;42(11):1685-94. ">Holst 2014</a>; <a href="./references#CD002042-bbs2-0036" title="PalmieriTL , HolmesJH , ArnoldoB , PeckM , CochranA , KingBT , et al.Restrictive transfusion strategy is more effective in massive burns: results of the TRIBE multicenter prospective randomized trial. Military Medicine2019;184 (Suppl 1):11-5. [DOI: doi: 10.1093/milmed/usy279]PalmieriTL , HolmesJH , ArnoldoB , PeckM , PotenzaB , CochranA , et al.Transfusion requirement in burn care evaluation (TRIBE). A multicenter randomized prospective trial of blood transfusion in major burn injury. Annals of Surgery2017;266:595-602. ">Palmieri 2017</a>; <a href="./references#CD002042-bbs2-0046" title="WalshTS , BoydJA , WatsonD , HopeD , LewisS , KrishanA , et al.Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. Critical Care Medicine2013;41(10):2354-63. ">Walsh 2013</a>); </p> </li> <li> <p>six examined acute blood loss (<a href="./references#CD002042-bbs2-0003" title="BlairSD , JanvrinSB , McCollumCN , GreenhalghRM .Effect of early blood transfusion on gastrointestinal haemorrhage. British Journal of Surgery1986;73(10):783-5. ">Blair 1986</a>; <a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>; <a href="./references#CD002042-bbs2-0028" title="KolaG , SureshkumarS , MohsinaS , SreenathGS , KateV .Restrictive versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi Journal of Gastroenterology2020;27(1):13-9. [DOI: 10.4103/sjg.SJG_152_20]">Kola 2020</a>; <a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>; <a href="./references#CD002042-bbs2-0044" title="FisherMR , TopleyET .The illness of trauma. British Journal of Clinical Practice1956;10(11):770-6. ">Topley 1956</a>; <a href="./references#CD002042-bbs2-0045" title="ColomoA , Hernandez-GeaV , Muniz-DiazE , MadozP , AracilC , Alvarez-UrturiC .Transfusion strategies in patients with cirrhosis and acute gastrointestinal bleeding. Hepatology2008;48(4 Suppl):413A. VillanuevaC , ColomoA , BoschA , ConcepciónM , Hernandez-GeaV , AracilC , et al.Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine2013;368(1):11-21. ">Villanueva 2013</a>), four of which concerned gastrointestinal bleeding, one postpartum haemorrhage (<a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>), and one trauma (<a href="./references#CD002042-bbs2-0044" title="FisherMR , TopleyET .The illness of trauma. British Journal of Clinical Practice1956;10(11):770-6. ">Topley 1956</a>); </p> </li> <li> <p>eight included cardiac  surgery (<a href="./references#CD002042-bbs2-0004" title="BraceyAW , RadovancevicR , RiggsSA , HoustonS , CozartH , VaughnWK , et al.Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion1999;39(10):1070-7. ">Bracey 1999</a>; <a href="./references#CD002042-bbs2-0019" title="HajjarLA , VincentJL , GalasFR , NakamuraRE , SilvaCM , SantosMH , et al.Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA2010;304(14):1559-67. ">Hajjar 2010</a>; <a href="./references#CD002042-bbs2-0026" title="JohnsonRG , ThurerRL , KruskallMS , SiroisC , GervinoEV , CritchlowJ , et al.Comparison of two transfusion strategies after elective operations for myocardial revascularization. Journal of Thoracic and Cardiovascular Surgery1992;104(2):307-14. ">Johnson 1992</a>; <a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a>; <a href="./references#CD002042-bbs2-0030" title="Laine, A, Niemi, T, Schramko Al.Transfusion threshold of hemoglobin 80g/L is comparable to 100g/L in terms of bleeding in cardiac surgery: a prospective randomized study. Journal of Cardiothoracic and Vascular Anesthesia2018;32(1):131-9. ">Laine 2018</a>; <a href="./references#CD002042-bbs2-0032" title="GalanJ , MateoE , CarmonaP , GajateL , MazerCD , Martinez-ZapataMJ .Restrictive or liberal transfusion for cardiac surgery: Spanish TRICCS results of a randomized multicenter international parallel open-label clinical trial [Transfusión Restrictiva o liberal en cirugía cardiaca: Resultados españoles de un ensayo clínico aleatorizado, multicéntrico, internacional, paralelo y abierto]. Medicina Intensiva (English edition)2020;In press/epub: no volume:Epub: no pagination. [DOI: 10.1016/j.medin.2020.07.011]GargAX , BadnerN , BagshawSM , CuerdenMS , FergussonDA , GregoryAJ , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Safety of a restrictive versus liberal approach to red blood cell transfusion on the outcome of AKI in patients undergoing cardiac surgery: a randomized clinical trial. Journal of the American Society of Nephrology: JASN2019;30(7):1294-304. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Restrictive or liberal red-cell transfusion for cardiac surgery. New England Journal of Medicine2017;377(22):2133-44. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. New England Journal of Medicine2018;379(13):1224-33. ">Mazer 2017</a>; <a href="./references#CD002042-bbs2-0033" title="MurphyGJ , PikeK , RogersCA , WordsworthS , StokesEA , AngeliniGD , et al.Liberal or restrictive transfusion after cardiac surgery. New England Journal of Medicine2015;372:997-1008. StokesEA , WordsworthS , BargoD , PikeK , RogersCA , BrierleyRC , et al.Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open2016;6(8):e011311. ">Murphy 2015</a>; <a href="./references#CD002042-bbs2-0040" title="ShehataN , BurnsLA , NathanH , HebertP , HareGM , FergussonD , et al.A randomized controlled pilot study of adherence to transfusion strategies in cardiac surgery. Transfusion2012;52(1):91-9. ">Shehata 2012</a>); </p> </li> <li> <p>three involved acute coronary syndrome (<a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1608190206454582114384736063601&amp;format=REVMAN#STD-Cooper--2011" target="_blank">Cooper 2011</a>; <a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a>); </p> </li> <li> <p>eight involved cancer, leukaemia, and haematological malignancies (<a href="./references#CD002042-bbs2-0002" title="BergaminFS , AlmeidaJP , LandoniG , GalasF , FukushimaJT , FominskiyE , et al.Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients: randomized controlled trial. Critical Care Medicine2017;45(5):766-73. ">Bergamin 2017</a>; <a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>; <a href="./references#CD002042-bbs2-0025" title="JansenAJ , vanden BoschJ .Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold [Letter to the Editor]. Transfusion2020;60(4):879-81. [ISRCTN: ISRCTN43616311]">Jansen 2020</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>; <a href="./references#CD002042-bbs2-0043" title="TayJ , AllanDS , ChatelainE , CoyleD , ElemaryM , FulfordA , et al.Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial. Journal of Clinical Oncology2020;38(13):1463-73. ">Tay 2020</a>; <a href="./references#CD002042-bbs2-0047" title="WebertKE , CookRJ , CoubanS , CarruthersJ , LeeKA , BlajchmanMA , et al.A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion2008;48(1):81-91. ">Webert 2008</a>; <a href="./references#CD002042-bbs2-0048" title="YakymenkoD , FrandsenKB , ChristensenIJ , NorgaardA , JohanssonPI , DaugaardG , et al.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfusion Medicine2018;28(3):208-15. ">Yakymenko 2018</a>); </p> </li> <li> <p>two were in vascular surgery (<a href="./references#CD002042-bbs2-0005" title="BushRL , PevecWC , HolcroftJW .A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. American Journal of Surgery1997;174(2):143-8. ">Bush 1997</a>; <a href="./references#CD002042-bbs2-0034" title="MøllerA , NielsenHB , WetterslevJ , PedersenOB , HellemannD , WinkelP , et al.Low vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial. Blood2019;133(25):2639-50. MøllerA , ShahidiS , WetterslevJ , HellemanD , PedersenOB , MarcussenKV , et al.Cardiac output in the transfusion triggers in vascular surgery trial. Acta Anaesthesiologica Scandinavica2019;63:e12. ">Møller 2019</a>); </p> </li> <li> <p>three enrolled paediatric participants (<a href="./references#CD002042-bbs2-0001" title="AkyildizB , Ulgen TekerekN , PamukcuO , DursunA , KarakukcuM , NarinN , et al.Comprehensive analysis of liberal and restrictive transfusion strategies in pediatric intensive care unit. Journal of Tropical Pediatrics2018;64(2):118-25. ">Akyildiz 2018</a>; <a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>; <a href="./references#CD002042-bbs2-0039" title="RobitailleN , LacroixJ , AlexandrovL , ClaytonL , CortierM , SchultzKR , et al.Excess of veno-occlusive disease in a randomized trial on a higher trigger for red cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biology of Blood and Marrow Transplantation2013;19:468-73. ">Robitaille 2013</a>). Two trials were conducted in paediatric intensive care units (<a href="./references#CD002042-bbs2-0001" title="AkyildizB , Ulgen TekerekN , PamukcuO , DursunA , KarakukcuM , NarinN , et al.Comprehensive analysis of liberal and restrictive transfusion strategies in pediatric intensive care unit. Journal of Tropical Pediatrics2018;64(2):118-25. ">Akyildiz 2018</a>; <a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>), and one trial involved bone marrow transplant recipients (<a href="./references#CD002042-bbs2-0039" title="RobitailleN , LacroixJ , AlexandrovL , ClaytonL , CortierM , SchultzKR , et al.Excess of veno-occlusive disease in a randomized trial on a higher trigger for red cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biology of Blood and Marrow Transplantation2013;19:468-73. ">Robitaille 2013</a>). </p> </li> </ul> </p> </section> <section id="CD002042-sec-0044"> <h5 class="title">Interventions</h5> <p>We noted variation in the definitions of transfusion strategies specified in the protocols, but most commonly, haemoglobin concentrations were used as 'triggers'. Four trials specified haematocrit values for the threshold (<a href="./references#CD002042-bbs2-0009" title="CooperHA , RaoSV , GreenbergMD , RumseyMP , MckenzieM , AlcornKW , et al.Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). American Journal of Cardiology2011;108(8):1108-11. ">Cooper 2011</a>; <a href="./references#CD002042-bbs2-0019" title="HajjarLA , VincentJL , GalasFR , NakamuraRE , SilvaCM , SantosMH , et al.Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA2010;304(14):1559-67. ">Hajjar 2010</a>; <a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a>; <a href="./references#CD002042-bbs2-0026" title="JohnsonRG , ThurerRL , KruskallMS , SiroisC , GervinoEV , CritchlowJ , et al.Comparison of two transfusion strategies after elective operations for myocardial revascularization. Journal of Thoracic and Cardiovascular Surgery1992;104(2):307-14. ">Johnson 1992</a>). Four trials incorporated symptoms in addition to haemoglobin threshold in the restrictive transfusion strategy (<a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>; <a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>; <a href="./references#CD002042-bbs2-0037" title="ParkerMJ .Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery. Injury2013;44(12):1916-8. ">Parker 2013</a>; <a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>). </p> <p>Transfusion thresholds by haemoglobin concentration in restrictive transfusion arms (44 trials) varied from 7.0 g/dL to 9.7 g/dL. The most common restrictive haemoglobin threshold for interventions was between 7.0 g/dL to 8.0 g/dL (35 trials). Two trials recruited patients in the outpatient chronic transfusion‐dependent population setting based on haemoglobin concentrations (<a href="./references#CD002042-bbs2-0025" title="JansenAJ , vanden BoschJ .Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold [Letter to the Editor]. Transfusion2020;60(4):879-81. [ISRCTN: ISRCTN43616311]">Jansen 2020</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>), and thresholds for the intervention arms in these trials were higher, as might be expected for this population. Three trials defined a no‐transfusion strategy for the 'restrictive' arm (<a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>; <a href="./references#CD002042-bbs2-0037" title="ParkerMJ .Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery. Injury2013;44(12):1916-8. ">Parker 2013</a>; <a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>), with provisions made for participants with clear signs of anaemia. </p> <p>Restrictive haematocrit varied between 24% and 25% (equivalent to haemoglobin levels of around 8 g/dL) (<a href="./references#CD002042-bbs2-0009" title="CooperHA , RaoSV , GreenbergMD , RumseyMP , MckenzieM , AlcornKW , et al.Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). American Journal of Cardiology2011;108(8):1108-11. ">Cooper 2011</a>; <a href="./references#CD002042-bbs2-0019" title="HajjarLA , VincentJL , GalasFR , NakamuraRE , SilvaCM , SantosMH , et al.Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA2010;304(14):1559-67. ">Hajjar 2010</a>; <a href="./references#CD002042-bbs2-0026" title="JohnsonRG , ThurerRL , KruskallMS , SiroisC , GervinoEV , CritchlowJ , et al.Comparison of two transfusion strategies after elective operations for myocardial revascularization. Journal of Thoracic and Cardiovascular Surgery1992;104(2):307-14. ">Johnson 1992</a>; <a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a>).  </p> <p>The most common transfusion threshold by haemoglobin concentration in the liberal transfusion arm was 9.0 g/dL to 10.0 g/dL. However, the liberal transfusion threshold varied and included: </p> <p> <ul id="CD002042-list-0009"> <li> <p>100% of 'normal red cell volume' (<a href="./references#CD002042-bbs2-0044" title="FisherMR , TopleyET .The illness of trauma. British Journal of Clinical Practice1956;10(11):770-6. ">Topley 1956</a>); </p> </li> <li> <p>two units of blood irrespective of clinical state (immediately in one trial (<a href="./references#CD002042-bbs2-0003" title="BlairSD , JanvrinSB , McCollumCN , GreenhalghRM .Effect of early blood transfusion on gastrointestinal haemorrhage. British Journal of Surgery1986;73(10):783-5. ">Blair 1986</a>), postoperatively in another (<a href="./references#CD002042-bbs2-0031" title="LotkePA , BarthP , GarinoJP , CookEF .Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration. Journal of Arthroplasty1999;14(6):647-50. ">Lotke 1999</a>)); and </p> </li> <li> <p>transfusion sufficient to maintain haemoglobin levels:</p> <ul id="CD002042-list-0010"> <li> <p>above 10 g/dL (<a href="./references#CD002042-bbs2-0017" title="BlandfortS , GregersenM , BorrisLC , DamsgaardEM .Blood transfusion strategy and risk of postoperative delirium in nursing homes residents with hip fracture. A post hoc analysis based on the TRIFE randomized controlled trial. Aging Clinical and Experimental Research2017;29(3):459-66. GregersenM , BorrisLC , DamsgaardEM .Blood transfusion and overall quality of life after hip fracture in frail elderly patients - the transfusion requirements in frail elderly randomized controlled trial. Journal of the American Medical Directors Association2015;16(9):762-6. GregersenM , BorrisLC , DamsgaardEM .Postoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture: the TRIFE randomized controlled trial. Acta Orthopaedica2015;86(3):1-10. GregersenM , DamsgaardEM , BorrisLC .Blood transfusion and risk of infection in frail elderly after hip fracture surgery: the TRIFE randomized controlled trial. European Journal of Orthopaedic Surgery &amp; Traumatology2015;25(6):1031-8. ">Gregersen 2015</a>; <a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>; <a href="./references#CD002042-bbs2-0025" title="JansenAJ , vanden BoschJ .Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold [Letter to the Editor]. Transfusion2020;60(4):879-81. [ISRCTN: ISRCTN43616311]">Jansen 2020</a>; <a href="./references#CD002042-bbs2-0039" title="RobitailleN , LacroixJ , AlexandrovL , ClaytonL , CortierM , SchultzKR , et al.Excess of veno-occlusive disease in a randomized trial on a higher trigger for red cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biology of Blood and Marrow Transplantation2013;19:468-73. ">Robitaille 2013</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>; <a href="./references#CD002042-bbs2-0047" title="WebertKE , CookRJ , CoubanS , CarruthersJ , LeeKA , BlajchmanMA , et al.A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion2008;48(1):81-91. ">Webert 2008</a>; <a href="./references#CD002042-bbs2-0048" title="YakymenkoD , FrandsenKB , ChristensenIJ , NorgaardA , JohanssonPI , DaugaardG , et al.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfusion Medicine2018;28(3):208-15. ">Yakymenko 2018</a>); </p> </li> <li> <p>at 10 g/dL (<a href="./references#CD002042-bbs2-0005" title="BushRL , PevecWC , HolcroftJW .A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. American Journal of Surgery1997;174(2):143-8. ">Bush 1997</a>; <a href="./references#CD002042-bbs2-0006" title="CarsonJL , TerrinML , BartonFB , AaronR , GreenburgAG , HeckDA , et al.A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion1998;38(6):522-9. ">Carson 1998</a>; <a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>; <a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>; <a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a>; <a href="./references#CD002042-bbs2-0014" title="FossNB , KristensenMT , JensenPS , PalmH , KrasheninnikoffM , KehletH .The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion2009;49(2):227-34. ">Foss 2009</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1608190206454582114384736063601&amp;format=REVMAN#STD-Grover-2005" target="_blank">Grover 2005</a>; <a href="./references#CD002042-bbs2-0019" title="HajjarLA , VincentJL , GalasFR , NakamuraRE , SilvaCM , SantosMH , et al.Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA2010;304(14):1559-67. ">Hajjar 2010</a>; <a href="./references#CD002042-bbs2-0020" title="HébertPC , WellsG , MarshallJ , MartinC , TweeddaleM , PagliarelloG , et al.Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group [published erratum appears in JAMA 1995 Sep 27;274(12):944]. JAMA1995;273(18):1439-44. ">Hébert 1995</a>; <a href="./references#CD002042-bbs2-0021" title="HébertPC , WellsG , BlajchmanMA , MarshallJ , MartinC , PagliarelloG , et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine1999;340(6):409-17. McIntyreL , HébertPC , WellsG , FergussonD , MarshallJ , YetisirE , et al, Canadian Critical Care Trials Group.Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?Journal of Trauma2004;57(3):563-8. ">Hébert 1999</a>; <a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>; <a href="./references#CD002042-bbs2-0037" title="ParkerMJ .Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery. Injury2013;44(12):1916-8. ">Parker 2013</a>); </p> </li> <li> <p>at 9.5 g/dL (<a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>; <a href="./references#CD002042-bbs2-0040" title="ShehataN , BurnsLA , NathanH , HebertP , HareGM , FergussonD , et al.A randomized controlled pilot study of adherence to transfusion strategies in cardiac surgery. Transfusion2012;52(1):91-9. ">Shehata 2012</a>); </p> </li> <li> <p>at 9 g/dL (<a href="./references#CD002042-bbs2-0002" title="BergaminFS , AlmeidaJP , LandoniG , GalasF , FukushimaJT , FominskiyE , et al.Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients: randomized controlled trial. Critical Care Medicine2017;45(5):766-73. ">Bergamin 2017</a>; <a href="./references#CD002042-bbs2-0004" title="BraceyAW , RadovancevicR , RiggsSA , HoustonS , CozartH , VaughnWK , et al.Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion1999;39(10):1070-7. ">Bracey 1999</a>; <a href="./references#CD002042-bbs2-0010" title="deAlmeidaJP , VincentJL , GalasFR , deAlmeidaEP , FukushimaJT , OsawaEA , et al.Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology2015;122(1):29-38. ">de Almeida 2015</a>; <a href="./references#CD002042-bbs2-0015" title="GilliesMA , GhaffarS , MoppettIK , DochertyAB , ClarkeS , ReaN , et al.A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). British Journal of Anaesthesia2020;126:77-86. ">Gillies 2020</a>; <a href="./references#CD002042-bbs2-0016" title="GobattoAL , LinkMA , SollaDJ , BassiE , TiernoPF , PaivaW , et al.Transfusion requirements after head trauma: a randomized feasibility controlled trial. Critical Care2019;23(1):89. [CTG: NCT02203292 ]">Gobatto 2019</a>; <a href="./references#CD002042-bbs2-0023" title="HolstLB , HaaseN , WetterslevJ , WernermanJ , GuttormsenAB , KarlssonS , et al.Lower versus higher hemoglobin threshold for transfusion in septic shock. New England Journal of Medicine2014;371(15):1381-91. RygårdSL , HolstLB , WetterslevJ , WinkelP , JohanssonPI , WernermanJ , et al, TRISS Trial Group, Scandinavian Critical Care Trials Group.Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Medicine2016;42(11):1685-94. ">Holst 2014</a>; <a href="./references#CD002042-bbs2-0033" title="MurphyGJ , PikeK , RogersCA , WordsworthS , StokesEA , AngeliniGD , et al.Liberal or restrictive transfusion after cardiac surgery. New England Journal of Medicine2015;372:997-1008. StokesEA , WordsworthS , BargoD , PikeK , RogersCA , BrierleyRC , et al.Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open2016;6(8):e011311. ">Murphy 2015</a>; <a href="./references#CD002042-bbs2-0043" title="TayJ , AllanDS , ChatelainE , CoyleD , ElemaryM , FulfordA , et al.Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial. Journal of Clinical Oncology2020;38(13):1463-73. ">Tay 2020</a>; <a href="./references#CD002042-bbs2-0045" title="ColomoA , Hernandez-GeaV , Muniz-DiazE , MadozP , AracilC , Alvarez-UrturiC .Transfusion strategies in patients with cirrhosis and acute gastrointestinal bleeding. Hepatology2008;48(4 Suppl):413A. VillanuevaC , ColomoA , BoschA , ConcepciónM , Hernandez-GeaV , AracilC , et al.Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine2013;368(1):11-21. ">Villanueva 2013</a>; <a href="./references#CD002042-bbs2-0046" title="WalshTS , BoydJA , WatsonD , HopeD , LewisS , KrishanA , et al.Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. Critical Care Medicine2013;41(10):2354-63. ">Walsh 2013</a>); </p> </li> <li> <p>at 8.9 g/dL (<a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>); and </p> </li> <li> <p>at 8 g/dL (<a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0028" title="KolaG , SureshkumarS , MohsinaS , SreenathGS , KateV .Restrictive versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi Journal of Gastroenterology2020;27(1):13-9. [DOI: 10.4103/sjg.SJG_152_20]">Kola 2020</a>; <a href="./references#CD002042-bbs2-0034" title="MøllerA , NielsenHB , WetterslevJ , PedersenOB , HellemannD , WinkelP , et al.Low vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial. Blood2019;133(25):2639-50. MøllerA , ShahidiS , WetterslevJ , HellemanD , PedersenOB , MarcussenKV , et al.Cardiac output in the transfusion triggers in vascular surgery trial. Acta Anaesthesiologica Scandinavica2019;63:e12. ">Møller 2019</a>). </p> </li> </ul> </li> </ul> </p> <p>Four trials used haematocrit levels when determining triggers (<a href="./references#CD002042-bbs2-0009" title="CooperHA , RaoSV , GreenbergMD , RumseyMP , MckenzieM , AlcornKW , et al.Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). American Journal of Cardiology2011;108(8):1108-11. ">Cooper 2011</a> and <a href="./references#CD002042-bbs2-0019" title="HajjarLA , VincentJL , GalasFR , NakamuraRE , SilvaCM , SantosMH , et al.Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA2010;304(14):1559-67. ">Hajjar 2010</a> specified the liberal triggers as haematocrit levels of 30%; <a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a> specified a level of 28%, and <a href="./references#CD002042-bbs2-0026" title="JohnsonRG , ThurerRL , KruskallMS , SiroisC , GervinoEV , CritchlowJ , et al.Comparison of two transfusion strategies after elective operations for myocardial revascularization. Journal of Thoracic and Cardiovascular Surgery1992;104(2):307-14. ">Johnson 1992</a> a level of 32%).   </p> </section> <section id="CD002042-sec-0045"> <h5 class="title">Trial setting and design</h5> <p>See <a href="#CD002042-tbl-0002">Table 1</a>. </p> <div class="table" id="CD002042-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Trial setting details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants at baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country/Countries</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of sites</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Year recruitment started</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mazer 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 countries<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carson 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Murphy 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Holst 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark, Sweden, Norway, Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 general ICUs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jairath 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Villanueva 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hébert 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary (22), community ICU (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1994</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Koch 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1), India (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 academic affiliated hospital in the USA, a private hospital in India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ducrocq 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>France, Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lacroix 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada, Belgium, USA, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary paediatric ICU</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>So‐Osman 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varied ‐ university and general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prick 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varied ‐ university and general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hajjar 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hoff 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>??</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oncology centres</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bracey 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palmieri 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US (16 sites), Canada (1), New Zealand (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specialist burn centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tay 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCT sites</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bergamin 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gregersen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grover 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kola 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parker 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>de Almeida 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary oncology university hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fan 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akyildiz 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yakymenko 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lotke 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foss 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walsh 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varied ‐ university and general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bush 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1995</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DeZern 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary referral centre for oncology</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carson 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (3), UK (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1996</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laine 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hébert 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital and general hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gillies 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Webert 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary oncology centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Møller 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shehata 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blair 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gobatto 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veterans' Affairs hospital centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stanworth 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK, Australia, New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topley 1956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'Accident hospital'</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Januarysen 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 university hospital, 2 general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Robitaille 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not identified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Mazer 2017 (TRICS‐III): majority of sites in USA; sites also in Australia, Brazil, Canada, China, Colombia, Denmark, Egypt, Germany, Greece, India, Israel, Malaysia, New Zealand, Romania, Singapore, South Africa, Spain, and Switzerland. </p> </div> </div> <p>The included studies were conducted at a total of nearly 400 sites within 26 countries. High‐income countries including Canada, the UK, and the USA contributed the bulk of both single‐site and multicentre studies, as well as co‐ordinating international multicentre studies. The next most common countries, in terms of providing settings for eligible trials, were Denmark, the Netherlands, Brazil, and France. Recruitment start dates for studies included within this review ran between 1955 and 2017, with a marked increase in the rate of new studies commencing recruitment from 2009 onwards. </p> <p>A total of 24 of the 48 included studies were unregistered or were registered by investigators long after recruitment began. Although a majority of unregistered trials were relatively old, lack of prospective registration is a problem that persists to the present day. </p> <p>In 47 of the 48 trials, the participant was the unit of randomisation and analysis. One trial used cluster randomisation by hospital (<a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>). Sample sizes of included studies varied enormously (from 6 to 5092 participants randomised at baseline). Twenty‐six trials included 100 or more participants, and four trials included over 1000 participants each (<a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>; <a href="./references#CD002042-bbs2-0023" title="HolstLB , HaaseN , WetterslevJ , WernermanJ , GuttormsenAB , KarlssonS , et al.Lower versus higher hemoglobin threshold for transfusion in septic shock. New England Journal of Medicine2014;371(15):1381-91. RygårdSL , HolstLB , WetterslevJ , WinkelP , JohanssonPI , WernermanJ , et al, TRISS Trial Group, Scandinavian Critical Care Trials Group.Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Medicine2016;42(11):1685-94. ">Holst 2014</a>; <a href="./references#CD002042-bbs2-0032" title="GalanJ , MateoE , CarmonaP , GajateL , MazerCD , Martinez-ZapataMJ .Restrictive or liberal transfusion for cardiac surgery: Spanish TRICCS results of a randomized multicenter international parallel open-label clinical trial [Transfusión Restrictiva o liberal en cirugía cardiaca: Resultados españoles de un ensayo clínico aleatorizado, multicéntrico, internacional, paralelo y abierto]. Medicina Intensiva (English edition)2020;In press/epub: no volume:Epub: no pagination. [DOI: 10.1016/j.medin.2020.07.011]GargAX , BadnerN , BagshawSM , CuerdenMS , FergussonDA , GregoryAJ , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Safety of a restrictive versus liberal approach to red blood cell transfusion on the outcome of AKI in patients undergoing cardiac surgery: a randomized clinical trial. Journal of the American Society of Nephrology: JASN2019;30(7):1294-304. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Restrictive or liberal red-cell transfusion for cardiac surgery. New England Journal of Medicine2017;377(22):2133-44. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. New England Journal of Medicine2018;379(13):1224-33. ">Mazer 2017</a>; <a href="./references#CD002042-bbs2-0033" title="MurphyGJ , PikeK , RogersCA , WordsworthS , StokesEA , AngeliniGD , et al.Liberal or restrictive transfusion after cardiac surgery. New England Journal of Medicine2015;372:997-1008. StokesEA , WordsworthS , BargoD , PikeK , RogersCA , BrierleyRC , et al.Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open2016;6(8):e011311. ">Murphy 2015</a>). Eleven of the included studies were described as pilot or feasibility studies (<a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>; <a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0015" title="GilliesMA , GhaffarS , MoppettIK , DochertyAB , ClarkeS , ReaN , et al.A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). British Journal of Anaesthesia2020;126:77-86. ">Gillies 2020</a>; <a href="./references#CD002042-bbs2-0016" title="GobattoAL , LinkMA , SollaDJ , BassiE , TiernoPF , PaivaW , et al.Transfusion requirements after head trauma: a randomized feasibility controlled trial. Critical Care2019;23(1):89. [CTG: NCT02203292 ]">Gobatto 2019</a>; <a href="./references#CD002042-bbs2-0020" title="HébertPC , WellsG , MarshallJ , MartinC , TweeddaleM , PagliarelloG , et al.Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group [published erratum appears in JAMA 1995 Sep 27;274(12):944]. JAMA1995;273(18):1439-44. ">Hébert 1995</a>; <a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>; <a href="./references#CD002042-bbs2-0034" title="MøllerA , NielsenHB , WetterslevJ , PedersenOB , HellemannD , WinkelP , et al.Low vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial. Blood2019;133(25):2639-50. MøllerA , ShahidiS , WetterslevJ , HellemanD , PedersenOB , MarcussenKV , et al.Cardiac output in the transfusion triggers in vascular surgery trial. Acta Anaesthesiologica Scandinavica2019;63:e12. ">Møller 2019</a>; <a href="./references#CD002042-bbs2-0040" title="ShehataN , BurnsLA , NathanH , HebertP , HareGM , FergussonD , et al.A randomized controlled pilot study of adherence to transfusion strategies in cardiac surgery. Transfusion2012;52(1):91-9. ">Shehata 2012</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>; <a href="./references#CD002042-bbs2-0047" title="WebertKE , CookRJ , CoubanS , CarruthersJ , LeeKA , BlajchmanMA , et al.A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion2008;48(1):81-91. ">Webert 2008</a>; <a href="./references#CD002042-bbs2-0048" title="YakymenkoD , FrandsenKB , ChristensenIJ , NorgaardA , JohanssonPI , DaugaardG , et al.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfusion Medicine2018;28(3):208-15. ">Yakymenko 2018</a>). We counted two linked studies in patients with head and neck squamous cell carcinoma before radiotherapy as one trial for the purpose of this review (<a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a>); the two component studies, DAHANCA 5 and DAHANCA 7, tested the same main trial intervention (nimorazole) and then applied a similar subrandomisation question to evaluate transfusion versus no transfusion, given concerns about poorer responses to radiation therapy due to a hypothesis of hypoxia‐induced radio‐resistance. </p> </section> </section> <section id="CD002042-sec-0046"> <h4 class="title">Excluded studies</h4> <p>In 2016, this review contained records of four excluded studies. In this 2021 update, we have excluded a further 17 studies; data for these studies were published in 22 publications (see <a href="./references#CD002042-sec-0133" title="">Characteristics of excluded studies</a>). Of the 21 excluded studies, 17 are ineligible RCTs (excluded largely on grounds of intervention or population); the remaining four are non‐randomised studies of different designs. </p> <section id="CD002042-sec-0047"> <h5 class="title">Studies awaiting classification</h5> <p>Brief details of five trials that are awaiting assessment are shown in the <a href="./references#CD002042-bbs1-0003" title="">Studies awaiting classification</a> section. Four have been completed but remain unpublished; we are considering how to handle data reported in the fifth (published) trial, which was of a complex, multifactorial design. </p> </section> <section id="CD002042-sec-0048"> <h5 class="title">Ongoing studies</h5> <p>Brief details of 14 ongoing studies identified from searches of international trial registers are shown in the <a href="./references#CD002042-bbs1-0004" title="">Ongoing studies</a> section. When completed, and if eligibility criteria remain stable, results from these studies may add data from approximately 14,880 participants to this review, with five trials aiming to recruit over 1000 participants each. The latter (larger) studies are focusing on populations that are currently under‐represented in the studies included in this review, specifically, those with traumatic brain injury or cardiac/vascular disease. </p> </section> </section> </section> <section id="CD002042-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias tables detail the assessment of studies for each domain and are summarised in <a href="#CD002042-fig-0002">Figure 2</a> and <a href="#CD002042-fig-0003">Figure 3</a>.   </p> <div class="figure" id="CD002042-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Forty‐eight trials are included in this review." data-id="CD002042-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Forty‐eight trials are included in this review. </p> </div> </div> </div> <div class="figure" id="CD002042-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each methodological quality item for each included trial" data-id="CD002042-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each methodological quality item for each included trial </p> </div> </div> </div> <section id="CD002042-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD002042-sec-0051"> <h5 class="title">Sequence generation</h5> <p>We judged 41 trials to be at low risk of bias for this domain. We judged three trials to be at high risk of bias: one for basing the randomisation sequence on hospital record number, one for using coin‐tossing, and one because it mentioned using both a table of random numbers and odd/even (restrictive/liberal) allocation strategy. The remaining four trials presented insufficient information for us to be able to assess the adequacy of sequence generation, so we rated them as being at unclear risk. </p> </section> <section id="CD002042-sec-0052"> <h5 class="title">Allocation concealment</h5> <p>We judged the risk of bias for this item to be low for 36 trials that used central allocation or sealed envelopes if appropriate safeguards (e.g. sequentially numbered envelopes) were used. We judged four trials to be at high risk of bias: one of these trials used a cluster design, so everyone in all hospitals knew to which group all participants had been assigned (<a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>), one used a coin toss, one used hospital numbers that could be seen, and one used closed envelopes. We rated the risk for eight trials as unclear because the publications did not provide any information about how allocation was concealed. </p> </section> </section> <section id="CD002042-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD002042-sec-0054"> <h5 class="title">Performance bias </h5> <p>The nature of the intervention meant that blinding of clinicians involved in the care and administration of blood transfusions would not have been possible. Blinding of personnel for this intervention is also not feasible. In our view, for objective outcomes such as mortality (the primary outcome used within this review), it is appropriate to assess risk of bias as low. </p> </section> <section id="CD002042-sec-0055"> <h5 class="title">Detection bias</h5> <p>Outcomes are assessed optimally when assessors are blinded to assignment. It is possible to blind the assessment of many outcomes by using, for example, an adjudication committee. In contrast, for some outcomes such as death, blinded assessment is less relevant. We classified risk of bias on the basis of the primary outcome of the trial (mortality) and on subjective outcomes, if reported, including functional measures and quality of life. We judged the risk of bias to be high for 11 trials for subjective outcomes. </p> </section> </section> <section id="CD002042-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We rated seven trials as being at high risk of bias for this domain, as data were missing for a large proportion of participants (20% to 45% of data for an outcome important to this review in six cases) or were missing disproportionately between arms (one trial). </p> </section> <section id="CD002042-sec-0057"> <h4 class="title">Selective reporting</h4> <p>We rated 20 trials as being at unclear risk of bias for this domain, largely because evidence of prospective registration could not be confirmed. One trial (the oldest in the review, which recruited in the early 1950s) was assessed as being at high risk of bias for not reporting the groups in which deaths occurred. The remaining trials were assessed as having a low risk of bias for this domain. </p> </section> <section id="CD002042-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>We identified few other sources of bias. Small trials, including feasibility or pilot studies (which account for 20% of included trials), often reported small imbalances at baseline, as might be expected. Some trials were obliged to terminate prematurely due to slow recruitment. Only a limited number of trials described protocol violations for transfusions in detail, but these applied to both intervention arms. Overall, we assessed six of the 48 trials as having unclear risk of bias for this domain. </p> </section> </section> <section id="CD002042-sec-0059"> <h3 class="title" id="CD002042-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD002042-tbl-0001"><b>Summary of findings 1</b> Liberal compared with restrictive transfusion protocols for guiding red blood cell transfusion</a> </p> <p>Substantial variation in outcomes was reported in the included trials, which, in part, reflects their clinical settings.  </p> <p>Nearly all trials contributed to the analysis comparing the proportion of participants transfused in liberal and restrictive transfusion groups. Despite the heterogeneous methods and transfusion triggers reported in these RCTs, it was possible to pool data, to varying degrees, for each of the review outcomes. See <a href="./full#CD002042-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD002042-sec-0060"> <h4 class="title">Primary outcome</h4> <section id="CD002042-sec-0061"> <h5 class="title">30‐Day mortality</h5> <p>The primary outcome of 30‐day mortality was reported by 31 trials (including 16,729 participants) in a form suitable for meta‐analysis. There was no difference in 30‐day mortality between restrictive and liberal transfusion strategies (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.86 to 1.15; <a href="./references#CD002042-fig-0007" title="">Analysis 1.1</a>). Heterogeneity between these trials was not important (Chi² = 40.06, degrees of freedom (df) = 28 (P = 0.07); I² = 30%). The funnel plot demonstrates that the RR for 30‐day mortality is symmetrically distributed, which indicates there is not likely to be publication bias for this outcome (<a href="#CD002042-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD002042-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Mortality, outcome: 1.1 30‐Day mortality" data-id="CD002042-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mortality, outcome: 1.1 30‐Day mortality</p> </div> </div> </div> <section id="CD002042-sec-0062"> <h6 class="title">Subgroup analysis of 30‐day mortality: restrictive threshold of 7.0 g/dL to 7.5 g/dL versus 8.0 g/dL to 9.0 g/dL </h6> <p>We examined 30‐day mortality and stratified it by the restrictive transfusion threshold used in the trials.  Fifteen trials with 11,572 participants used a 7.0‐g/dL restrictive threshold. The RR for 30‐day mortality was 1.00 (95% CI 0.83 to 1.19; <a href="./references#CD002042-fig-0008" title="">Analysis 1.2</a>). Sixteen trials with 5157 participants used a restrictive threshold of 8.0 g/dL to 9.0 g/dL. The RR for 30‐day mortality was 0.97 (95% CI 0.75 to 1.24; <a href="./references#CD002042-fig-0008" title="">Analysis 1.2</a>). The test for subgroup differences did not show any differences between subgroups (Chi² = 0.04, df = 1 (P = 0.83), I² = 0%), indicating there was no difference in the mortality risk between the two thresholds. </p> </section> <section id="CD002042-sec-0063"> <h6 class="title">Subgroup analyses of 30‐day mortality: clinical context</h6> <p>We examined 30‐day mortality and stratified it by the clinical context used in the trials: cardiac surgery, orthopaedic surgery, vascular surgery, acute blood loss or trauma (analyses for this grouping for 30‐day mortality included gastrointestinal (GI) bleeding only), critical care, acute myocardial infarction, and haematological malignancies. The overall RR for 30‐day mortality stratified by clinical specialty was 0.99 (95% CI 0.86 to 1.14; 31 trials, 16,729 participants; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>). There were no differences in 30‐day mortality between subgroups (Chi² = 6.73, df = 6 (P = 0.35); I² = 10.9%). </p> <section id="CD002042-sec-0064"> <p><b>Cardiac surgery</b></p> <p>Four trials conducted in 7411 patients undergoing cardiac surgery reported 30‐day mortality. The RR for 30‐day mortality for a restrictive compared to a liberal transfusion strategy was 0.99 (95% CI 0.74 to 1.33; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.1). </p> </section> <section id="CD002042-sec-0065"> <p><b>Orthopaedic surgery</b></p> <p>Eight trials of orthopaedic surgery contributed data from 3111 participants for 30‐day mortality. There was no clear effect of a restrictive compared to a liberal transfusion threshold (RR 1.16, 95% CI 0.75 to 1.79; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.2). </p> </section> <section id="CD002042-sec-0066"> <p><b>Vascular surgery</b></p> <p>Two trials contributed data from 157 participants for 30‐day mortality. The RR for 30‐day mortality was 0.98 (95% CI 0.30 to 3.25; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.3). </p> </section> <section id="CD002042-sec-0067"> <p><b>Acute blood loss or trauma</b></p> <p>Three trials reported mortality at 30 days among 1522 participants with acute blood loss or trauma (GI bleeding). Mortality was significantly lower when a restrictive strategy rather than a liberal strategy was used (RR 0.65, 95% CI 0.43 to 0.97; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.4).  </p> </section> <section id="CD002042-sec-0068"> <p><b>Critical care</b></p> <p>Nine trials including 3529 participants receiving critical care for heterogeneous reasons contributed data for this outcome. The RR showed no clear effect of a restrictive compared to a liberal transfusion strategy (RR 1.06, 95% CI 0.85 to 1.32; 9 trials, 3529 participants; I² = 55%; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.5). </p> </section> <section id="CD002042-sec-0069"> <p><b>Acute myocardial infarction</b></p> <p>Three trials provided data from 820 participants with acute myocardial infarction and evaluated mortality; for this subgroup, mortality risk was higher in the restrictive strategy group than in the liberal strategy group (RR 1.61, 95% CI 0.38 to 6.88, <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.6). We carried out a post hoc subgroup analysis that compared 30‐day mortality for acute myocardial infarction participants versus all other participants but found no differences. The P value for subgroup differences was 0.50 (Chi² = 0.45, df = 1; I² = 0%; <a href="./references#CD002042-fig-0010" title="">Analysis 1.4</a>). Although we observed a moderately elevated RR for myocardial infarction participants (RR 1.61), the three included trials were modest in size, and hence, the pooled 95% confidence interval is very wide. </p> </section> <section id="CD002042-sec-0070"> <p><b>Haematological malignancies</b></p> <p>Two small trials provided data on 30‐day mortality among 149 participants. The 95% confidence interval was very wide, and no conclusions can be drawn for this subgroup (RR 0.37, 95% CI 0.07 to 1.95; 2 trials, 149 participants; I² = 0%; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.7). </p> </section> <section id="CD002042-sec-0071"> <p><b>Mortality by cardiac surgery, vascular surgery, myocardial infarction, and all others</b></p> <p>We examined 30‐day mortality and stratified it by the clinical context used in trials in a grouping comparing cardiac surgery, vascular surgery, myocardial infarction, and a group combining all other included trials. The overall RR for 30‐day mortality stratified by clinical specialty was (to repeat findings above) 0.99 (95% CI 0.86 to 1.14; 31 trials, 16,729 participants; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>). Again there were no differences in 30‐day mortality (test for subgroup differences: Chi² = 0.43, df = 3 (P = 0.93), I² = 0%; <a href="./references#CD002042-fig-0011" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD002042-sec-0072"> <h6 class="title">Subgroup analysis of 30‐day mortality: prospectively registered versus unregistered trials or trials for which registration was post hoc </h6> <p>We stratified 30‐day mortality according to whether or not trials were prospectively registered. Of the 31 trials that contributed data to our primary outcome, 18 (with 12,932 participants) were prospectively registered. The RR for 30‐day mortality provided by pooling data from these trials was 1.08 (95% CI 0.89 to 1.31). Pooling of the 13 unregistered trials (3797 participants) led to a RR of 0.81 (95% CI 0.66 to 1.00). The test for subgroup differences indicated a difference between subgroups: Chi² = 4.06, df = 1 (P = 0.04), I² = 75.4%; <a href="./references#CD002042-fig-0012" title="">Analysis 2.1</a>), but in neither group was there a clear effect for either transfusion strategy. </p> </section> <section id="CD002042-sec-0073"> <h6 class="title">Sensitivity analysis</h6> <p>There were no differences in 30‐day mortality between trials with low versus unclear or high risk of bias in one bias domain (i.e. allocation concealment) (<a href="./references#CD002042-fig-0013" title="">Analysis 3.1</a>). The RR was 1.01 (95% CI 0.87 to 1.18) in trials with low risk of bias for allocation concealment and 0.84 (95% CI 0.51 to 1.39) for trials with unclear or high risk of bias for allocation concealment. Testing for subgroup differences yielded the following: Chi² = 0.47, df = 1 (P = 0.49); I² = 0%. </p> </section> </section> </section> <section id="CD002042-sec-0074"> <h4 class="title">Secondary outcomes</h4> <p>As detailed below, none of the other analyses on mortality or morbidity showed differences between the groups compared. </p> <section id="CD002042-sec-0075"> <h5 class="title">Mortality at other time intervals</h5> <p>We analysed mortality at hospital discharge (15 trials; 6597 participants; <a href="./references#CD002042-fig-0014" title="">Analysis 4.1</a>), at 90 days (7 trials, 4143 participants; <a href="./references#CD002042-fig-0015" title="">Analysis 4.2</a>), and at six months or longer (2 trials, 4702 participants; <a href="./references#CD002042-fig-0016" title="">Analysis 4.3</a>). </p> <p>There were no differences in mortality between transfusion strategies at hospital discharge (RR 0.86, 95% CI 0.72 to 1.03; Chi² = 15.36, df = 13 (P = 0.29); I² = 15%), but the 90‐day mortality was higher for the restrictive strategy (RR 1.13, 95% CI 1.02 to 1.25; Chi² = 5.28, df = 6; P = 0.41; I² = 0%).   </p> <p>The two largest included trials (<a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>; <a href="./references#CD002042-bbs2-0032" title="GalanJ , MateoE , CarmonaP , GajateL , MazerCD , Martinez-ZapataMJ .Restrictive or liberal transfusion for cardiac surgery: Spanish TRICCS results of a randomized multicenter international parallel open-label clinical trial [Transfusión Restrictiva o liberal en cirugía cardiaca: Resultados españoles de un ensayo clínico aleatorizado, multicéntrico, internacional, paralelo y abierto]. Medicina Intensiva (English edition)2020;In press/epub: no volume:Epub: no pagination. [DOI: 10.1016/j.medin.2020.07.011]GargAX , BadnerN , BagshawSM , CuerdenMS , FergussonDA , GregoryAJ , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Safety of a restrictive versus liberal approach to red blood cell transfusion on the outcome of AKI in patients undergoing cardiac surgery: a randomized clinical trial. Journal of the American Society of Nephrology: JASN2019;30(7):1294-304. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Restrictive or liberal red-cell transfusion for cardiac surgery. New England Journal of Medicine2017;377(22):2133-44. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. New England Journal of Medicine2018;379(13):1224-33. ">Mazer 2017</a>), reported mortality at six months or beyond in separate publications (<a href="./references#CD002042-bbs2-0099" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9.">Carson 2015</a>; <a href="./references#CD002042-bbs2-0119" title="MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. New England Journal of Medicine2018;379(13):1224-33.">Mazer 2018</a>). Results suggest no clear differences (RR 0.98, 95% CI 0.79 to 1.22; P = 0.84; <a href="./references#CD002042-fig-0016" title="">Analysis 4.3</a>). Both trials employed similar transfusion strategies. </p> <p>The results of mortality analyses at hospital discharge, at 30 days, and at six months are consistent. The results of mortality analyses at 90 days were gathered from a smaller number of participants and are dominated by two particular trials (<a href="./references#CD002042-bbs2-0002" title="BergaminFS , AlmeidaJP , LandoniG , GalasF , FukushimaJT , FominskiyE , et al.Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients: randomized controlled trial. Critical Care Medicine2017;45(5):766-73. ">Bergamin 2017</a>; <a href="./references#CD002042-bbs2-0023" title="HolstLB , HaaseN , WetterslevJ , WernermanJ , GuttormsenAB , KarlssonS , et al.Lower versus higher hemoglobin threshold for transfusion in septic shock. New England Journal of Medicine2014;371(15):1381-91. RygårdSL , HolstLB , WetterslevJ , WinkelP , JohanssonPI , WernermanJ , et al, TRISS Trial Group, Scandinavian Critical Care Trials Group.Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Medicine2016;42(11):1685-94. ">Holst 2014</a>), limiting interpretation. </p> <p>Complex analysis in <a href="./references#CD002042-bbs2-0022" title="HoffCM , HansenHS , OvergaardM , GrauC , JohansenJ , BentzenO , et al.The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiotherapy and Oncology2011;1998:28-33. [DOI: 10.1016/j.radonc.2010.09.024]HoffCM , LassenP , EriksenJG , HansenHS , SpechtL , OvergaardM , et al.Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. Acta Oncologica2011;50(7):1006-14. OvergaardJ , HansenHS , OvergaardM , BastholtL , BerthelsenA , SpechtL , et al.A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology1998;46:135-46. OvergaardJ , HansenHS , SpechtL , OvergaardM , GrauC , AndersonE , et al.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 &amp; 7 randomised controlled trial. Lancet2003;362:933-40. ">Hoff 2011</a> had the main purpose of defining a role for the drug nimorazole in patients receiving radiotherapy with head and neck squamous cell carcinoma (HNSCC); additional randomisation steps addressed the value of transfusion in participants who had low haemoglobin levels preradiation. This analysis combined data from a trial comparing the drug with placebo and from another comparing drug delivery at different intervals. We could not incorporate five‐year mortality data within our meta‐analysis, but investigators found that although transfusion improved haemoglobin levels before and during radiation treatment, it did not improve other outcomes for patients and may have had a negative impact on survival.  </p> </section> <section id="CD002042-sec-0076"> <h5 class="title">Clinical outcomes</h5> <p>We noted no differences in any groups compared for any of the clinical outcomes. </p> <section id="CD002042-sec-0077"> <h6 class="title">Cardiac events</h6> <p>Eleven trials reported data on post‐enrolment cardiac events in 5577 participants. Risks of cardiac events (myocardial infarction, cardiac arrhythmias, cardiac arrest, pulmonary oedema, and angina) were not increased by the use of restrictive transfusion strategies (RR 1.03, 95% CI 0.80 to 1.32; <a href="./references#CD002042-fig-0017" title="">Analysis 5.1</a>). Heterogeneity between these trials was moderate (Chi² = 24.09, df = 10 (P = 0.007); I² = 58%). It is possible that participants were counted in more than one category for this composite outcome because these disorders are clinically inter‐related (e.g. a participant could have angina that might lead to pulmonary oedema). </p> </section> <section id="CD002042-sec-0078"> <h6 class="title">Myocardial infarction</h6> <p>Twenty‐three trials reported data for myocardial infarction (fatal and non‐fatal) for 14,730 participants after random allocation to liberal or restrictive transfusion arms. There was no difference between restrictive and liberal transfusion strategies (RR 1.04, 95% CI 0.87 to 1.24; <a href="./references#CD002042-fig-0018" title="">Analysis 5.2</a>). We found no evidence of heterogeneity between trials (Chi² = 18.63, df = 21; P = 0.61; I² = 0%). </p> </section> <section id="CD002042-sec-0079"> <h6 class="title">Congestive heart failure</h6> <p>Sixteen trials reported data for congestive heart failure in 7247 participants. There was no difference between restrictive and liberal transfusion strategies (RR 0.83, 95% CI 0.53 to 1.29; <a href="./references#CD002042-fig-0019" title="">Analysis 5.3</a>). Heterogeneity between trials was moderate (Chi² = 22.06, df = 13; P = 0.05; I² = 41%). </p> </section> <section id="CD002042-sec-0080"> <h6 class="title">Cerebrovascular accident: stroke</h6> <p>Nineteen trials reported data for stroke in 13,985 participants. There was no difference between restrictive and liberal transfusion strategies (RR 0.84, 95% CI 0.64 to 1.09; <a href="./references#CD002042-fig-0020" title="">Analysis 5.4</a>). Heterogeneity between trials was not important (Chi² = 12.80, df = 18; P = 0.80; I² = 0%). </p> </section> <section id="CD002042-sec-0081"> <h6 class="title">Rebleeding</h6> <p>Eight trials reported data for rebleeding in 3412 participants. There was no difference between restrictive and liberal transfusion strategies (RR 0.80, 95% CI 0.59 to 1.09; <a href="./references#CD002042-fig-0021" title="">Analysis 5.5</a>). Heterogeneity between trials was not important (Chi² = 12.24, df = 7; P = 0.09; I² = 43%). </p> </section> <section id="CD002042-sec-0082"> <h6 class="title">Sepsis/bacteraemia</h6> <p>Nine trials reported data for sepsis/bacteraemia in 4352 participants. There was no difference between restrictive and liberal transfusion strategies (RR 1.06, 95% CI 0.86 to 1.30; <a href="./references#CD002042-fig-0022" title="">Analysis 5.6</a>). Heterogeneity between these trials was not important (Chi² = 8.56, df = 7; P = 0.29; I² = 18%). </p> </section> <section id="CD002042-sec-0083"> <h6 class="title">Pneumonia</h6> <p>Sixteen trials reported data for pneumonia in 6666 participants. There was no difference between restrictive and liberal transfusion strategies (RR 0.97, 95% CI 0.84 to 1.13; <a href="./references#CD002042-fig-0023" title="">Analysis 5.7</a>). Heterogeneity between these trials was not important (Chi² = 11.48, df = 15; P = 0.72; I² = 0.0%). </p> </section> <section id="CD002042-sec-0084"> <h6 class="title">Infection</h6> <p>Twenty‐five trials including 17,104 participants reported data for all infections defined as sepsis/bacteraemia, pneumonia, and wound infection. There was no difference between restrictive and liberal transfusion strategies (RR 0.97, 95% CI 0.88 to 1.07; <a href="./references#CD002042-fig-0024" title="">Analysis 5.8</a>). Heterogeneity between these trials was not important (Chi² = 21.42, df = 14; P = 0.09; I² = 35%). </p> </section> <section id="CD002042-sec-0085"> <h6 class="title">Thromboembolism</h6> <p>Thirteen trials reported data for thromboembolism for 4201 participants. We calculated the odds ratio using the Peto method because the risk of thromboembolism was less than 1%. There was no difference between restrictive and liberal transfusion strategies (Peto odds ratio 1.11, 95% CI 0.65 to 1.88; <a href="./references#CD002042-fig-0025" title="">Analysis 5.9</a>). Heterogeneity between these trials was not important (Chi² = 14.48, df = 11; P = 0.21; I² = 24%). </p> </section> <section id="CD002042-sec-0086"> <h6 class="title">Renal failure</h6> <p>Fifteen trials reported data on renal failure in 12,531 participants. There was no difference between restrictive and liberal transfusion strategies (RR 1.03, 95% CI 0.92 to 1.16; <a href="./references#CD002042-fig-0026" title="">Analysis 5.10</a>). Heterogeneity between these trials was not important (Chi² = 12.77, df = 14; P = 0.55%; I² = 0%). </p> </section> <section id="CD002042-sec-0087"> <h6 class="title">Mental confusion</h6> <p>Nine trials reported data for mental confusion in 6442 participants. There was no difference between restrictive and liberal transfusion strategies (RR 1.11, 95% CI 0.88 to 1.40; <a href="./references#CD002042-fig-0027" title="">Analysis 5.11</a>). Heterogeneity between these trials was not important (Chi² = 10.29, df = 8; P = 0.24; I² = 22%). </p> </section> <section id="CD002042-sec-0088"> <h6 class="title">Functional recovery and fatigue</h6> <p>In total, 24 trials reported results showing differing scores for functional and mental outcomes and fatigue (<a href="./references#CD002042-bbs2-0004" title="BraceyAW , RadovancevicR , RiggsSA , HoustonS , CozartH , VaughnWK , et al.Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion1999;39(10):1070-7. ">Bracey 1999</a>; <a href="./references#CD002042-bbs2-0006" title="CarsonJL , TerrinML , BartonFB , AaronR , GreenburgAG , HeckDA , et al.A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion1998;38(6):522-9. ">Carson 1998</a>; <a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>; <a href="./references#CD002042-bbs2-0010" title="deAlmeidaJP , VincentJL , GalasFR , deAlmeidaEP , FukushimaJT , OsawaEA , et al.Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology2015;122(1):29-38. ">de Almeida 2015</a>; <a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0013" title="FanYX , LiuFF , JiaM , YangJJ , ShenJC , ZhuGM , et al.Comparison of restrictive and liberal transfusion strategy on postoperative delirium in aged patients following total hip replacement: a preliminary study. Archives of Gerontology and Geriatrics2014;59(1):181-5. ">Fan 2014</a>; <a href="./references#CD002042-bbs2-0014" title="FossNB , KristensenMT , JensenPS , PalmH , KrasheninnikoffM , KehletH .The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion2009;49(2):227-34. ">Foss 2009</a>; <a href="./references#CD002042-bbs2-0015" title="GilliesMA , GhaffarS , MoppettIK , DochertyAB , ClarkeS , ReaN , et al.A restrictive versus liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). British Journal of Anaesthesia2020;126:77-86. ">Gillies 2020</a>; <a href="./references#CD002042-bbs2-0016" title="GobattoAL , LinkMA , SollaDJ , BassiE , TiernoPF , PaivaW , et al.Transfusion requirements after head trauma: a randomized feasibility controlled trial. Critical Care2019;23(1):89. [CTG: NCT02203292 ]">Gobatto 2019</a>; <a href="./references#CD002042-bbs2-0017" title="BlandfortS , GregersenM , BorrisLC , DamsgaardEM .Blood transfusion strategy and risk of postoperative delirium in nursing homes residents with hip fracture. A post hoc analysis based on the TRIFE randomized controlled trial. Aging Clinical and Experimental Research2017;29(3):459-66. GregersenM , BorrisLC , DamsgaardEM .Blood transfusion and overall quality of life after hip fracture in frail elderly patients - the transfusion requirements in frail elderly randomized controlled trial. Journal of the American Medical Directors Association2015;16(9):762-6. GregersenM , BorrisLC , DamsgaardEM .Postoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture: the TRIFE randomized controlled trial. Acta Orthopaedica2015;86(3):1-10. GregersenM , DamsgaardEM , BorrisLC .Blood transfusion and risk of infection in frail elderly after hip fracture surgery: the TRIFE randomized controlled trial. European Journal of Orthopaedic Surgery &amp; Traumatology2015;25(6):1031-8. ">Gregersen 2015</a>; <a href="./references#CD002042-bbs2-0019" title="HajjarLA , VincentJL , GalasFR , NakamuraRE , SilvaCM , SantosMH , et al.Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA2010;304(14):1559-67. ">Hajjar 2010</a>; <a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>; <a href="./references#CD002042-bbs2-0025" title="JansenAJ , vanden BoschJ .Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold [Letter to the Editor]. Transfusion2020;60(4):879-81. [ISRCTN: ISRCTN43616311]">Jansen 2020</a>; <a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a>; <a href="./references#CD002042-bbs2-0031" title="LotkePA , BarthP , GarinoJP , CookEF .Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration. Journal of Arthroplasty1999;14(6):647-50. ">Lotke 1999</a>; <a href="./references#CD002042-bbs2-0033" title="MurphyGJ , PikeK , RogersCA , WordsworthS , StokesEA , AngeliniGD , et al.Liberal or restrictive transfusion after cardiac surgery. New England Journal of Medicine2015;372:997-1008. StokesEA , WordsworthS , BargoD , PikeK , RogersCA , BrierleyRC , et al.Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open2016;6(8):e011311. ">Murphy 2015</a>; <a href="./references#CD002042-bbs2-0035" title="NielsenK , JohanssonPI , DahlB , WagnerM , FrausingB , BørglumJ , et al.Perioperative transfusion threshold and ambulation after hip revision surgery - a randomized trial. BMC Anesthesiology2014;14:89-98. ">Nielsen 2014</a>; <a href="./references#CD002042-bbs2-0037" title="ParkerMJ .Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery. Injury2013;44(12):1916-8. ">Parker 2013</a>; <a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>; <a href="./references#CD002042-bbs2-0041" title="So-OsmanC , NelissenR , BrandR , FaberF , SlaaRT , StiggelboutA , et al.The impact of a restrictive transfusion trigger on post-operative complication rate and well-being following elective orthopaedic surgery: a post-hoc analysis of a randomised study. Blood Transfusion (Trasfusione del sangue)2013;11(2):289-95. So-OsmanC , NelissenR , Te SlaaR , CoeneL , BrandR , BrandA .A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells. Vox Sanguinis2010;98(1):56-64. So-OsmanC .A restrictive transfusion trigger is a method for blood saving in elective orthopaedic surgery. Vox Sanguinis2004;87(Suppl 3):52. ">So‐Osman 2013</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>; <a href="./references#CD002042-bbs2-0043" title="TayJ , AllanDS , ChatelainE , CoyleD , ElemaryM , FulfordA , et al.Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial. Journal of Clinical Oncology2020;38(13):1463-73. ">Tay 2020</a>; <a href="./references#CD002042-bbs2-0046" title="WalshTS , BoydJA , WatsonD , HopeD , LewisS , KrishanA , et al.Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. Critical Care Medicine2013;41(10):2354-63. ">Walsh 2013</a>; <a href="./references#CD002042-bbs2-0048" title="YakymenkoD , FrandsenKB , ChristensenIJ , NorgaardA , JohanssonPI , DaugaardG , et al.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfusion Medicine2018;28(3):208-15. ">Yakymenko 2018</a>). However, there was considerable heterogeneity in the methods and questionnaires used, and in the timing of assessments, which precluded meta‐analysis. No larger trials reported significant differences in trial‐specific functional or mental outcomes, or fatigue. Exploratory findings for quality of life measures from two trials in a haematological setting showed possible beneficial effects of liberal transfusion, but these results need to be evaluated in larger trials (<a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>; <a href="./references#CD002042-bbs2-0048" title="YakymenkoD , FrandsenKB , ChristensenIJ , NorgaardA , JohanssonPI , DaugaardG , et al.Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfusion Medicine2018;28(3):208-15. ">Yakymenko 2018</a>). Three trials reported functional outcomes for orthopaedic surgery participants, but assessment of these functional measures in different ways precluded pooling in a meta‐analysis. </p> </section> </section> </section> <section id="CD002042-sec-0089"> <h4 class="title">Other outcomes ‐ blood transfusions and haemoglobin</h4> <p>Results for transfusion and haemoglobin data were presented across the included trials, and provide key information about the implementation of transfusion protocols in trials. We anticipated high levels of heterogeneity in the analysis of transfusion outcomes, for several reasons. In particular, standard 'control' rates of transfusion practice are highly variable across the clinical specialties in which trials were identified for this update. These differing policies regarding rates of transfusion reflect practice defined in specialty guidelines and recommendations. It is usually recommended that pooled estimates are not presented when heterogeneity is so high. However, we present the pooled results here, as there was consistency regarding the direction of effect; further justification for this is provided in the <a href="#CD002042-sec-0096">Discussion</a>. </p> <section id="CD002042-sec-0090"> <h5 class="title">Proportion of participants transfused</h5> <p>This analysis demonstrates differences in the proportions of participants transfused with RBCs in the liberal and restrictive trial arms. Data on the proportions of transfused participants were available from 42 trials (20,057 participants). The implementation of a restrictive transfusion trigger across all trials reduced the relative risk of receiving at least one RBC transfusion by 41% (RR 0.59, 95% CI 0.53 to 0.66; <a href="./references#CD002042-fig-0028" title="">Analysis 6.1</a>). Heterogeneity between these trials was substantial (Chi² = 1104.24, df = 41 (P &lt; 0.00001); I² = 96%); however, there was consistency in the direction of the effect. </p> <p>The proportions of participants transfused in liberal and restrictive trial arms were very different across different clinical contexts (<a href="./references#CD002042-fig-0029" title="">Analysis 6.2</a>); differences between subgroups were manifest (Chi² = 25.33, df = 6 (P = 0.0003); I² = 76.3%). There was a tendency for great variation within subgroups also (e.g. in the subgroup of critical care trials, heterogeneity was high (I² = 92%)). The acute blood loss/trauma subgroup included diverse underlying illnesses for haemorrhage, including comorbidities, leading to an I² of 96%. For example, <a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a> recruited young (otherwise healthy) women with postpartum haemorrhage, and <a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a> enrolled older participants with gastrointestinal bleeding, characterised by many comorbidities. <a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a> contributed to a large extent to the high heterogeneity in this subgroup, and temporarily removing it from the analysis reduced heterogeneity to 77%. By contrast, participants enrolled in the subgroup of cardiac surgery trials demonstrated less variability in risk of transfusion across trials, and in this subgroup, we observed no important heterogeneity. This sensitivity analysis, although post hoc, highlights how transfusion policies in this setting differed from adult protocols in a critical care setting. </p> <p>When the difference in haemoglobin thresholds between restrictive and liberal arms was 2.0 g/dL or more, the RR of transfusion was 0.57 (95% CI 0.50 to 0.64; <a href="./references#CD002042-fig-0030" title="">Analysis 6.3</a>.1), which means there was a reduction in transfusion of 43% in the restrictive arm compared to the liberal arm. When the difference in haemoglobin transfusion thresholds between restrictive and liberal transfusion arms was less than 2.0 g/dL, the RR was 0.80 (95% CI 0.63 to 1.02; <a href="./references#CD002042-fig-0030" title="">Analysis 6.3</a>.2), which means there was a reduction in transfusion of 20% (test for subgroup differences: Chi² = 6.11, df = 1 (P = 0.01), I² = 83.6%). </p> <p>There was no clear difference in the proportions of participants transfused between the 17 studies (11,919 partipants) that used a restrictive strategy of 7.5 g/dL or less as a threshold (RR 0.55, 95% CI 0.48 to 0.64) versus the 19 studies (6035 participants) that used a restrictive threshold of 8.0 g/dL to 9.0 g/dL (RR 0.59, 95% CI 0.48 to 0.72; test for subgroup differences: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%; <a href="./references#CD002042-fig-0031" title="">Analysis 6.4</a>). </p> <p>The forest plot for the proportions of participants transfused displays grouping of trials with a RR around 0.5 for receiving a transfusion in the restrictive transfusion arm (<a href="#CD002042-fig-0005">Figure 5</a>), which is consistent with the overall observation that participants in the restrictive arm were transfused approximately half as often as those in the liberal arm. As expected, there were no trials in which participants in the restrictive arm were transfused more often than those in the liberal arm. </p> <div class="figure" id="CD002042-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Blood transfusions, outcome: 2.1 Participants exposed to blood transfusion (all trials)" data-id="CD002042-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Blood transfusions, outcome: 2.1 Participants exposed to blood transfusion (all trials) </p> </div> </div> </div> </section> <section id="CD002042-sec-0091"> <h5 class="title">Quantity of RBCs transfused</h5> <p>Seventeen trials reported the quantities of blood transfused. Most trials (40) provided some information on dose of red cells, or an algorithm or a target haemoglobin for transfusion, although the level of detail varied considerably. Among the three paediatric trials, two trials indicated a range for transfusion dose of 10 mL/kg or 10 mL/kg to 15 mL/kg (<a href="./references#CD002042-bbs2-0001" title="AkyildizB , Ulgen TekerekN , PamukcuO , DursunA , KarakukcuM , NarinN , et al.Comprehensive analysis of liberal and restrictive transfusion strategies in pediatric intensive care unit. Journal of Tropical Pediatrics2018;64(2):118-25. ">Akyildiz 2018</a>; <a href="./references#CD002042-bbs2-0039" title="RobitailleN , LacroixJ , AlexandrovL , ClaytonL , CortierM , SchultzKR , et al.Excess of veno-occlusive disease in a randomized trial on a higher trigger for red cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biology of Blood and Marrow Transplantation2013;19:468-73. ">Robitaille 2013</a>), and one trial reported a target haemoglobin of 8.5 g/dL to 9.5 g/dL in the restrictive arm, and 11.0 g/dL to 12.0 g/dL in the liberal arm (<a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>). </p> <p>Use of a restrictive transfusion trigger resulted in an average saving of 1.21 units of RBCs per transfused participant (weighted mean difference (MD) ‐1.21, 95% CI ‐1.67 to ‐0.75; <a href="./references#CD002042-fig-0032" title="">Analysis 6.5</a>). Heterogeneity between these trials again was substantial (Chi² = 1173.58, df = 16 (P &lt; 0.00001); I² = 91%); however, there was consistency in the direction of the effect. </p> </section> <section id="CD002042-sec-0092"> <h5 class="title">Transfusion‐specific reactions  </h5> <p>Transfusion reactions appeared to be neither well nor consistently reported, and over half (26/48) of the trials provided no information (a further two trials mentioned collecting data on such reactions but did not report them). Of the remaining 20 trials, eight reported prospectively seeking transfusion‐related reactions, but found that none had occurred in either group. Twelve trials reported transfusion reactions in a heterogeneous manner that was not suited to quantitative pooling, given the variability in methods of reporting and the assigning of severity and causality assessment to transfusion. </p> <section id="CD002042-sec-0093"> <h6 class="title">Haemoglobin or haematocrit concentration</h6> <p>Nineteen trials reported the difference in haemoglobin or haematocrit levels between liberal and restrictive transfusion arms. Measures included averages (e.g. averages of different data points across a participant's stay in ICU) as well as single data points (e.g. the last measurement before discharge). When we pooled data (without regard to timing), participants assigned to a restrictive strategy had a lower haemoglobin concentration than participants assigned to a liberal transfusion strategy (mean difference ‐1.26, 95% CI ‐1.55 to ‐0.96; analysis not shown). Heterogeneity between these trials was substantial (Chi² = 914.39, df = 18 (P &lt; 0.00001); I² = 98%), however, there was consistency in the direction of the effect. </p> </section> <section id="CD002042-sec-0094"> <h6 class="title">Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery and in those with myocardial infarction  </h6> <p>We analysed morbidity outcomes for a subgroup of participants with underlying cardiovascular disease, defined as those undergoing cardiac surgery or vascular surgery and those with myocardial infarction. There was no difference between restrictive and liberal transfusion strategies for myocardial infarction (RR 1.01, 95% CI 0.81 to 1.26; 8 trials, 8219 participants; <a href="./references#CD002042-fig-0033" title="">Analysis 7.1</a>); renal failure (RR 1.07, 95% CI 0.89 to1.28; 7 trials, 9198 participants; <a href="./references#CD002042-fig-0034" title="">Analysis 7.2</a>); infection (RR 1.00, 0.79 to 1.28; 8 trials, 9219 participants; <a href="./references#CD002042-fig-0035" title="">Analysis 7.3</a>); thromboembolism (RR 1.02, 95% CI 0.11 to 9.55; 3 trials, 239 participants; <a href="./references#CD002042-fig-0037" title="">Analysis 7.5</a>); congestive heart failure (RR 0.77, 95% CI 0.24 to 2.43; 4 trials, 858 participants; <a href="./references#CD002042-fig-0036" title="">Analysis 7.4</a>); or cerebrovascular accident (RR 0.98, 95% CI 0.22 to 4.26; 4 trials, 905 participants; <a href="./references#CD002042-fig-0038" title="">Analysis 7.6</a>).  </p> </section> </section> <section id="CD002042-sec-0095"> <h5 class="title">Economic and costing analyses</h5> <p>The protocol for this review did not include plans for formal economic analysis: findings from included trials are reported as a narrative summary only. Many trials included within this review discussed the potential cost implications of favouring a restrictive strategy or recommended cost‐effectiveness analysis in future research without providing data (e.g. <a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0031" title="LotkePA , BarthP , GarinoJP , CookEF .Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration. Journal of Arthroplasty1999;14(6):647-50. ">Lotke 1999</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>). </p> <p>Investigators in three trials went further, making estimates based on their own data when different transfusion strategies were compared for patients with severe burns (<a href="./references#CD002042-bbs2-0036" title="PalmieriTL , HolmesJH , ArnoldoB , PeckM , CochranA , KingBT , et al.Restrictive transfusion strategy is more effective in massive burns: results of the TRIBE multicenter prospective randomized trial. Military Medicine2019;184 (Suppl 1):11-5. [DOI: doi: 10.1093/milmed/usy279]PalmieriTL , HolmesJH , ArnoldoB , PeckM , PotenzaB , CochranA , et al.Transfusion requirement in burn care evaluation (TRIBE). A multicenter randomized prospective trial of blood transfusion in major burn injury. Annals of Surgery2017;266:595-602. ">Palmieri 2017</a>), requiring hematopoietic cell transplantation (HCT) (<a href="./references#CD002042-bbs2-0043" title="TayJ , AllanDS , ChatelainE , CoyleD , ElemaryM , FulfordA , et al.Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial. Journal of Clinical Oncology2020;38(13):1463-73. ">Tay 2020</a>), or with cardiac issues (<a href="./references#CD002042-bbs2-0027" title="KochCG , SesslerDI , MaschaEJ , Sabik JF 3rd, LiL , DuncanAI , et al.A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Annals of Thoracic Surgery2017;104(4):1243-50. ">Koch 2017</a>). The former two reported that a restrictive strategy would reduce costs considerably; the latter stated only that "health care costs were similar between groups". </p> <p>Of the six RCTs in which formal economic analysis was specified as an outcome, two were conducted in elective surgery (cardiac or infrainguinal) (<a href="./references#CD002042-bbs2-0005" title="BushRL , PevecWC , HolcroftJW .A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. American Journal of Surgery1997;174(2):143-8. ">Bush 1997</a>; <a href="./references#CD002042-bbs2-0033" title="MurphyGJ , PikeK , RogersCA , WordsworthS , StokesEA , AngeliniGD , et al.Liberal or restrictive transfusion after cardiac surgery. New England Journal of Medicine2015;372:997-1008. StokesEA , WordsworthS , BargoD , PikeK , RogersCA , BrierleyRC , et al.Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open2016;6(8):e011311. ">Murphy 2015</a>). The smaller, older trial (n = 99) found a substantial difference favouring the restrictive group; the latter trial included more than 2000 participants and reported, "Total costs did not differ significantly between the groups". One trial on older, critically ill patients requiring mechanical ventilation reported increased costs for this population within the group treated with a restrictive strategy, but this was a small trial, and there was a small difference in survival outcomes (<a href="./references#CD002042-bbs2-0046" title="WalshTS , BoydJA , WatsonD , HopeD , LewisS , KrishanA , et al.Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. Critical Care Medicine2013;41(10):2354-63. ">Walsh 2013</a>). </p> <p>A large trial considering outcomes of women with acute anaemia after postpartum haemorrhage concluded that intervention was more expensive per woman than non‐intervention, with only a small improvement in health‐related quality of life after RBC transfusion (<a href="./references#CD002042-bbs2-0038" title="PrickBW , DuvekotJJ , van derMoerPE , vanGemundN , van derSalmPC , JansenAJ , et al.Cost-effectiveness of red blood cell transfusion vs. non-intervention in women with acute anaemia after postpartum haemorrhage. Vox Sanguinis2014;107(4):381-8. [DOI: 10.1111/vox.12181]PrickBW , JansenAJ , SteegersEA , HopWC , Essink-BotML , Uyl-de GrootCA , et al.Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121(8):1005-14. ">Prick 2014</a>). </p> <p>A trial on upper GI bleeding was a feasibility trial and did report results, confirming that transfusions were an important driver of costs alongside inpatient stay and endoscopy (<a href="./references#CD002042-bbs2-0095" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230.">Campbell 2015</a>; <a href="./references#CD002042-bbs2-0024" title="CampbellHE , StokesEA , BargoD , LoganRF , MoraA , HodgeR , et al.Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open2015;5(4):e007230. JairathV , KahanBC , GrayA , DoréCJ , MoraA , JamesMW , et al.Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet2015;386(9989):137-44. [ISRCTN: ISRCTN85757829]">Jairath 2015</a>). A large trial on myocardial infarction concluded that significant savings were likely with the use of a restrictive strategy, although a formal publication is still pending (<a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a>). For this trial, the cost‐effectiveness endpoint was the incremental cost‐effectiveness ratio (ICER) at 30 days. It is reported that "the restrictive strategy had an 84% probability of being cost‐saving while improving clinical outcomes, i.e. "dominant" from a medico‐economic standpoint" (conference proceeding; <a href="https://protect-eu.mimecast.com/s/RLjwCnO14c6OpNRf9y2j_?domain=eurekalert.org" target="_blank">https://www.eurekalert.org/news-releases/775135</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002042-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002042-sec-0096"></div> <section id="CD002042-sec-0097"> <h3 class="title" id="CD002042-sec-0097">Summary of main results</h3> <p>When compared with liberal transfusion strategies, restrictive transfusion strategies did not increase or decrease the risk of 30‐day mortality (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.86 to 1.15; 31 trials, 16,729 participants; I² = 30%; moderate‐quality evidence) or of any of the other outcomes assessed (i.e. myocardial infarction, stroke (high‐quality evidence), thromboembolism (moderate‐quality evidence), and congestive heart failure (low‐quality evidence)). Restrictive transfusion strategies led to a reduction of 41% in the number of participants who received at least one unit of blood; an overall red blood cell (RBC) transfusion requirement that was approximately 1.2 units lower per participant; and a mean haemoglobin concentration that was around 1.26 g/dL lower than in liberal transfusion groups. </p> <p>These findings are based on an analysis of 48 randomised controlled trials (RCTs) in this updated review that compared outcomes for participants allocated to receive transfusions of RBCs at different haemoglobin concentration thresholds. These trials enrolled 20,967 participants across diverse patient populations; most participants were adults. Since our previous 2016 review, we have included an additional 17 randomised trials. </p> <p>Meta‐analyses provided no evidence that restrictive transfusion policies harmed participants, or that participants benefited from the use of liberal transfusion policies, within the parameters defined in these trials. Put another way, there was no evidence of an impact on clinically important outcomes when a restrictive RBC transfusion policy rather than a liberal RBC transfusion policy was followed. Results indicate that transfusion strategy did not influence the risk of cardiovascular events, including myocardial infarction, congestive heart failure, or stroke, although statistical heterogeneity was observed in trials that evaluated congestive heart failure (P = 0.01; I² = 57%).  </p> <p>In this updated review, only three trials enrolled children and the results in paediatrics were dominated by findings from a single, large pragmatic trial (<a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>), which observed no benefit for liberal transfusion in critically ill children. Another very small randomised trial recruited only six children undergoing bone marrow transplantation and was stopped because of concerns about an excess of veno‐occlusive disease in the liberal arm (<a href="./references#CD002042-bbs2-0039" title="RobitailleN , LacroixJ , AlexandrovL , ClaytonL , CortierM , SchultzKR , et al.Excess of veno-occlusive disease in a randomized trial on a higher trigger for red cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biology of Blood and Marrow Transplantation2013;19:468-73. ">Robitaille 2013</a>); we await the results of a further ongoing trial in this setting (<a href="./references#CD002042-bbs2-0077" title="ISRCTN17438123.A small pilot feasibility study for a possible randomised control trial comparing clinical outcomes and quality of life following two different transfusion strategies in children undergoing allogeneic hematopoietic stem cell transplant (HSCT) [RePAST: Red cell transfusion in Paediatric Allogeneic HSCT - A feasibility randomised controlled trial comparing restrictive versus liberal red cell (RBC) transfusion strategies in children undergoing allogeneic haematopoietic stem cell transplant (HSCT)]. www.isrctn.com/ISRCTN17438123 (first posted 23 May 2019). [ISRCTN: ISRCTN17438123]">ISRCTN17438123</a>; see <a href="./references#CD002042-bbs1-0004" title="">Ongoing studies</a>).  </p> <section id="CD002042-sec-0098"> <h4 class="title">Subgroup analyses</h4> <p>With regard to our predefined clinical subgroups, results indicate that risk of death and other adverse events were not impacted by liberal or restrictive transfusion thresholds for most analyses. This is important because there are pathophysiological reasons to postulate why transfusion might impact clinical outcomes differently in different patient populations as the result of factors such as duration of anaemia (short‐term transfusion dependence in critical illness versus long‐term transfusion dependence in bone marrow failure) or presence or absence of an underlying restriction in cardiac function (<a href="./references#CD002042-bbs2-0106" title="DochertyAB , O'DonnellR , BrunskillS , TrivellaM , DoreeC , HolstL , et al.Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ2016;352:i1351.">Docherty 2016</a>).  </p> <p>However, for patients with acute blood loss and for those with acute myocardial infarction, mortality may be influenced by a liberal or restrictive transfusion strategy, although the test for differences in 30‐day mortality between subgroups showed no differences (P = 0.13; I² = 41.2%). In three trials (1522 participants) including people with gastrointestinal bleeding (included in the acute blood loss or trauma grouping), a restrictive transfusion strategy was associated with a 35% lower risk of 30‐day mortality compared with a liberal transfusion strategy. The mechanism responsible for this significantly reduced risk of death may be lower risk of rebleeding under restrictive transfusion regimens (RR 0.65, 95% CI 0.43 to 0.97; <a href="./references#CD002042-fig-0009" title="">Analysis 1.3</a>.4). The reason for this effect is not known, but it may reflect higher vascular pressures following transfusion in the liberal transfusion group compared with the restrictive transfusion group.  </p> <p>Patients with acute myocardial infarction are another important patient subpopulation. In the 2016 update (<a href="./references#CD002042-bbs2-0176" title="CarsonJL , StanworthSJ , RoubinianN , FergussonDA , TriulziD , DoreeC , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Carson 2016b</a>), two small trials included people with myocardial infarction (154 participants) for whom 30‐day mortality was 3.88 times higher in the restrictive transfusion group than in the liberal transfusion group (95% CI 0.83 to 18.13). In one trial, 12.7% of participants (n = 14) undergoing cardiac catheterisation had stable coronary artery disease but did not have acute myocardial infarction (<a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>). These results have been extended by inclusion in the meta‐analysis of <a href="./references#CD002042-bbs2-0012" title="DucrocqG , Gonzalez-JuanateyJR , PuymiratE , LemesleG , CachanadoM , Durand-ZaleskiI , et al.Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA2021;325(6):552-60. ">Ducrocq 2021</a>, which enrolled 666 patients and reported results for a composite major adverse cardiac events (MACE) outcome of all‐cause mortality, stroke, recurrent myocardial infarction, or emergency revascularisation in 11.1% of the restrictive group and in 14.2% of the liberal group. Deaths from any cause occurred in 5.6% of the restrictive group and in 7.7% of the liberal group. With the addition of this trial, the relative risk for 30‐day mortality was closer to 1.0, with wide confidence intervals (RR 1.61, 95% CI 0.38 to 6.88). A 3500‐patient trial in acute myocardial infarction, called 'MINT', is currently under way and will inform this subgroup further (<a href="./references#CD002042-bbs2-0079" title="NCT02619136.Myocardial ischemia and transfusion (MINT) [Myocardial ischemia and transfusion: a pilot, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in patients with myocardial infarction]. www.clinicaltrials.gov/ct2/show/NCT02619136 (first posted 2 December 2015). [CTG: NCT02619136]NCT02981407.Myocardial Ischemia and Transfusion (MINT). clinicaltrials.gov/ct2/show/NCT02981407 (first posted 5 December 2016). [CTG: NCT02981407]">NCT02981407</a>). </p> </section> <section id="CD002042-sec-0099"> <h4 class="title">The nature of the restrictive transfusion intervention</h4> <p>Around half of the trials identified applied a restrictive threshold of 7.0 g/dL; the other half used 8.0 g/dL. The largest trial including cardiac surgery patients used a 7.5‐g/dL threshold (<a href="./references#CD002042-bbs2-0032" title="GalanJ , MateoE , CarmonaP , GajateL , MazerCD , Martinez-ZapataMJ .Restrictive or liberal transfusion for cardiac surgery: Spanish TRICCS results of a randomized multicenter international parallel open-label clinical trial [Transfusión Restrictiva o liberal en cirugía cardiaca: Resultados españoles de un ensayo clínico aleatorizado, multicéntrico, internacional, paralelo y abierto]. Medicina Intensiva (English edition)2020;In press/epub: no volume:Epub: no pagination. [DOI: 10.1016/j.medin.2020.07.011]GargAX , BadnerN , BagshawSM , CuerdenMS , FergussonDA , GregoryAJ , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Safety of a restrictive versus liberal approach to red blood cell transfusion on the outcome of AKI in patients undergoing cardiac surgery: a randomized clinical trial. Journal of the American Society of Nephrology: JASN2019;30(7):1294-304. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , et al, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Restrictive or liberal red-cell transfusion for cardiac surgery. New England Journal of Medicine2017;377(22):2133-44. MazerCD , WhitlockRP , FergussonDA , Belley-CoteE , ConnollyK , KhanykinB , TRICS Investigators and Perioperative Anesthesia Clinical Trials Group.Six-month outcomes after restrictive or liberal transfusion for cardiac surgery. New England Journal of Medicine2018;379(13):1224-33. ">Mazer 2017</a>). Most participants in the 7.0 g/dL restrictive transfusion threshold trials were based in critical care and acute settings of anaemia. Clinical specialties were more varied in trials that tested an 8.0 g/dL restrictive transfusion threshold and included orthopaedic and cardiac surgery, gastrointestinal bleeding, and acute myocardial infarction. However, there was no apparent difference in risk of death at 30 days between the two strata. </p> <p>We compared 30‐day mortality in trials where the difference between liberal and restrictive transfusion thresholds in the trial protocol was at least 2.0 g/dL versus trials where the difference was less than 2.0 g/dL. Again, there was no evidence of a dose effect on clinical outcomes of RBC transfusion by different threshold levels of haemoglobin concentration. </p> </section> <section id="CD002042-sec-0100"> <h4 class="title">Risks of infection and outcomes of recovery</h4> <p>In view of potential immunomodulatory effects of blood transfusion, we compared the risk of infection in three ways. We did not find evidence of an increased risk of infection associated with liberal transfusion. We combined all infections and also examined sepsis or bacteraemia and pneumonia (alone); comparative risks of infection between the two transfusion strategies were nearly identical for all of these analyses. These results varied from prior analyses in another systematic review, which reported an elevated risk of infection in the liberal transfusion group (<a href="./references#CD002042-bbs2-0137" title="RohdeJM , DimcheffDE , BlumbergN , SaintS , LangaKM , KuhnL , et al.Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA2014;311(13):1317-26.">Rohde 2014</a>). However, they are consistent with later analyses (<a href="./references#CD002042-bbs2-0176" title="CarsonJL , StanworthSJ , RoubinianN , FergussonDA , TriulziD , DoreeC , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Carson 2016b</a>; <a href="./references#CD002042-bbs2-0101" title="CarsonJL , StanworthSJ , AlexanderJH , RoubinianN , FergussonDA , TriulziDJ , et al.Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease. American Heart Journal2018;200:96-101.">Carson 2018</a>), which were based on a substantially larger number of trials. </p> <p>Although 23 trials assessed functional recovery or quality of life and fatigue, these trials applied different measures or tools for assessment; therefore quantitative meta‐analysis could not be supported for these outcomes.  </p> </section> </section> <section id="CD002042-sec-0101"> <h3 class="title" id="CD002042-sec-0101">Overall completeness and applicability of evidence</h3> <p>As the number of trials expands, the completeness of evidence continues to increase. Clinical trials have now evaluated many of the most common clinical specialties in which RBCs are transfused. Thus, the findings of this review are widely applicable to most clinical contexts. However, we continue to lack knowledge and sufficient precision about the safety of different transfusion thresholds for some groups of patients who frequently receive transfusion, as an insufficient number of trials with adequate power have been published for these groups. These understudied clinical contexts include people with myocardial infarction, neurological injury/traumatic brain injury, acute neurological disorder, stroke, cancer/haematological malignancy, and chronic bone marrow failure. We anticipate some of these gaps may be filled relatively soon as new trials are completed, for which details and recruitment targets are listed in <a href="./references#CD002042-sec-0135" title="">Characteristics of ongoing studies</a>. </p> <p>A core rationale for RBC transfusion is to improve tissue and cellular oxygenation, but technologies for monitoring this directly, or at a cellular level, are not available routinely. Therefore, haemoglobin concentration continues to be applied as the main surrogate marker of need for transfusion in our included trials, but it may not be a reliable biomarker and it may not support a more precise or personalised approach to transfusion therapy (<a href="./references#CD002042-bbs2-0091" title="BaekJH , BuehlerPW .Can molecular markers of oxygen homeostasis and the measurement of tissue oxygen be leveraged to optimize red blood cell transfusions?Current Opinion in Hematology2019;26(6):453-60. [DOI: 10.1097/MOH.0000000000000533]">Baek 2019</a>). Trials that evaluate mechanistic and physiological variables alongside haemoglobin concentration are required (<a href="./references#CD002042-bbs2-0034" title="MøllerA , NielsenHB , WetterslevJ , PedersenOB , HellemannD , WinkelP , et al.Low vs high hemoglobin trigger for transfusion in vascular surgery: a randomized clinical feasibility trial. Blood2019;133(25):2639-50. MøllerA , ShahidiS , WetterslevJ , HellemanD , PedersenOB , MarcussenKV , et al.Cardiac output in the transfusion triggers in vascular surgery trial. Acta Anaesthesiologica Scandinavica2019;63:e12. ">Møller 2019</a>). </p> </section> <section id="CD002042-sec-0102"> <h3 class="title" id="CD002042-sec-0102">Quality of the evidence</h3> <p>Overall, the quality of evidence across trials is good and continues to show improvement over time. The number of trials and enrolled participants has increased substantially, and the precision of the estimate of the effect of transfusion improves with updates of this review. We found relatively little heterogeneity for each clinical outcome across all analyses. </p> <p>Risk of bias evaluations revealed a variety of methodological issues between trials. For more recent trials, including those reporting on larger sample sizes, evaluations of risk of bias remained generally low risk. We applied Cochrane methods for defining high or low risk of bias to all trials, but we acknowledge a number of challenges, including how to assign a single level of bias for multiple outcomes, for example, incomplete data or blinding (masking). We therefore considered risk of bias for objective (mortality) and subjective (functional and quality of life) outcomes separately. We will explore this further in future updates of this review, possibly by employing the new Cochrane 'Risk of bias 2' tool. We recognise that blinding the use of transfusion at the bedside is difficult to achieve unless trial personnel are assigned to each participant, which would be an expensive procedure. The importance of blinding will differ according to the choice of primary trial outcome; mortality is a hard endpoint (as in this review) that is less open to bias than other functional outcomes. </p> <p>Outcome assessment by observers who are blind to the treatment group is probably the most rigorous practical approach for transfusion threshold trials, but this is less relevant for outcomes such as mortality. We judged the risk of bias to be high for 11 trials for subjective outcomes, including functional outcomes and quality of life. This issue of detection bias for subjective outcomes will be explored in greater detail in a further update of this review, and informed by additional trial data (see <a href="./references#CD002042-sec-0135" title="">Characteristics of ongoing studies</a>; <a href="./references#CD002042-sec-0134" title="">Characteristics of studies awaiting classification</a>). Maintaining the integrity of the randomisation process becomes important if the trial is not to overestimate the benefit of the intervention (<a href="./references#CD002042-bbs2-0141" title="SchulzKF , ChalmersI , HayesRJ , AltmanDJ .Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled clinical trials. JAMA1995;273(5):408-12.">Schulz 1995</a>). We judged the risk of bias for allocation concealment ‐ a key methodological domain ‐ to be low for 36 trials. Only a few trials in this review did not report the methods used to conceal the allocation sequence from treating clinicians. </p> <p>We recognise a number of further limitations to the quality of trial evidence, beyond those considered by the Cochrane risk of bias assessment. As described by authors of other reviews, these include variable degrees of difference in numbers of transfusions between arms, and variable degrees of actual separation of haemoglobin concentration achieved between trial arms, which often is less than defined thresholds for trial interventions stated in the protocol (<a href="./references#CD002042-bbs2-0158" title="TrentinoKM , FarmerSL , LeahyMF , SanfilippoFM , IsbisterJP , MayberryR , et al.Systematic reviews and meta-analyses comparing mortality in restrictive and liberal haemoglobin thresholds for red cell transfusion: an overview of systematic reviews. BMC Medicine2020;18:154; https://doi.org/10.1186/s12916-020-01614-w. [DOI: 10.1186/s12916-020-01614-w]">Trentino 2020a</a>; <a href="./references#CD002042-bbs2-0159" title="TrentinoKM , FarmerSL , IsbisterJP , SanfilippoFM , LeahyMF , HofmannA , et al.Restrictive versus liberal transfusion trials: are they asking the right question?Anesthesia and Analgesia2020;131(6):1950-5. [DOI: 10.1213/ANE.0000000000005227]">Trentino 2020b</a>). Reasons for protocol violations, whether given as extra transfusions in the restrictive arm, or for lack of transfusions in the liberal arm, are often not reported in sufficient detail. </p> <p>We considered the policy of the Cochrane Injuries Group for research integrity (<a href="./references#CD002042-bbs2-0136" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE .The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463.">Roberts 2015</a>). We have explored possible reasons for subgroup differences between trials that were prospectively registered and those not prospectively registered (Chi² = 4.06, df = 1 (P = 0.04), I² = 75.4%). First, we created a funnel plot and found little evidence to support selection bias (<a href="#CD002042-fig-0006">Figure 6</a>). Second, it is possible that this statistically significant finding is a chance observation given the large number of statistical tests performed in this review. Third, we note that of the 13 trials that were not prospectively registered, seven were conducted before 2000 or 2001 when legislation regarding prospective registration was introduced in the USA and European Union, respectively, and nine of the trials were conducted before September 2007 when it was mandated by the Food and Drug Administration (FDA). </p> <div class="figure" id="CD002042-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Subgroup analysis by prospective registration, outcome: 2.1 30‐Day mortality" data-id="CD002042-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Subgroup analysis by prospective registration, outcome: 2.1 30‐Day mortality </p> </div> </div> </div> <p>Whilst we cannot exclude the presence of selection bias, we are confident we did not miss any large trials published before 2007 that would have impacted our inferences. Indeed, the overall RR for an analysis including all trials was 0.99 (95% CI 0.86 to 1.15), while an analysis limited to the trials with prospective registration was RR 1.08 (95% CI 0.89 to 1.31). </p> <p>We observed a substantial amount of statistical heterogeneity in analyses evaluating the proportions of participants transfused, the quantity of RBCs transfused, and differences in haemoglobin/haematocrit concentrations. It is conventional practice not to pool data from studies in which there is a large amount of heterogeneity, however, we chose to present pooled results for these transfusion outcomes for several reasons. First, the impact of restrictive transfusion on the proportion of participants transfused varied only by the magnitude of the reduction in transfusion ‐ not the direction. In all trials, participants in the restrictive transfusion group received fewer transfusions, although the number varied because transfusion protocols were different and clinical contexts required different frequencies of transfusion. Second, we expected this heterogeneity because of the variety of contexts for clinical trials, including participant age, degrees of comorbidity, and policies for standard transfusion practice, which, in turn, reflect specialty‐specific guidelines and recommendations. At one extreme, nearly all participants, if not all, with leukaemia and cancer were transfused (<a href="./references#CD002042-bbs2-0011" title="DeZernAE , WilliamsK , ZahurakM , HandW , StephensRS , KingKE , et al.Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion2016;56(7):1750-7. ">DeZern 2016</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>). Transfusion risk in participants in critical care (<a href="./references#CD002042-bbs2-0020" title="HébertPC , WellsG , MarshallJ , MartinC , TweeddaleM , PagliarelloG , et al.Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group [published erratum appears in JAMA 1995 Sep 27;274(12):944]. JAMA1995;273(18):1439-44. ">Hébert 1995</a>; <a href="./references#CD002042-bbs2-0021" title="HébertPC , WellsG , BlajchmanMA , MarshallJ , MartinC , PagliarelloG , et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine1999;340(6):409-17. McIntyreL , HébertPC , WellsG , FergussonD , MarshallJ , YetisirE , et al, Canadian Critical Care Trials Group.Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?Journal of Trauma2004;57(3):563-8. ">Hébert 1999</a>; <a href="./references#CD002042-bbs2-0029" title="LacroixJ , HébertPC , HutchisonJS , HumeHA , TucciM , DucruetT , et al.Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine2007;356(16):1609-19. ">Lacroix 2007</a>), or with acute blood loss (<a href="./references#CD002042-bbs2-0045" title="ColomoA , Hernandez-GeaV , Muniz-DiazE , MadozP , AracilC , Alvarez-UrturiC .Transfusion strategies in patients with cirrhosis and acute gastrointestinal bleeding. Hepatology2008;48(4 Suppl):413A. VillanuevaC , ColomoA , BoschA , ConcepciónM , Hernandez-GeaV , AracilC , et al.Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine2013;368(1):11-21. ">Villanueva 2013</a>), was about 50% at the time of the trials. </p> <p>In summary, we have chosen to present pooled results for outcomes of transfusion because we are evaluating the effects of restrictive transfusion practice, and because all trial estimates for changes in transfusion are consistently in the same direction. The substantial heterogeneity, therefore, reflects diversity in the strength of estimates, rather than efficacy of the policy. Reasons for diversity in the strength of trial estimates include known and expected clinical contexts and different practice guidelines used by different specialties. Subgroup explorations for transfusion outcomes reported earlier demonstrated these differences.  </p> </section> <section id="CD002042-sec-0103"> <h3 class="title" id="CD002042-sec-0103">Potential biases in the review process</h3> <p>We performed extensive searches in an attempt to identify all eligible trials irrespective of publication status or language. Inspection of funnel plots did not reveal a major risk of publication bias (<a href="#CD002042-fig-0004">Figure 4</a>; <a href="#CD002042-fig-0005">Figure 5</a>). </p> <p>Other trial limitations apply to the findings of this review. Timing of mortality reporting varied between trials, in part as a consequence of the clinical context. To address this issue, an initiative to undertake an individual patient data analysis has been commenced, including contact with all trial investigators to explore willingness to share trial data.  </p> <p>Randomised trials in this review may not have evaluated important clinical outcomes adequately that are specifically relevant to the use of RBC transfusions, such as quality of life. The identified trials evaluated the effects of transfusion only in hospitalised patients, and only two small trials have tested different thresholds in an outpatient population (<a href="./references#CD002042-bbs2-0025" title="JansenAJ , vanden BoschJ .Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold [Letter to the Editor]. Transfusion2020;60(4):879-81. [ISRCTN: ISRCTN43616311]">Jansen 2020</a>; <a href="./references#CD002042-bbs2-0042" title="StanworthSJ , KillickS , McQuiltenZK , KarakantzaM , WeinkoveR , SmethurstH , et al, REDDS Investigators.Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology2020;189(2):279-90. [ISRCTN26088319]">Stanworth 2020</a>), for whom function and fatigue would be more important endpoints. </p> <p>Different grades of severity of cardiovascular events, such as myocardial infarction, congestive heart failure, or stroke, and different risks of overall infection will occur in patients; these events may present in ways that are not always clinically overt and so are more subjective in interpretation. This is important because RBC transfusions may have both harmful and beneficial effects on the risk of these outcomes, for example, balancing prothrombotic tendencies against protective mechanisms to limit restrictions in myocardial oxygen delivery. Future trials need to establish robust definitions of all outcomes (<a href="./references#CD002042-bbs2-0106" title="DochertyAB , O'DonnellR , BrunskillS , TrivellaM , DoreeC , HolstL , et al.Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ2016;352:i1351.">Docherty 2016</a>). Despite the large number of participants included in these trials, there remains inadequate power for many outcomes. </p> </section> <section id="CD002042-sec-0104"> <h3 class="title" id="CD002042-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>The results of this review are consistent with previous published systematic reviews and guidance documents (<a href="./references#CD002042-bbs2-0098" title="CarsonJL , GrossmanBJ , KleinmanS , TinmouthAT , MarquesMB , FungMK , et al, Clinical Transfusion Medicine Committee of theAABB.Red blood cell transfusion: a clinical practice guideline from the AABB. Annals of Internal Medicine2012;157(1):49-58.">Carson 2012a</a>; <a href="./references#CD002042-bbs2-0106" title="DochertyAB , O'DonnellR , BrunskillS , TrivellaM , DoreeC , HolstL , et al.Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ2016;352:i1351.">Docherty 2016</a>; <a href="./references#CD002042-bbs2-0114" title="HolstLB , PetersenMW , HaaseN , PernerA , WetterslevJ .Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ2015;350:h1354.">Holst 2015</a>; <a href="./references#CD002042-bbs2-0120" title="MeybohmP , StraubN , FüllenbachC , JuddL , KleinerüschkampA , TaeuberI , et al.Health economics of Patient Blood Management: a cost-benefit analysis based on a meta-analysis. Vox Sanguinis2020;115(2):182-8. [DOI: 10.1186/s13063-019-3200-3]">Meybohm 2020</a>). A review of reviews reported no evidence that a difference in mortality exists between patients assigned to a restrictive or a liberal transfusion strategy (<a href="./references#CD002042-bbs2-0158" title="TrentinoKM , FarmerSL , LeahyMF , SanfilippoFM , IsbisterJP , MayberryR , et al.Systematic reviews and meta-analyses comparing mortality in restrictive and liberal haemoglobin thresholds for red cell transfusion: an overview of systematic reviews. BMC Medicine2020;18:154; https://doi.org/10.1186/s12916-020-01614-w. [DOI: 10.1186/s12916-020-01614-w]">Trentino 2020a</a>). These overall findings provide no evidence that restrictive transfusion policies harm patients within the limits defined by the trials.  </p> <p>Multiple reviews have addressed outcomes in selected subgroups or subpopulations of patients. A review by Fominskiy aimed to assess effects of liberal and restrictive RBC transfusion strategies on mortality in perioperative and critically ill adult patients through a meta‐analysis of relevant trials (<a href="./references#CD002042-bbs2-0108" title="FominskiyE , PutzuA , MonacoF , ScandroglioAM , KaraskovA , GalasFR , et al.Liberal transfusion strategy improves survival in perioperative but not in critically ill patients. A meta-analysis of randomised trials. British Journal of Anaesthesia2015;115(4):511-9.">Fominskiy 2015</a>); a more recent review focused on cardiac surgery (<a href="./references#CD002042-bbs2-0147" title="ShehataN , MistryN , da CostaBR , PereiraTV , WhitlockR , CurleyGF , et al.Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis. European Heart Journal2019;40(13):1081-8.">Shehata 2019</a>). A meta‐analysis of trials in gastrointestinal bleeding reported evidence of harm with application of liberal thresholds in this patient group (<a href="./references#CD002042-bbs2-0127" title="OdutayoA , DesboroughMJ , TrivellaM , StanleyAJ , DoréeC , CollinsGS , et al.Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterology and Hepatology2017;2(5):354-60. [DOI: 10.1016/S2468-1253(17)30054-7]">Odutayo 2017</a>), as found in our review, although our review has identified one further trial in gastrointestinal bleeding (<a href="./references#CD002042-bbs2-0028" title="KolaG , SureshkumarS , MohsinaS , SreenathGS , KateV .Restrictive versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi Journal of Gastroenterology2020;27(1):13-9. [DOI: 10.4103/sjg.SJG_152_20]">Kola 2020</a>). We suggest some caution in interpretation of systematic reviews that report only separate subpopulations of the wider trial literature. Anaemia is the common presenting clinical problem for all patients when a red cell transfusion is considered, irrespective of clinical setting. There is a risk that the patterns of findings in different clinical contexts are inappropriately selective to a small subpopulation. The clinical decision process for transfusion in one clinical context may need to draw on findings of safety as reported across all randomised trials in different clinical settings, for a common intervention of RBC. </p> <p>The results of our meta‐analyses need to be viewed against studies or reviews of large observational studies that have reported comparisons of clinical outcomes at varying haemoglobin levels in transfused and non‐transfused patients. Publications of the observational literature have reported findings at variance with the randomised trial literature (<a href="./references#CD002042-bbs2-0006" title="CarsonJL , TerrinML , BartonFB , AaronR , GreenburgAG , HeckDA , et al.A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion1998;38(6):522-9. ">Carson 1998</a>; <a href="./references#CD002042-bbs2-0109" title="HébertPC , WellsG , TweeddaleM , MartinC , MarshallJ , PhamB , et al.Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. American Journal of Respiratory and Critical Care Medicine1997;155(5):1618-23.">Hébert 1997</a>; <a href="./references#CD002042-bbs2-0021" title="HébertPC , WellsG , BlajchmanMA , MarshallJ , MartinC , PagliarelloG , et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine1999;340(6):409-17. McIntyreL , HébertPC , WellsG , FergussonD , MarshallJ , YetisirE , et al, Canadian Critical Care Trials Group.Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?Journal of Trauma2004;57(3):563-8. ">Hébert 1999</a>; <a href="./references#CD002042-bbs2-0130" title="PatelNN , AvlonitisVS , JonesHE , ReevesBC , SterneJA , MurphyGJ .Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. Lancet Haematology2015;2(12):e543-53. [DOI: doi: 10.1016/S2352-3026(15)00198-2]">Patel 2015</a>; <a href="./references#CD002042-bbs2-0152" title="SpiessBD , LeyC , BodySC , SiegelLC , StoverEP , MaddiR , et al.Hematocrit value on intensive care unit entry influences the frequency of Q-wave myocardial infarction after coronary artery bypass grafting. The Institutions of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Journal of Thoracic &amp; Cardiovascular Surgery1998;116(3):460-7.">Spiess 1998</a>; <a href="./references#CD002042-bbs2-0167" title="WuWC , RathoreSS , WangY , RadfordMJ , KrumholzHM .Blood transfusion in elderly patients with acute myocardial infarction. New England Journal of Medicine2001;345(17):1230-6.">Wu 2001</a>; <a href="./references#CD002042-bbs2-0168" title="WuWC , SchifftnerTL , HendersonWG , EatonCB , PosesRM , UttleyG , et al.Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA2007;297(22):2481-8.">Wu 2007</a>; <a href="./references#CD002042-bbs2-0169" title="WuWC , SmithTS , HendersonWG , EatonCB , PosesRM , UttleyG , et al.Operative blood loss, blood transfusion, and 30-day mortality in older patients after major noncardiac surgery. Annals of Surgery2010;252(1):11-7.">Wu 2010</a>). Reviews of observational data have reported an increase in risk of death associated with transfusion (<a href="./references#CD002042-bbs2-0102" title="ChatterjeeS , WetterslevJ , SharmaA , LichsteinE , MukherjeeD .Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Internal Medicine2013;173(2):132-9.">Chatterjee 2013</a>; <a href="./references#CD002042-bbs2-0118" title="MarikPE , CorwinHL .Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Critical Care Medicine2008;36(9):2667-74.">Marik 2008</a>). However, a limitation of observational studies is that there may be residual confounding by indication, despite extensive statistical adjustment of the results. It is possible that differences in patient characteristics between those who were transfused and those who were not transfused may not have been identified or adjusted for adequately. In contrast, results of the meta‐analysis of clinical trials performed in this review update show no increase in risk of death for liberal transfusion thresholds compared with restrictive transfusion thresholds. Despite assertions to the contrary (<a href="./references#CD002042-bbs2-0093" title="BensonK , HartzAJ .A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine2000;342(25):1878-86.">Benson 2000</a>; <a href="./references#CD002042-bbs2-0103" title="ConcatoJ , ShahN , HorwitzRI .Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine2000;342(25):1887-92.">Concato 2000</a>), we continue to believe there is a need for adequately powered, rigorously performed, randomised trials to provide the highest level of evidence when effects of different transfusion policies are tested, as the way of overcoming these limitations.  </p> <p>The transfusion policies reviewed here represent fairly small but significant modifications to routine clinical practice. They are consistent with the recommendations of published clinical practice guidelines (<a href="./references#CD002042-bbs2-0089" title="Association of Anaesthetists of Great Britain and Ireland.Blood transfusion and the anaesthetist - red cell transfusion. www.aagbi.org/publications/guidelines/docs/red_cell_08.pdf 2008 (accessed 11 October 2016).">AAGBI 2008</a>; <a href="./references#CD002042-bbs2-0090" title="American Society of Anesthesiologists (ASA) Task Force on Perioperative Blood Transfusion and Adjuvant Therapies.Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology2006;105(1):198-208.">ASA 2006</a>; <a href="./references#CD002042-bbs2-0092" title="British Columbia Transfusion Medicine Advisory Group (BCTMAG).Guidelines for red blood cell transfusion. British Columbia Transfusion Medicine Advisory Group2003;November:1-3.">BCTMAG 2003</a>; <a href="./references#CD002042-bbs2-0098" title="CarsonJL , GrossmanBJ , KleinmanS , TinmouthAT , MarquesMB , FungMK , et al, Clinical Transfusion Medicine Committee of theAABB.Red blood cell transfusion: a clinical practice guideline from the AABB. Annals of Internal Medicine2012;157(1):49-58.">Carson 2012a</a>; <a href="./references#CD002042-bbs2-0176" title="CarsonJL , StanworthSJ , RoubinianN , FergussonDA , TriulziD , DoreeC , et al.Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD002042. [DOI: 10.1002/14651858.CD002042]">Carson 2016b</a>; <a href="./references#CD002042-bbs2-0121" title="MuellerMM , Van RemoortelH , MeybohmP , ArankoK , AubronC , BurgerR , et al, Group LCC Pbm Frankfurt.Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA2019;321(10):983-97.">Mueller 2019</a>; <a href="./references#CD002042-bbs2-0122" title="NapolitanoLM , KurekS , LuchetteFA , CorwinHL , BariePS , TishermanSA , et al.Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Critical Care Medicine2009;37(12):3124-57.">Napolitano 2009</a>; <a href="./references#CD002042-bbs2-0123" title="National Blood Users Group Ireland (NBUGI).A guideline for transfusion of red blood cells in surgical patients. www.dohc.ie/publications/transfusion_of_red_blood_cells.html (accessed 11 October 2016).">NBUGI 2001</a>; <a href="./references#CD002042-bbs2-0132" title="RetterA , WyncollD , PearseR , CarsonD , McKechnieS , StanworthS , et al.Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. British Journal of Haematology2013;160(4):445-64.">Retter 2013</a>; <a href="./references#CD002042-bbs2-0155" title="Society of Thoracic Surgeons Blood Conservation Guideline Task Force (STSBCGTF), FerrarisVA , BrownJR , DespotisGJ , HammonJW , ReeceTB , SahaSP , et al.2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Annals of Thoracic Surgery2011;91(3):944-82.">STSBCGTF 2011</a>). Transfusion triggers (in terms of haemoglobin levels) were most often in the range of 7.0 g/dL to 10.0 g/dL. In fact, the 'restrictive' transfusion triggers in some trials were equivalent to the 'liberal' triggers used in other trials. Nevertheless, trials documented significant reduction in exposure of patients to unnecessary RBC transfusion. Our findings for red cell transfusion strategies should be interpreted alongside findings for the use of 'alternative' agents to red cells or blood‐sparing techniques, such as intravenous iron (<a href="./references#CD002042-bbs2-0135" title="RichardsT , BaikadyRR , ClevengerB , ButcherA , AbeysiriS , ChauM , et al.Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet2020;396:1353–61.">Richards 2020</a>), cell salvage/blood conservation (<a href="./references#CD002042-bbs2-0096" title="CarlessPA , HenryDA , MoxeyAJ , O'ConnellD , BrownT , FergussonDA .Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD001888. [DOI: 10.1002/14651858.CD001888.pub4]">Carless 2010a</a>; <a href="./references#CD002042-bbs2-0155" title="Society of Thoracic Surgeons Blood Conservation Guideline Task Force (STSBCGTF), FerrarisVA , BrownJR , DespotisGJ , HammonJW , ReeceTB , SahaSP , et al.2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Annals of Thoracic Surgery2011;91(3):944-82.">STSBCGTF 2011</a>), and antifibrinolytic drugs (<a href="./references#CD002042-bbs2-0110" title="HenryDA , CarlessPA , MoxeyAJ , O'ConnellD , StokesBJ , FergussonDA , et al.Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews2011, Issue 3. Art. No: CD001886. [DOI: 10.1002/14651858.CD001886.pub4]">Henry 2011</a>). Adoption of a conservative transfusion threshold appears to be as effective, if not more effective, in the context of Patient Blood Managment implementation, and is likely to cost less (<a href="./references#CD002042-bbs2-0138" title="RomanMA , AbbascianoRG , PathakS , OoS , YusoffS , WozniakM , et al.Patient blood management interventions do not lead to important clinical benefits or cost-effectiveness for major surgery: a network meta-analysis. British Journal of Anaesthesia2020;S0007-0912(20):30342-1. [DOI: 10.1016/j.bja.2020.04.087]">Roman 2020</a>). </p> <p>Some guidelines have recommended RBC transfusion for symptoms or haemodynamic instability, rather than for a specific trigger haemoglobin level (<a href="./references#CD002042-bbs2-0089" title="Association of Anaesthetists of Great Britain and Ireland.Blood transfusion and the anaesthetist - red cell transfusion. www.aagbi.org/publications/guidelines/docs/red_cell_08.pdf 2008 (accessed 11 October 2016).">AAGBI 2008</a>; <a href="./references#CD002042-bbs2-0090" title="American Society of Anesthesiologists (ASA) Task Force on Perioperative Blood Transfusion and Adjuvant Therapies.Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology2006;105(1):198-208.">ASA 2006</a>; <a href="./references#CD002042-bbs2-0122" title="NapolitanoLM , KurekS , LuchetteFA , CorwinHL , BariePS , TishermanSA , et al.Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Critical Care Medicine2009;37(12):3124-57.">Napolitano 2009</a>; <a href="./references#CD002042-bbs2-0123" title="National Blood Users Group Ireland (NBUGI).A guideline for transfusion of red blood cells in surgical patients. www.dohc.ie/publications/transfusion_of_red_blood_cells.html (accessed 11 October 2016).">NBUGI 2001</a>). Three studies tested this approach to transfusion: a pilot study involving 84 participants (<a href="./references#CD002042-bbs2-0006" title="CarsonJL , TerrinML , BartonFB , AaronR , GreenburgAG , HeckDA , et al.A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion1998;38(6):522-9. ">Carson 1998</a>), a trial involving 2016 participants (<a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>), and a 110‐participant trial for acute myocardial infarction (<a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>), in which patients could be transfused if they exhibited symptoms or had a haemoglobin concentration less than 8.0 g/dL. These studies found no differences in functional recovery, mortality, or morbidity among patients in the restrictive (symptomatic) transfusion group in orthopaedic surgery trials (<a href="./references#CD002042-bbs2-0006" title="CarsonJL , TerrinML , BartonFB , AaronR , GreenburgAG , HeckDA , et al.A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion1998;38(6):522-9. ">Carson 1998</a>; <a href="./references#CD002042-bbs2-0007" title="CarsonJL , SieberF , CookDR , HooverDR , NoveckH , ChaitmanBR , et al.Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet2015;385(9974):1183-9. CarsonJL , TerrinML , NoveckH , SandersDW , ChaitmanBR , RhoadsGG , et al.Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine2011;365(26):2453-62. Gruber-BaldiniAL , MarcantonioE , OrwigD , MagazinerJ , TerrinM , BarrE , et al.Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. Journal of the American Geriatrics Society2013;61(8):1286-95. ">Carson 2011</a>), although in the trial involving patients with acute myocardial infarction (<a href="./references#CD002042-bbs2-0008" title="CarsonJL , BrooksMM , AbbottJD , ChaitmanB , KelseySF , TriulziDJ , et al.Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. American Heart Journal2013;165(6):964-71. [CTG: NCT01167582]">Carson 2013</a>), there was a tendency towards worse outcomes in the restrictive transfusion group. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002042-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow of studies for 2021 update" data-id="CD002042-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow of studies for 2021 update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Forty‐eight trials are included in this review." data-id="CD002042-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Forty‐eight trials are included in this review. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each methodological quality item for each included trial" data-id="CD002042-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each methodological quality item for each included trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Mortality, outcome: 1.1 30‐Day mortality" data-id="CD002042-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mortality, outcome: 1.1 30‐Day mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Blood transfusions, outcome: 2.1 Participants exposed to blood transfusion (all trials)" data-id="CD002042-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Blood transfusions, outcome: 2.1 Participants exposed to blood transfusion (all trials) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Subgroup analysis by prospective registration, outcome: 2.1 30‐Day mortality" data-id="CD002042-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Subgroup analysis by prospective registration, outcome: 2.1 30‐Day mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at 30 days, Outcome 1: 30‐Day mortality" data-id="CD002042-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Mortality at 30 days, Outcome 1: 30‐Day mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at 30 days, Outcome 2: 30‐Day mortality subgroup by restrictive haemoglobin level" data-id="CD002042-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Mortality at 30 days, Outcome 2: 30‐Day mortality subgroup by restrictive haemoglobin level </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at 30 days, Outcome 3: 30‐Day mortality subgroup analysis by clinical specialties" data-id="CD002042-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Mortality at 30 days, Outcome 3: 30‐Day mortality subgroup analysis by clinical specialties </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at 30 days, Outcome 4: 30‐Day mortality by clinical specialties: myocardial infarction vs all others" data-id="CD002042-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Mortality at 30 days, Outcome 4: 30‐Day mortality by clinical specialties: myocardial infarction vs all others </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at 30 days, Outcome 5: Mortality by cardiac surgery, vascular surgery, myocardial infarction, and all others" data-id="CD002042-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Mortality at 30 days, Outcome 5: Mortality by cardiac surgery, vascular surgery, myocardial infarction, and all others </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis by prospective registration, Outcome 1: 30‐Day mortality" data-id="CD002042-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis by prospective registration, Outcome 1: 30‐Day mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis by allocation concealment, Outcome 1: 30‐Day mortality" data-id="CD002042-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis by allocation concealment, Outcome 1: 30‐Day mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mortality: other time intervals, Outcome 1: Hospital mortality" data-id="CD002042-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Mortality: other time intervals, Outcome 1: Hospital mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mortality: other time intervals, Outcome 2: 90‐Day mortality" data-id="CD002042-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Mortality: other time intervals, Outcome 2: 90‐Day mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Mortality: other time intervals, Outcome 3: 6‐Month mortality" data-id="CD002042-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Mortality: other time intervals, Outcome 3: 6‐Month mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 1: Cardiac events" data-id="CD002042-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 1: Cardiac events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 2: Myocardial infarction" data-id="CD002042-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 2: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 3: Congestive heart failure" data-id="CD002042-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 3: Congestive heart failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 4: Cerebrovascular accident (CVA) ‐ stroke" data-id="CD002042-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 4: Cerebrovascular accident (CVA) ‐ stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 5: Rebleeding" data-id="CD002042-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 5: Rebleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 6: Sepsis/bacteraemia" data-id="CD002042-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 6: Sepsis/bacteraemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 7: Pneumonia" data-id="CD002042-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 7: Pneumonia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 8: Infection" data-id="CD002042-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 8: Infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 9: Thromboembolism" data-id="CD002042-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 9: Thromboembolism</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 10: Renal failure" data-id="CD002042-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 10: Renal failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Morbidity: clinical outcomes, Outcome 11: Mental confusion" data-id="CD002042-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Morbidity: clinical outcomes, Outcome 11: Mental confusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Blood transfusions, Outcome 1: Participants exposed to blood transfusion (all trials)" data-id="CD002042-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Blood transfusions, Outcome 1: Participants exposed to blood transfusion (all trials) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Blood transfusions, Outcome 2: Participants exposed to blood transfusion by clinical specialties" data-id="CD002042-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Blood transfusions, Outcome 2: Participants exposed to blood transfusion by clinical specialties </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Blood transfusions, Outcome 3: Participants exposed to blood transfusion (by transfusion threshold)" data-id="CD002042-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Blood transfusions, Outcome 3: Participants exposed to blood transfusion (by transfusion threshold) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Blood transfusions, Outcome 4: Participants exposed to blood transfusion by transfusion threshold" data-id="CD002042-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Blood transfusions, Outcome 4: Participants exposed to blood transfusion by transfusion threshold </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Blood transfusions, Outcome 5: Units of blood transfused" data-id="CD002042-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Blood transfusions, Outcome 5: Units of blood transfused</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 1: Myocardial infarction" data-id="CD002042-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 1: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 2: Renal failure" data-id="CD002042-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 2: Renal failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 3: Infection" data-id="CD002042-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 3: Infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 4: Congestive heart failure" data-id="CD002042-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 4: Congestive heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 5: Thromboembolism" data-id="CD002042-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 5: Thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002042-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/urn:x-wiley:14651858:media:CD002042:CD002042-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 6: Cerebrovascular accident" data-id="CD002042-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_t/tCD002042-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI, Outcome 6: Cerebrovascular accident </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/media/CDSR/CD002042/image_n/nCD002042-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002042-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Liberal compared with restrictive transfusion protocols for guiding red blood cell transfusion</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Liberal compared with restrictive transfusion protocols for guiding red blood cell transfusion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children (haemodynamically stable) with potential need for RBC transfusion<br/><b>Setting:</b> inpatients<br/><b>Intervention:</b> restrictive transfusion threshold<br/><b>Comparison:</b> liberal transfusion threshold </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with liberal transfusion protocol</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with restrictive transfusion protocol</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants exposed to blood transfusion (all studies)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/>(0.53 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20,057<br/>(42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>815 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000<br/>(432 to 538) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30‐Day mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.86 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16,729<br/>(31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000<br/>(71 to 96) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.87 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,370<br/>(23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/>(28 to 40) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Congestive heart failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.53 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7247<br/>(16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(19 to 45) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cerebrovascular accident ‐ stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/>(0.64 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13,985<br/>(19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(11 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rebleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.59 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3412<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/>(93 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thromboembolism</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.11<br/>(0.65 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4201<br/>(13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(10 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.88 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17,104<br/>(25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(126 to 153) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RBC:</b> red blood cell; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded once for inconsistency, as there was no consistency in the direction of the effect (despite the relatively low statistical heterogeneity), and we downgraded once for imprecision, as there were very low numbers of events. </p> <p><sup>b</sup>Despite relatively low statistical heterogeneity, there was no consistency in the direction of the effect, hence we downgraded once for inconsistency. </p> <p><sup>c</sup>Downgraded once for imprecision, as there were few events (and hence a wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Liberal compared with restrictive transfusion protocols for guiding red blood cell transfusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002042-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Trial setting details</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants at baseline</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country/Countries</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of sites</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Year recruitment started</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mazer 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 countries<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carson 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Murphy 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Holst 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark, Sweden, Norway, Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 general ICUs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jairath 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Villanueva 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hébert 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary (22), community ICU (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1994</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Koch 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (1), India (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 academic affiliated hospital in the USA, a private hospital in India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ducrocq 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>France, Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2016</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lacroix 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada, Belgium, USA, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary paediatric ICU</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>So‐Osman 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varied ‐ university and general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prick 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varied ‐ university and general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hajjar 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hoff 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>??</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oncology centres</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1986</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bracey 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1997</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palmieri 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>US (16 sites), Canada (1), New Zealand (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specialist burn centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tay 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCT sites</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bergamin 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gregersen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grover 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kola 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parker 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>de Almeida 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary oncology university hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fan 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akyildiz 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yakymenko 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lotke 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Foss 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walsh 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varied ‐ university and general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bush 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1995</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DeZern 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary referral centre for oncology</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carson 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (3), UK (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1996</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laine 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hébert 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1993</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nielsen 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital and general hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gillies 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2017</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Webert 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary oncology centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Møller 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shehata 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2007</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blair 1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gobatto 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veterans' Affairs hospital centres</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2003</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>University teaching hospital</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stanworth 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK, Australia, New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 sites ‐ varied</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topley 1956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'Accident hospital'</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Januarysen 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 university hospital, 2 general hospitals</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Robitaille 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not identified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Mazer 2017 (TRICS‐III): majority of sites in USA; sites also in Australia, Brazil, Canada, China, Colombia, Denmark, Egypt, Germany, Greece, India, Israel, Malaysia, New Zealand, Romania, Singapore, South Africa, Spain, and Switzerland. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Trial setting details</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/full#CD002042-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mortality at 30 days</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 30‐Day mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 30‐Day mortality subgroup by restrictive haemoglobin level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Restrictive 7.0 g/dL to 7.5 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Restrictive &lt; 8.0 g/dL to 9.0 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.75, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 30‐Day mortality subgroup analysis by clinical specialties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.74, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Orthopaedic surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.75, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Vascular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.30, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Acute blood loss/trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Critical care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.85, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.38, 6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.7 Haematological malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.07, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 30‐Day mortality by clinical specialties: myocardial infarction vs all others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.38, 6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 All but myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mortality by cardiac surgery, vascular surgery, myocardial infarction, and all others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.74, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.38, 6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Vascular surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.30, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.83, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mortality at 30 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis by prospective registration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 30‐Day mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Prospectively registered trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Trials without prospective registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.66, 1.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis by prospective registration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis by allocation concealment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 30‐Day mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.87, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Unclear or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.51, 1.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis by allocation concealment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mortality: other time intervals</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Hospital mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.72, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 90‐Day mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.02, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 6‐Month mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.79, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mortality: other time intervals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Morbidity: clinical outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Cardiac events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.80, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.53, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Cerebrovascular accident (CVA) ‐ stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Rebleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Sepsis/bacteraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.86, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.65, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Mental confusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.88, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Morbidity: clinical outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Blood transfusions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Participants exposed to blood transfusion (all trials) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.53, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Participants exposed to blood transfusion by clinical specialties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.53, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.66, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Orthopaedic surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.38, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Vascular surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.4 Acute blood loss/trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.23, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.5 Critical care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.57, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.6 Acute myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.28, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.7 Haematological malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Participants exposed to blood transfusion (by transfusion threshold) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Difference between liberal and restrictive haemoglobin thresholds ≥ 2.0 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 Difference between liberal and restrictive haemoglobin thresholds &lt; 2.0 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Participants exposed to blood transfusion by transfusion threshold <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.51, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Restrictive 7.0 g/dL to 7.5 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.48, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Restrictive &lt; 8.0 g/dL to 9.0 g/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.48, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Units of blood transfused <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.21 [‐1.67, ‐0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Blood transfusions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002042-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.81, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.89, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.24, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.11, 9.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Cerebrovascular accident <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.22, 4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Morbidity outcomes in participants undergoing cardiac surgery or vascular surgery, and with acute MI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002042.pub5/references#CD002042-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002042.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002042-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002042-note-0050">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002042-note-0042">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002042-note-0046">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002042-note-0038">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002042-note-0034">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002042-note-0030">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD002042-note-0022">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD002042-note-0021">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002042-note-0026">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002042-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002042\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002042\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002042\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002042\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002042\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002042.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002042.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002042.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002042.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002042.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729442102"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002042.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729442106"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002042.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edcfa5cb0bd65',t:'MTc0MDcyOTQ0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 